Acetyl-coa carboxylases

ABSTRACT

The present invention provides various combinations of genetic modifications to a. transformed host cell that provide increase conversion of carbon to a chemical product. The present invention also provides methods of fermentation and methods of making various chemical products.

CLAIM OF PRIORITY

This application is a Continuation of and claims the benefit of priority to U.S. patent application Ser. No. 14/215,379, Filed on Mar. 17, 2014, which claims the benefit of priority to U.S. Provisional Patent Application No. 61/852,387, filed on Mar. 15, 2013, the benefit of priority of each of which is claimed hereby, and each of which are incorporated by reference herein in its entirety.

BACKGROUND OF THE INVENTION

There is a need for alternative production methods of industrial chemicals used for various consumer products and fuels that are currently made from petroleum. One alternative method is the use of engineered microorganisms to produce industrial chemicals. Currently, in the field of bioproduced chemicals there is a need to improve microbial enzyme performance, enhanced production rate in order to reach the goal of becoming an at-cost replacement basis for petro-based chemicals.

A common challenge faced in field of bio-produced chemicals in microorganisms is that any one modification to a host cell may require coordination with other modifications in or ⁻r to successfully enhance chemical bioproduction.

The current invention provides methods, systems of fermentation, genetically modified microorganisms, modified enhanced enzymes for chemical production, all of which may be used in various combinations to increase chemical production of a desired chemical product.

INCORPORATION BY REFERENCE

All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.

SUMMARY OF THE INVENTION

The present invention relates to genetically modified organisms capable of producing an industrial chemical product of interest, wherein the genetic modification includes introduction of nucleic acid sequences coding for polynucleotides encoding one or more of the following: (1) an acetyl-CoA carboxylase gene with one or more of its subunits fused together in the genetic structure of the organism; (2) an acetyl-CoA carboxylase gene having a predefined stoichiometric ratio of each of the four ACCase subunits relative to one another; (3) a monofunctional malonyl-CoA reductase gene capable of catalyzing the conversion of malonyl-CoA to malonate semialdehyde and one or more genes encoding one or more of the following enzymes: ydfG, mmsB, NDSD, rutE, and nemA; (4) a monofunctional malonyl-CoA reductase gene capable of catalyzing the conversion of malonyl-CoA to malonate semialdehyde and one or more genes encoding one or more enzymes capable of converting malonate semialdehyde keto form to 3-HP, and one or more genes encoding one or more enzymes capable of converting either the malonate semialdehyde enol form or the malonate semialdehyde hydrated form to 3-HP; (5) a monofunctional malonyl-CoA reductase enzyme fused to a dehydrogenase enzyme that is either: (a) primarily not NADPH-dependent, (b) primarily NADH-dependent, (c) primarily flavin-dependent, (d) less susceptible to 3-HP inhibition at high concentration, and/or (e) catalyzes a reaction pathway to 3-HP that is substantially irreversible; (6) a monofunctional malonyl-CoA reductase enzyme fused to one or more malonate semialdehyde dehydrogenase enzymes; (7) a malonyl-CoA reductase gene that is mutated to enhance its activity at lower temperatures; (8) salt-tolerant enzymes; (9) a gene that facilitates the exportation of a chemical product of interest or the export of an inhibitory chemical from within the cell to the extracellular media; and/or (10) a gene that facilitates the importation from the extracellular media to within the cell of a reactant, precursor, and/or metabolite used in the organism's production pathway for producing a chemical product of interest.

The present invention further relates to methods of producing a chemical product using the genetically modified organisms of the invention. The present invention further includes products made from these methods. In accordance with certain embodiments that product is acetyl-CoA, malonyl-CoA, malonate semialdehyde, 3-hydroxypropionic acid (3-HP), acrylic acid, 1,3 propanediol, malonic acid, ethyl 3-HP, propiolactone, acrylonitrile, acrylamide, methyl acrylate, a polymer including super absorbent polymers and polyacrylic acid, or a consumer product.

The present invention further relates to a method of producing a chemical product from a renewable carbon source through a bioproduction process that comprises a controlled multi-phase production process wherein the initiation and/or completion of one or more phases of the production process is controlled by genetic modifications to the organism producing the chemical product and/or is controlled by changes made to the cell environment. In accordance with this aspect of the invention, the bioproduction process may include two or more of the following phases: (1) growth phase; (2) induction phase; and (3) production phase. The present invention further includes products made from these methods.

BRIEF DESCRIPTION OF THE DRAWINGS

The novel features of the invention are set forth with particularity in the appended claims. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:

FIG. 1 Depicts some embodiments of the metabolic pathways to produce 3-hydroxypropionic acid.

FIG. 2 Depicts some embodiments of the of various equilibrium states in the malonate semialdehyde to 3-HP reaction in a cell environment.

FIG. 3 Depicts some embodiments of the reaction catalyzed by acetyl-CoA carboxylase (ACCase)

FIG. 4 Shows the inhibition of ACCase enzyme activity by high salt concentration.

FIG. 5 Depicts some embodiments of the fusion ACCase subunit gene constructs overexpressed in E. coli. CAT=chloramphenicol resistance marker; p15a rep=replication origin; red arrow=promoter.

FIG. 6 Show improved production of 3-HP in fermentors by genetically modified organism with DA fusion ACCase.

FIG. 7 Shows improved production of 3-HP in fermentors by genetically modified organism with overexpression of rhtA exporter.

FIG. 8 Shows various embodiments of the genetic modules used for optimizing expression in host cells.

FIG. 9 Shows various chemical products that can made from various embodiments of the invention.

Table 1 Lists the accession numbers for genes encoding ACCase subunits from Halomonas elongate.

Table 2 Depicts some embodiments of the RBS sequences used to enhance expression of H. elongate ACCase subunits.

Table 3 Shows the improvement in 3-HP production by RBS-optimized expression of H. elongata ACCase subunits.

Table 4 Shows some embodiments of ACCase subunit fusions that increase and ACCase enzyme complex activity.

Table 5 Shows some of the genetic modifications of a host cell for increase chemical production.

DETAILED DESCRIPTION OF THE INVENTION

Definitions

The term “homology” refers to the optimal alignment of sequences (either nucleotides or amino acids), which may be conducted by computerized implementations of algorithms. “Homology”, with regard to polynucleotides, for example, may be determined by analysis with BLASTN version 2.0 using the default parameters. “Homology”, with respect to polypeptides (i.e., amino acids), may be determined using a program, such as BLASTP version 2.2.2 with the default parameters, which aligns the polypeptide or fragments (and can also align nucleotide fragments) being compared and determines the extent of amino acid identity or similarity between them. It will be appreciated that amino acid “homology” includes conservative substitutions, i.e. those that substitute a given amino acid in a polypeptide by another amino acid of similar characteristics. Typically seen as conservative substitutions are the following replacements: replacements of an aliphatic amino acid such as Ala, VaI, Leu and He with another aliphatic amino acid; replacement of a Ser with a Thr or vice versa; replacement of an acidic residue such as Asp or GIu with another acidic residue; replacement of a residue bearing an amide group, such as Asn or GIn, with another residue bearing an amide group; exchange of a basic residue such as Lys or Arg with another basic residue; and replacement of an aromatic residue such as Phe or Tyr with another aromatic residue. For example, homologs can have at least 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%₀ 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81% or 80% overall amino acid or nucleotide identity to the gene or proteins of the invention; or can have 99%. 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%,89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81% or 80% amino acid or nucleotide to the essential protein functional domains of the gene or proteins of the invention; or at least 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81% or 80% overall amino acid or nucleotide to the essential binding amino acids within an essential functional domain of the gene or proteins of the invention.

The above descriptions and methods for sequence homology are intended to be exemplary and it is recognized that this concept is well-understood in the art. Further, it is appreciated that nucleic acid sequences may be varied and still provide a functional enzyme, and such variations are within the scope of the present invention. The term “enzyme homolog” can also mean a functional variant.

The term “Functional homolog” means a polypeptide that is determined to possess an enzymatic activity and specificity of an enzyme of interest but which has an amino acid sequence different from such enzyme of interest. A corresponding “homolog nucleic acid sequence” may be constructed that is determined to encode such an identified enzymatic functional variant.

The term “3-HP” means 3-hydroxypropionic acid.

The term “heterologous DNA,” “heterologous nucleic acid sequence,” and the like as used herein refers to a nucleic acid sequence wherein at least one of the following is true: (a) the sequence of nucleic acids is foreign to (i.e., not naturally found in) a given host microorganism; (b) the sequence may be naturally found in a given host microorganism, but in an unnatural (e.g., greater than expected) amount; or (c) the sequence of nucleic acids comprises two or more subsequences that are not found in the same relationship to each other in nature. For example, regarding instance (c), a heterologous nucleic acid sequence that is recombinantly produced will have two or more sequences from unrelated genes arranged to make a new functional nucleic acid. Embodiments of the present invention may result from introduction of an expression vector into a host microorganism, wherein the expression vector contains a nucleic acid sequence coding for an enzyme that is, or is not, normally found in a host microorganism. With reference to the host microorganism's genome prior to the introduction of the heterologous nucleic acid sequence, then, the nucleic acid sequence that codes for the enzyme is heterologous (whether or not the heterologous nucleic acid sequence is introduced into that genome). The term “heterologous” is intended to include the term “exogenous” as the latter term is generally used in the art as well as “endogenous”.

As used in the specification and the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to an “expression vector” includes a single expression vector as well as a plurality of expression vectors, either the same (e.g., the same operon) or different; reference to “microorganism” includes a single microorganism as well as a plurality of microorganisms; and the like.

I. Introduction

The present invention relates to various genetically modified microorganisms, methods for making the same, and use of the same in making industrial products. Any and all of the microorganisms herein may include a combination of genetic alterations as described herein. The present invention contemplates, for example, a genetically modified microorganism having one or more of the following genetic modifications (i) an alteration that affects the stoichiometric ratio, expression or production of one or more ACCase enzyme genes (ii) a recombinant ACCase gene having at least 80% sequence homology to an ACCase gene from a salt tolerant organism (iii) a genetic alteration in one or more non-ACCase genes (iv) one or more genetic alterations that encodes for one or more exporters capable of exporting 3-HP out of a cell (v) new hybrid molecules or co-expressed of a mono-functional malonyl-CoA reductase enzyme with various 3-HP dehydrogenase proteins that: (a) exhibit less inhibition by high 3-HP concentrations (b) that is less reversible or irreversible (c) enzymes that utilized NADH (d) enzymes that utilized flavin (vi) one or more genetic alterations that can be used to switch the carbon in the standard metabolic pathways of the cells to a pathway engineered to produce a chemical. More details about each of the above modifications and how the modification are used together to increase chemical production in a host cell is described below.

The present invention also relates to methods of fermentation. The genetically modified microorganisms are cultured under conditions that optimized a host cell for increase chemical production. The bio-production process may include two or more of the following phases of fermentation: (1) growth phase where the culture organism replicates itself and the carbon intermediate product is built up; (2) the induction phase, where the expression of key enzymes critical to the chemical production is induced and the enzymes accumulate within the organism to carry out the engineered pathway reactions required to further produce the chemical product (3) production phase is where the organism expresses proteins that provide for continuously production the desired chemical product. The above phases are further controlled by (1) addition and amount of the initiating reactant added to the reaction vessel (2) key enzymes engineered into the organism using promoters that are sensitive to (e.g., activated by) the depletion of the initiating reactant. Addition details about the fermentation process of the invention are disclosed below.

II. Acetyl-CoA Carboxylase

Malonyl-CoA Flux

One of the steps in the biosynthesis of 3-HP involves the reaction catalyzed by acetyl-CoA carboxylase (ACCase) enzyme. ACCase is a primary control point in the 3-HP pathway shown in FIG. 1 (previously described in) for the converting acetyl-CoA to malonyl-CoA and hence to malonate semialdehyde and 3-HP. The present invention contemplates the use of genetic modifications that increase activity of ACCase complex enzymes to thereby increase 3-HP production in a host cell.

Fused Subunits

The acetyl-CoA carboxylase complex (ACCase) is a multi-subunit protein. Prokaryotes and plants have multi-subunit ACCs composed of several polypeptides encoded by distinct genes. However, humans and most other eukaryotes, such as yeast, have evolved an ACC with CT and BC catalytic domains and biotin carboxyl carrier domains on a single polypeptide. The biotin carboxylase (BC) activity, biotin carboxyl carrier protein (BCCP), and carboxyl transferase (CT) activity are each contained on a different subunit. In E. coli the ACCase complex is derived from multi polypeptide transcribed by distinct, separable protein components known as accA, accB, accC, and accD.

Acetyl-CoA carboxylase is a biotin-dependent enzyme that catalyzes the irreversible carboxylation of acetyl-CoA to produce malonyl-CoA through its two catalytic activities, biotin carboxylase (BC) and carboxyltransferase (CT). The first reaction is carried out by BC and involves the ATP-dependent carboxylation of biotin with bicarbonate. The carboxyl group is transferred from biotin to acetyl-CoA to form malonyl-CoA in the second reaction, which is catalyzed by CT. The main function of ACCase complex in the cell is to provide the malonyl-CoA substrate for the biosynthesis of fatty acids.

The conversion of acetyl-CoA to malonyl-CoA is an important step in the bioconversion of a renewable carbon source (such as, for example, sugar or natural gas) to a useful industrial chemical (such as, for example, 3-hydroxypropionic acid (3-HP)). In certain organisms, such as E. coli or yeast, the native ACCase expression from the chromosome alone is insufficient to enable the organism to produce chemicals such as 3-HP at a rate to support a commercial scale operation. Overexpression of the ACCase complex has been shown to provide some advantage [U.S. Ser. No. 12/891,760 U.S. Ser. No. 12/891,790 U.S. Ser. No. 13/055,138].

Applicants have discovered that the introduction of an acetyl-CoA carboxylase gene with one or more of its subunits fused is beneficial to the production of a chemical product in a host cell. In certain aspects of the invention, fusion is the two gene products produced from a single polypeptide controlled by a single promoter, will further enhance an organism's bioproduction of an industrial chemical. In certain aspects of the invention, fusion is the two gene products produced by at least one promoter, will further enhance an organism's bioproduction of an industrial chemical. In certain aspects of the invention, fusion is the two gene products produced from a single polypeptide controlled by at least one inducible promoter, will further enhance an organism's bioproduction of an industrial chemical. Keeping components of the ACCase complex fused together in the genetic structure of an organism can be advantageous because it enhances the stability of the non-native ACCase genetic modification and it facilitates equimolar expression of the fused acc subunits.

In particular, the subunit-fused ACCase may be an accA-accB, accA-accC, accA-accD, accB-accC, accB-accD, accC-accD, accA-accB-accC, accA-accB-accD, accA-accC-accD, accB-accC-accD or accA-accB-accC-accD fused subunit that have having at least 80% sequence homology to E. coli accA, accB, accC and accD or is a functional homolog thereof. In addition, the organism may include any combination of these fused subunits, or any combination of these fused subunits together with one or more of the four non-fused subunits. When such combinations are used, the subunits (fused and non-fused) may be expressed on the same plasmid or on different plasmids or on the chromosome of the organism.

In accordance with a preferred embodiment, an accA-accD fused subunit is introduced into an organism either alone or in combination with the accB-accC fused subunit, the accB gene, and/or the accC gene. In accordance with a preferred embodiment, the organism is a bacteria, and preferably E. coli or Cupriavidus necator.

Composition Stoichiometry

Composition stoichiometry is the quantitative relationships among elements that comprise a compound. A stoichiometric ratio of a reagent is the optimum amount or ratio where, assuming that the reaction proceeds to completion. Although stoichiometric terms are traditionally reserved for chemical compounds, theses theoretical consideration of stoichiometry are relevant when considering the optimal function of heterologous multi-subunit protein in a host cell.

In accordance with another aspect of the invention, the stoichiometric ratio of each of the four ACCase subunits relative to one another is important, and each such ratio can be between 0 and about 10, and preferably between about 0.5 to about 2 or about 7 to about 9. In accordance with a preferred embodiment the ratios for the protein subunits are accA:accB:accC:accD are 1:2:1:1. In accordance with a preferred embodiment, an organism is genetically modified to include an accA-accD fused subunit, an accB non-fused subunit, and an accC non-fused subunit, with the molar ratios of the accDA fusion:accB:accC being about 1:2:1, which is close to the optimum for enzymatic activity.

In certain embodiments where an organism is engineered to make 3-HP, order to get optimal function in a host cell of a heterologous ACCase enzyme complex it is important to engineer the stoichiometry of these subunits in such a way that provides maximal production of 3-HP such that the subunit can make a more stable enzyme complex when overexpressed in the cell.

In certain aspects the invention provides for the controlled expression of the natural accA, accB, accC, and accD subunits of E. coli or having at least 80% sequence homology to E.coli accA, accB, accC and accD. In certain aspects the invention provides for the inducible expression of the natural accA, accB, accC, and accD subunits of E. coli or having at least 80% sequence homology to E. coli accA, accB, accC, and accD. In certain aspects the invention provides for the low, medium, high and/or inducible expression of the natural accA, accB, accC, and accD subunits of E. coli or having at least 80% sequence homology to E. coli accA, accB, accC and accD.

In certain aspects the invention provides for the expression of the natural accC and accD subunits of E. coli or having at least 80% sequence homology to E. coli accA, accB, accC and accD in low, medium, high or inducible expression. In certain aspects the invention provides for the expression of the natural accB and accA subunits of E. coli or having at least 80% sequence homology to E. coli accA, accB, accC, and accD in low, medium, high or inducible expression. In certain aspects the invention provides for the expression of the natural accC and accD subunits with the accA subunit of E. coli or having at least 80% sequence homology to E. coli accA, accB, accC, and accD in low, medium, high or inducible expression. In certain aspects the invention provides for the expression of the natural accC and accD subunits with the accB subunit of E. coli or having at least 80% sequence homology to E. coli accA, accB, accC, and accD in low, medium, high or inducible expression.

In certain aspects the invention provides for the expression of a fusion of two, three, or all of the four ACCase subunits in one polypeptide in low, medium, high or inducible expression. Such fusion may include any of the following combinations of the ACCase subunits: accA-accB, accA-accC, accA-accD, accB-accC, accB-accD, accC-accD, accA-accB-accC, accA-accB-accD, accA-accC-accD, accB-accC-accD, and accA-accB-accC-accD have having at least 80% sequence homology to E. coli accA, accB, accC and accD or is a functional homolog thereof.

In certain aspects the invention provides for ACC complex in the stoichiometry of these subunits of the accCB and accDA in a 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 2:1, 2:3, 2:4, 2:5, 2:6, 2:7, 2:8, 3:1, 3:3, 3:4, 3:5, 3:6, 3:7, 3:8, 3:1, 3:3, 3:4, 3:5, 3:6, 3:7, 3:8, 4:1, 4:3, 4:4, 4:5, 4:6, 4:7, 4:8, 5:1, 5:3, 5:4, 5:5, 5:6, 5:7, 5:8, 6:1, 6:3, 6:4, 6:5, 6:6, 6:7, 6:8, 7:1, 7:3, 7:4, 7:5, 7:6, 7:7, 7:8, 8:1, 8:3, 8:4, 8:5, 8:6, 8:7, or 8:8 in low, medium, high or inducible expression. In certain aspects the invention provides for ACC complex in the stoichiometry of these subunits of the accDA and accCB in a 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 2:1, 2:3, 2:4, 2:5, 2:6, 2:7, 2:8, 3:1, 3:3, 3:4, 3:5, 3:6, 3:7, 3:8, 3:1, 3:3, 3:4, 3:5, 3:6, 3:7, 3:8, 4:1, 4:3, 4:4, 4:5, 4:6, 4:7, 4:8, 5:1, 5:3, 5:4, 5:5, 5:6, 5:7, 5:8, 6:1, 6:3, 6:4, 6:5, 6:6, 6:7, 6:8, 7:1, 7:3, 7:4, 7:5, 7:6, 7:7, 7:8, 8:1, 8:3, 8:4, 8:5, 8:6, 8:7, or 8:8 in low, medium, high or inducible expression.

In certain aspects the invention provides for the stoichiometry of the accD-A subunits in a 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 2:1, 2:3, 2:4, 2:5, 2:6, 2:7, 2:8, 3:1, 3:3, 3:4, 3:5, 3:6, 3:7, 3:8, 3:1, 3:3, 3:4, 3:5, 3:6, 3:7, 3:8, 4:1, 4:3, 4:4, 4:5, 4:6, 4:7, 4:8, 5:1, 5:3, 5:4, 5:5, 5:6, 5:7, 5:8, 6:1, 6:3, 6:4, 6:5, 6:6, 6:7, 6:8, 7:1, 7:3, 7:4, 7:5, 7:6, 7:7, 7:8, 8:1, 8:3, 8:4, 8:5, 8:6, 8:7, or 8:8 in low, medium, high or inducible expression. In certain aspects the invention provides for the stoichiometry of the accC-B subunits in a 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 2:1, 2:3, 2:4, 2:5, 2:6, 2:7, 2:8, 3:1, 3:3, 3:4, 3:5, 3:6, 3:7, 3:8, 3:1, 3:3, 3:4, 3:5, 3:6, 3:7, 3:8, 4:1, 4:3, 4:4, 4:5, 4:6, 4:7, 4:8, 5:1, 5:3, 5:4, 5:5, 5:6, 5:7, 5:8, 6:1, 6:3, 6:4, 6:5, 6:6, 6:7, 6:8, 7:1, 7:3, 7:4, 7:5, 7:6, 7:7, 7:8, 8:1, 8:3, 8:4, 8:5, 8:6, 8:7, or 8:8 in low, medium, high or inducible expression. In certain aspects the invention provides for the stoichiometry of the accC-A subunits in a 1:1., 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 2:1, 2:3, 2:4, 2:5, 2:6, 2:7, 2:8, 3:1, 3:3, 3:4, 3:5, 3:6, 3:7, 3:8, 3:1, 3:3, 3:4, 3:5, 3:6, 3:7, 3:8, 4:1, 4:3, 4:4, 4:5, 4:6, 4:7, 4:8, 5:1, 5:3, 5:4, 5:5, 5:6, 5:7, 5:8, 6:1, 6:3, 6:4, 6:5, 6:6, 6:7, 6:8, 7:1, 7:3, 7:4, 7:5, 7:6, 7:7, 7:8, 8:1, 8:3, 8:4, 8:5, 8:6, 8:7, or 8:8 in low, medium, high or inducible expression. In certain aspects the invention provides for the stoichiometry of the accC-B subunits in a 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 2:1, 2:3, 2:4, 2:5, 2:6, 2:7, 2:8, 3:1, 3:3, 3:4, 3:5, 3:6, 3:7, 3:8, 3:1, 3:3, 3:4, 3:5, 3:6, 3:7, 3:8, 4:1, 4:3, 4:4, 4:5, 4:6, 4:7, 4:8, 5:1, 5:3, 5:4, 5:5, 5:6, 5:7, 5:8, 6:1, 6:3, 6:4, 6:5, 6:6, 6:7, 6:8, 7:1, 7:3, 7:4, 7:5, 7:6, 7:7, 7:8, 8:1, 8:3, 8:4, 8:5, 8:6, 8:7, or 8:8 in low, medium, high or inducible expression.

III. Conversion of Malonyl-CoA to Malonate Semialdehyde

One of the steps in the biosynthesis of 3-HP involves the conversion of malonyl-CoA (MCA) to malonate semialdehyde (MSA) and the conversion of malonate semialdehyde (MSA) to 3-HP (WO2011/038364). In accordance with another aspect of the present invention, the present invention contemplates the use of novel enzymes and/or combinations of enzymes to catalyze the reaction in a microorganism from MCA to MSA, which results in enhanced cellular bioproduction of 3-HP in the host cell.

In certain aspects the invention provides novel enzyme compositions or co-expression of a combinations of enzyme compositions to catalyze the conversion of malonyl-CoA to 3-HP. A general overview of the enzymes and the relevant reaction pathways methods are shown in FIG. 1.

In accordance with this aspect of the invention, malonyl-CoA is converted to malonate semialdehyde by a malonyl-CoA reductase and malonate semialdehyde is converted to 3-HP through either or both of two alternative pathways.

In accordance with one aspect of the invention, malonyl-CoA is converted to malonate semialdehyde by a monofunctional malonyl-CoA reductase that catalyzes the malonyl-CoA conversion, but does not catalyze the malonate semialdehyde conversion.

In one embodiment, the microorganism herein comprise a genetic modification that include the monofunctional malonyl-CoA reductase may be derived from Sulfolobus tokodaii (stMCR) (SEQ ID NO. 15 nucleic acid, SEQ ID NO. 16 protein sequence) or a functional homolog of stMCR or a homolog with at least 80% identity.

In some embodiments, the microorganism herein comprise a genetic modification that include the bi-functional malonyl-CoA reductase comprised of two protein fragments with one fragment having malonyl-CoA reductase activity and the other fragment having malonate semialdehyde dehydrogenase activity may be derived from Chloroflexus aurantiacus (caMCR).

MCR-Dehydrogenase Enzymes for Conversion of 3-HP Ions

Following the conversion of the malonyl-CoA to malonate semialdehyde, the malonate semialdehyde is converted to 3-HP through either or both of two alternative pathways. Malonate semialdehyde may exist in at least three states; the keto form, the enol form, and hydrate form, as shown in FIG. 2. Malonate semialdehyde in the enol form, which will stabilize this form when compared to other aldehydes where the enol form is highly unfavored in the equilibrium among the three forms.

The malonate semialdehyde keto form is converted to 3-HP utilizing a 3-hydroxy acid dehydrogenase enzyme (ydfG SEQ ID NO. 21 nucleic acid, SEQ ID NO. 22 protein), a 3-hydroxyisobutyrate dehydrogenase enzyme (Pseudomonas aeruginosa mmsB, SEQ ID No. 23 nucleic acid, SEQ ID NO. 24 protein), and/or NAD+-dependent serine dehydrogenase (Pseudomonas NDSD, SEQ ID NO. 25 nucleic acid, SEQ ID NO. 26 protein). In accordance with a preferred embodiment, Pseudomonas mmsB, Pseudomonas NDSD, and E. coli ydfG are used. The gene, ydfG from E. coli is largely NADPH dependent, whereas mmsB and NDSD from Pseudomonas can utilize either NADPH or NADH.

The malonate semialdehyde enol form is converted to 3-HP utilizing an N-ethylmaleimide reductase (nemA, SEQ ID NO. 17 nucleic acid, SEQ ID NO. 18 protein), and/or a malonic semialdehyde reductase (rutE, SEQ ID NO. 19 nucleic acid, SEQ ID NO. 20 protein) from E. coli. These enzymes does not directly utilize NADPH or NADH. Instead, these enzymes utilize a flavin mononucleotide that is cycled between oxidized and reduced states by NADPH or NADH. The enol pathway also has advantages over the keto pathway in that equilibrium between the malonate semialdehyde enol form and 3-HP significantly favors 3-HP, making the reaction much less reversible, and essentially irreversible.

The malonate semialdehyde hydrated form may also be converted to 3-HP by either the 3-HP dehydrogenase or malonate semialdehyde reductase enzymes, although the hydrated form is more likely to be converted to the enol form as the equilibrium continuously readjusts.

In one embodiment, the microorganism herein comprise a genetic modification that include (i.e., microorganism) includes a polynucleotide encoding: (1) a monofunctional malonyl-CoA reductase gene capable of catalyzing the conversion of malonyl-CoA to malonate semialdehyde; and (2) one or more genes encoding one or more of the following enzymes: ydfG, mmsB, NDSD, rutE, and nemA or a functional homolog or a homolog with at least 80% identity.

In accordance with another aspect of the invention, there is provided an organism that is genetically modified to make 3-HP, wherein the genetic modification includes a polynucleotide encoding: (1) a monofunctional malonyl-CoA reductase gene capable of catalyzing the conversion of malonyl-CoA to malonate semialdehyde; (2) one or more genes encoding one or more enzymes capable of converting malonate semialdehyde keto form to 3-HP; and (3) one or more genes encoding one or more enzymes capable of converting either e malonate semialdehyde enol form or the malonate semialdehyde hydrated form to 3-HP.

In certain aspects the invention provides monofunctional malonyl-CoA reductase enzyme fused to a dehydrogenase enzyme that is either: (1) primarily not NADPH-dependent; (2) primarily NADH-dependent; (3) primarily flavin-dependent; (4) less susceptible to 3-HP inhibition at high concentration; and/or (5) catalyzes a reaction pathway to 3-HP that is substantially irreversible.

In certain aspects the invention also provides monofunctional malonyl-CoA reductase enzyme fused to a dehydrogenase enzyme that is NADPH-dependent.

Suitable 3-HP dehydrogenase enzymes that are largely NADH-dependent that can be used with the claimed invention include, but are not limited to, mmsB or NDSD. Suitable malonate reductase enzymes that are flavin-dependent include, but are not limited to, rutE and nemA. Suitable 3-HP dehydrogenase enzymes that are less susceptible 3-HP inhibition at high concentration that can be used with the claimed invention include, but are not limited to, ydfG and NDSD. Suitable 3-HP dehydrogenase or malonate semialdehyde dehydrogenase enzymes that catalyze a reaction pathway to 3-HP that is substantially irreversible are rutE and nemA.

In certain aspects the invention provides monofunctional malonyl-CoA reductase enzyme fused to one or more dehydrogenase enzymes. Malonate semialdehyde, which is the intermediate product in the conversion of malonyl-CoA to 3-HP can be very reactive. Therefore, it is advantageous to have a reaction pathway wherein the residence time of malonate semialdehyde within the cell is minimized, and its conversion to 3-HP occurs quickly. By fusing the malonyl-CoA reductase with the malonate semialdehyde dehydrogenase to create a multi-domain protein (e.g., two domain protein) and having the MCR and dehydrogenase domains adjacent in the sequence, when the themalonate semialdehyde is quickly is quickly converted to 3-HP.

In certain aspects the invention provides first monofunctional malonyl-CoA reductase enzyme fused to a first dehydrogenase enzyme of one type and second monofunctional malonyl-CoA reductase enzyme fused to a dehydrogenase enzyme of a different type than the first dehydrogenase enzyme. Suitable different dehydrogenase enzymes include, but are not limited to, enzymes that function on the different forms of malonate semialdehyde.

In certain aspects the invention provides for microorganisms comprising a genetic modification that include but are not limited to the malonyl-CoA reductase from S. tokadaii is fused to ydfG, mmsB, NDSD, rutE, or nemA (or some combination thereof). The fused enzyme may include any of the following configurations: mcr-ydfG, mcr-mmsB, mcr-NDSD, mcr-rutE, mcr-nemA, mcr-ydfG-mmsB, mcr-ydfG-NDSD, mcr-ydfG-rutE, mcr-ydfG-nemA, mcr-mmsB-ydfG, mcr-mmsB-NDSD, mcr-mmsB-rutE, mcr-mmsB-nemA, mcr-NDSD-ydfG, mcr-NDSD-mmsB, mcr-NDSD-rutE, mcr-NDSD-nemA, mcr-rutE-ydfG, mcr-rutE-mmsB, mcr-rutE-NDSD, mcr-rutE-nemA, mcr-nemA-ydfG, mcr-nemA-mmsB, mcr-nemA-NDSD, or mcr-nemA-rutE or functional homolog or homolog with 80% sequence identity thereof.

In certain aspects the invention provides for microorganisms comprising a genetic modification that include but are not limited to the malonyl-CoA reductase from C. aggregans is fused to ydfG, mmsB, NDSD, rutE, or nemA (or some combination thereof). The fused enzyme may include any of the following configurations: mcr-ydfG, mcr-mmsB, mcr-NDSD, mcr-rutE, mcr-nemA, mcr-ydfG-mmsB, mcr-ydfG-NDSD, mcr-ydfG-rutE, mcr-ydfG-nemA, mcr-mmsB-ydfG, mcr-mmsB-NDSD, mcr-mmsB-rutE, mcr-mmsB-nemA, mcr-NDSD-ydfG, mcr-NDSD-mmsB, mcr-NDSD-rutE, mcr-NDSD-nemA, mcr-rutE-ydfG, mcr-rutE-mmsB, mcr-rutE-NDSD, mcr-rutE-nemA, mcr-nemA-ydfG, mcr-nemA-mmsB, mer-nemA-NDSD, or mcr-nemA-rutE or functional homolog or homolog with 80% sequence identity thereof.

In certain aspects the invention provides for microorganisms comprising a genetic modification that include but are not limited to the malonyl-CoA reductase from O. trichoides is fused to ydRi, mmsB, NDSD, rutE, or nemA (or some combination thereof). The fused enzyme may include but are not limited to any of the following configurations: mcr-ydfG, mcr-mmsB, mcr-NDSD, mcr-rutE, mcr-nemA, mcr-ydfG-mmsB, mcr-ydfG-NDSD, mcr-ydfG-rutE, mcr-ydfG-nemA, mcr-mmsB-ydfG, mcr-mmsB-NDSD, mcr-mmsB-rutE, mcr-mmsB-nemA, mcr-NDSD-ydfG, mcr-NDSD-mmsB, mcr-NDSD-rutE, mcr-NDSD-nemA, mcr-rutE-ydfG, mcr-rutE-mmsB, mcr-rutE-NDSD, mcr-rutE-nemA, mcr-nemA-ydfG, mcr-nemA-mmsB, mcr-nemA-NDSD, or mcr-nemA-rutE or functional homolog or homolog with 80% sequence identity thereof.

Enhanced Mutated Monofunctional MCR for Bioproduction

In certain aspects the invention provides for microorganisms comprising a genetic modification that include mutated form of stMCR that has enhanced activity at about 20° C. to about 44° C., about 30° C. to about 37° C., or about 32° C. to about 38° C. Such mutate forms may be designed based on the crystal structure now available for stMCR [Demmer et al., J. Biol. Chem. 288: 6363-6370, 2013].

It is also contemplated the carboxylase domains of the malonyl-CoA reductase derived from Chloroflexus aggregans, Oscillochloris trichoides can be enhanced by mutations in the carboxylase binding domain to provide increased 3-HP production over the natural occurring enzyme.

The carboxylase activity of the malonyl-CoA reductase derived from Chloroflexus aurantiacus can be enhanced activity. In certain aspects the invention provides for mutated form of it carboxylase domain to provide increased 3-HP production over the natural occurring enzyme.

In certain aspects the invention provides for microorganisms comprising a genetic modification that include carboxylase domains of the malonyl-CoA reductase derived from C. aggregans is fused to ydfG, mmsB, NDSD, rutE, or nemA (or some combination thereof). It is contemplated that the any of the enhanced MCR by mutation, as provide above, may be fused in any of the following configurations including but not limited to mcr-ydfG, mcr-mmsB, mcr-NDSD, mcr-rutE, mcr-nemA, mcr-ydfG-mmsB, mcr-ydfG-NDSD, mcr-ydfG-rutE, mcr-ydfG-nemA, mcr-mmsB-ydfG, mcr-mmsB-NDSD, mcr-mmsB-rutE, mcr-mmsB-nemA, mcr-NDSD-ydfG, mcr-NDSD-mmsB, mcr-NDSD-rutE, mcr-NDSD-nemA, mcr-rutE-ydfG, mcr-rutE-mmsB, mcr-rutE-NDSD, mcr-rutE-nemA, mcr-nemA-ydfG, mcr-nemA-mmsB, mcr-nemA-NDSD, or mcr-nemA-rutE or functional homolog or homolog with 80% sequence identity thereof.

IV. Salt-Tolerant Enzymes

The growth of engineered microorganism for enhanced production of a chemical product, such as E. coli is severely inhibited by high salt concentrations accumulated when the chemical product is produced at high rate within the organism.

Dose-dependent studies with increasing amounts of NaCl and Na-3-HP show that salt has inhibitory effects on ACCase activity which is essential to fatty acid biosynthesis of membranes required for growth and propagation and for the production of 3-HP (see EXAMPLE 1). Thus, the use of salt-tolerant enzymes in 3-HP production should increase 3-HP production in a host cell.

A. Enzymes from Halophilic Organisms

Halophiles are characterized as organisms with a great affinity for salt. In some instances a halophilic organism is one that requires at least 0.05M, 0.1M, 0.2M, 0.3M or 0.4M concentrations of salt (NaCl) for growth. Halophiles live in hypersaline environments that are generally defined occurring to their salt concentration of their habitats. Halophilic organisms that are defined as “Slight salt affinity” have optimal growth at 2-5% NaCl, moderate halophiles have optimal growth at 5-20% NaCl and extreme halophiles have optimal growth at 20-30% NaCl.

Depending on the conditions of that the genetically engineered microorganism is under one might use homologous enzymes of the invention specifically, for example, from a moderate halophiles or an extreme halophiles depending on the engineered cell's environment.

In certain aspects the invention provides for microorganisms comprising a genetic modification that includes enzymes of the invention provided herein from slight halophiles organisms. In certain aspects the invention provides for microorganisms comprising a genetic modification that includes enzymes of the invention provided herein from moderate halophiles organisms. In certain aspects the invention provides for microorganisms comprising a genetic modification that includes homologous enzymes of the invention provided herein from extreme halophiles organisms.

Homology with genes provided by the invention may be determined by analysis with BLASTN version 2.0 provided through the NCBI website. Homology with proteins provided by the invention may be determined by analysis with BLASTP version 2.2.2 provided through the NCBI website. This program with aligns the disclosed fragments being compared and determines the extent of identity or similarity between them.

To date there are many sequenced halophilic organisms which can be used with the claimed invention. Examples of some sequenced halophilic organisms include but are not limited to Chromohalobacter salexigens, Flexistipes sinusarabici Strain (MASLOT), Halobacterium sp. NRC-1, Haloarcula marismortui, Natronomonas pharaonis, Haloquadratum walsbyi, Haloferax volcanii, Halorubrum lacusprofundi, Halobacterium sp. R-1, Halomicrobium mukohataei, Halorhabdus utahensis, Halogeometricum borinquense, Haloterrigena turkmenica, Natronobacterium gregoryi SP2, Halalkalicoccus jeotgali, Natrialba magadii, Haloarcula hispanica, Halopiger xanaduensis, Halophilic archaeon DL31, Haloferax mediterranei, Halovivax ruber, Natronococcus gregoryi, and Natronococcus occultus.

Examples of suitable moderate halophilic organisms in which homologous enzymes of the invention can be derived from include but are not limited to eukaryotes such as crustaceans (e.g. Artemia salina), insects (e.g. Ephydra hians), certain plants from the genera Salicornia spp, algae (e.g. Dunaliella viridis), fungi, and protozoa (e.g. Fabrea salina), phototrophic organisms, such as planktonic and microbial mat-formers cyanobacteria as well as other anaerobic red and green sulphur bacteria from the genera Ectothiorhodospira spp.) and non-sulphur bacteria from the genera Chromatium spp.; gram-negative anaerobic bacteria, for example from the genera Haloanaerobacter spp. some of which are methanogenic, for example from the genera Methanohalophilus spp. and either aerobic or facultative such as species from the genera Halomonas, Chromohalobacter, Salinovibrio, Pseudomonas, for example (e.g. Halomonase elongate); gram-positive bacteria from genera such as Halobacillus, Bacillus, Marinococcus, etc. as well as some actinomycetes, for example, Actinopolyspora halophila.

Genomic and Proteomic Hallmarks of Halophilic Organisms

Comparative genomic and proteomic studies of halophiles and non-halophiles reveal some common trends in the genomes and proteomes of halophiles. At the protein level, halophilic organisms are characterized by low hydrophobicity, over-representation of acidic residues, especially Asp, under-representation of Cys, lower propensities for helix formation and higher propensities for coil structure.

At the DNA level, halophilic organisms are characterized by the dinucleotide abundance profiles of halophilic genomes bear some common characteristics, which are quite distinct from those of non-halophiles, and hence may be regarded as specific genomic signatures for salt-adaptation. The synonymous codon usage in halophiles also exhibits similar patterns regardless of their long-term evolutionary history.

In certain aspects the invention provides for microorganisms comprising a genetic modification that the proteins provided by the invention that are modified for salt tolerance such that they has low hydrophobicity, over-representation of acidic residues, especially Asp, under-representation of Cys, lower propensities for helix formation and higher propensities for coil structure.

Suitable salt-tolerant enzymes can include enzymes from salt-tolerant organisms. Salt-tolerant organisms (such as, for example, halophiles) include any living organism that are adapted to living in conditions of high salinity. Suitable salt-tolerant enzymes can include enzymes from salt-tolerant organism that are homologs of the following enzymes: Sucrose-6-phosphate hydrolase (cscA from E. coli), glucose-6-phosphate isomerase (pgi from E. coli), fructokinase (cscK from E. coli), fructose-1,6-bisphosphatase (yggF from E. coli), fructose 1,6-bisphosphatase (ybhA from E. coli), fructose 1,6-bisphosphatase II (glpX from E. coli), fructose-1,6-bisphosphatase monomer (fbp from E. coli), 6-phosphofructokinase-1 monomer (pfkA from E. coli), 6-phosphofructokinase-2 monomer (pfkB from E. coli), fructose bisphosphate aldolase monomer (fbaB from E. coli), fructose bisphosphate aldolase monomer (fbaA from E. coli), triose phosphate isomerase monomer (tpiA), glyceraldehyde 3-phosphate dehydrogenase-A monomer (gapA from E. coli), phosphoglycerate kinase (pgk), 2,3-bisphosphoglycerate-independent phosphoglycerate mutase (gpmM from E. coli), 2,3-bisphosphoglycerate-dependent or tdcE (from E. coli), phosphoglycerate mutase (gpmA), enolase (eno from E. coli), phosphoenolpyruvate carboxylase (ppc from E. coli), malate dehydrogenase (mdh), fumarase A (fum from E. coli), fumarase B (fumB), fumarase C (fumC from E. coli), phosphoenolpyruvate synthetase (ppsA from E. coli), pyruvate kinase I monomer (pykF from E. coli), pyruvate kinase II monomer (pykA from E. coli), fumarate reductase (frdABCD from E. coli), lipoamide dehydrogenase (lpd from E. coli), pyruvate dehydrogenase (aceE from E. coli), pyruvate dehydrogenase (aceF from E. coli), pyruvate formate-lyase (pflB from E. coli), acetyl-CoA carboxylase (accABCD from E. coli), malonyl CoA reductase (mcr), 3HP dehydrogenase (mmsB, NDSD, or ydfG), malonate semialdehyde reductase (nemA, rutE from E. coli), or a combination thereof.

Suitable salt-tolerant enzyme homologs that can be used with the claimed invention can have at least 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%,90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81% or 80%, overall amino acid or nucleotide identity to the above enzymes. Suitable salt-tolerant enzyme homologs that can be used with the claimed invention can have at least 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81% or 80%, amino acid or nucleotide to the essential protein function domains of the enzymes above. Suitable salt-tolerant enzyme homologs that can be used with the claimed invention can have at least 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81% or 80% overall amino acid or nucleotide to the essential binding amino acids within an essential protein function domain of the enzymes above.

In accordance with a preferred embodiment of the invention, suitable salt-tolerant enzyme homologs are enzymes from one of the following organisms: Halomonas elongata, Salinibacter rubur, or Halobacterium species (Archaea).

In accordance with a preferred embodiment of the present invention, there is provided a non-salt-tolerant organism that is genetically modified to make 3-HP, wherein the genetic modification includes a polynucleotide encoding an acetyl-CoA carboxylase from a salt-tolerant organism. In accordance with a preferred embodiment, the acetyl-CoA carboxylase subunits accA, accB, accC and accD is from Halomonas elongata.

V. Chemical Transporter

In accordance with another aspect of the present invention, any of the microorganisms herein may be genetically modified to introduce a nucleic acid sequence coding for a polypeptide that: (1) facilitates the exportation of the chemical of interest or the export of an inhibitory chemical from within the cell to the extracellular media; and/or (2) facilitates the importation from the extracellular media to within the cell of a reactant, precursor, and/or metabolite used in the organism's production pathway for producing the chemical of interest.

3-HP Exporter

In accordance with a preferred embodiment, this invention relates to the bioproduction of 3-HP using a genetically modified E. coli organism. Thus, the present invention contemplates of a host cell genetically modified to express or increase expression of an exporter that can function to transfer 3HP from the cellular environment extracellularly.

Bacterial cells, such as E. coli, have at least five different types of exporters: the major facilitator superfamily MFS); the ATP-binding cassette superfamily (ABC); the small multidrug resistance family (SMR); the resistance-nodulation-cell division superfamily (RND); and the multi antimicrobial extrusion protein family (MATE). In addition, amino acid exporters, which are common to almost all host cells, are likely to export 3-HP. Additionally, solvent tolerance transporters, for example bromoacetate, butanol, isobutanol and the alike may be used to export 3-HP.

In certain aspects the invention provides a host cell with a recombinant exporter wherein the exporter is an MFS exporter, ABC exporter, SMR exporter, RND exporter, MATE exporter, amino acid exporter, solvent tolerance transporter or a combination thereof.

Suitable exporters that can be used with the s herein invention include but are not limited to acrD, bcr, cusA, dedA, eamA, eamB, eamH, emaA, emaB, emrB, emrD, emrKY, emrY, garP, gudP, hsrA, leuE, mdlB, mdtD, mdtG, mdtL, mdtM, mhpT, rhtA, rhtB, rhtC, thtB, yahN, yajR, ybbP, ybiF, ybjJ, ycaP, ydcO, yddG, ydeD, ydgE, yddG, ydhC, ydhP, ydiN, ydiM, ydjE, ydjI, ydjK, yeaS, yedA, yeeO, yegH, yggA, yfcJ, yfiK, yhjE, yidE, yigK, yigJ, yijE, yjiI, yjiJ, ypjD, ytfF ytifL or functional homolog or homolog with 80% sequence identity thereof. Other potential transporter proteins may be identified using topology analysis as illustrated in [Daley et al., Science 308: 1321-1323, 2005].

In certain aspects the invention provides the exporter to be improved for binding to 3-HP. In certain aspects the invention provides the exporters named to be further enhance by genetic modification of the predicted cytoplasmic domain to increase 3-HP binding. In certain aspects the invention provides the exporter to be improved for binding to 3-HP. In certain aspects the invention provides the exporters named to be further enhance by genetic modification of the predicted transmembrane binding domain to increase 3-HP binding or incorporation into the host cell membrane.

Suitable exporter homologs that can be used with the claimed invention can have at least 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81% or 80% overall amino acid or nucleotide identity to the above exporters. Suitable exporter homologs that can be used with the claimed invention can have 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90% ,89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81% or 80% amino acid or nucleotide to the essential protein function domains of the exporters above. Suitable exporter homologs that can be used with the claimed invention can have at least 99%, 98%, 97%, 96%, 95%, 94%, 93%, 92%, 91%, 90%, 89%, 88%, 87%, 86%, 85%, 84%, 83%, 82%, 81% or 80% overall amino acid or nucleotide to the essential binding amino acids within an essential exporter domain of the enzymes above.

In certain aspects the invention provides for at least of the exporters provided herein to be expressed in a host cell to increase the chemical production of 3-HP in a host cell. In certain aspects the invention provides for at least of the exporters provided herein to be expressed in a host cell and with a genetic modification of tig to increase the chemical production of 3-HP in a host -cell.

In certain aspects the invention provides for one exporter to be further modified by on one more genetic modulates so that the expression level and timing of expression of the exporter can be controlled in the host cell. In certain aspects the invention provides for one exporter to be further modified by an inducible promoter, RBS, high, mutlicopy plasmid or combination thereof, as provide herein, in order to control its expression in the host cell.

In certain aspects the invention provides exporters provide herein to be expressed in a host cell in equal ratio. In certain aspects the invention provides exporters provide herein to be expressed in a host cell in equal 1:2 ratio. In certain aspects the invention. provides exporters provide herein to be expressed in a host cell in equal 1:3 ratio. In certain aspects the invention provides exporters provide herein to be expressed in a host cell in equal 1:4 ratio. In certain aspects the invention provides exporters provide herein to be expressed in a host cell in equal 2:3 ratio.

In certain aspects the invention provides for the exporter to maintain the host cell at pH 7.0-7.4 during the continuous production phase. In certain aspects the invention provides for the exporter and the means for importing a base inside the cell in order to maintain the host cell at pH 7.0-7.4 during the continuous production phase. In certain aspects the invention provides for the exporter maintain the host cell at pH 3.0 to pH 4.0, pH 4.0 to pH 5.0, pH 5.0 to pH 6.0, pH 6.0 to pH 7.0, pH 7.0 to pH 8.0, pH 8.0 to pH 9.0, or pH 9.0 to pH 10.0 pH 7.0-7.3 during the continuous production phase. In certain aspects the invention provides for the exporter and the means for importing abase inside the cell in order to maintain the host cell at pH 3.0 to pH 4.0, pH 4.0 to pH 5.0, pH 5.0 to pH 6.0, pH 6.0 to pH 7.0, pH 7.0 to pH 8.0, pH 8.0 to pH 9.0, or pH 9.0 to pH 10.0 pH 7.0-7.3 during the continuous production phase.

In accordance with this aspect of the present invention, addition modifications to the host cell may be made to further enhance the transporter's function. In particular, deletion of the tig gene from the genome of the host cell may enhance expression and total activity of integral membrane proteins such as exporters and importers.

Bicarbonate Importer

One of the key steps in the conversion of biomass to 3-HP is the conversion of acetyl-CoA to malonyl-CoA, which is illustrated in FIG. 3.

As shown in FIG. 3, this reaction is catalyzed by the acetyl-CoA carboxylase, and bicarbonate is a reactant needed to drive the reaction. One of the primary sources of bicarbonate to drive this reaction is carbon dioxide within the cell. Carbon dioxide is readily diffusible through a cell's membrane, and a natural equilibrium will be reached between the intracellular and extracellular carbon dioxide. As a cell produces carbon dioxide it migrates through the cell, and since it is not very soluble in the media, it will bubble out of the system and more intracellular carbon dioxide will migrate out of the cell to maintain the equilibrium. This process impedes the production of 3-HP since bicarbonate (which is in equilibrium with the dissolved carbon dioxide in the form of carbonic acid) is needed to drive the acetyl-CoA→malonyl-CoA reaction, and the intracellular carbon dioxide is the primary source for intracellular bicarbonate.

In accordance with one aspect of the present invention, an organism is provided that includes a heterologous gene encoded therein that acts as a carbon dioxide importer (i.e., it enhances the importation of carbon dioxide into the cell or inhibits the exportation of carbon dioxide from the cell), which results in increased intracellular carbon dioxide. Use of CO2an importer mitigates against the natural outflow of carbon dioxide.

In accordance with this aspect of the invention, there is provided an organism that is genetically modified, wherein the genetic modification includes a polynucleotide encoding a gene capable of importing extracellular carbon dioxide from the media to within the cell membrane or inhibiting the exportation of intracellular carbon dioxide from within the cell membrane to the media. In accordance with a preferred embodiment of the present invention, a microorganism is genetically modified to encode one or more of the following heterologous genes: bicA from Synechococcus species, ychM gene product of E. coli, yidE gene product of E. coli, any of the bicarbonate transporters as described in [Pelee and Saier, J. Mol. Microbiol. Biotechnol. 8: 169-176, 2004 or any amino acid sequences homologous thereof (e.g., at least 80%, 85%, 90%, 95%, or 99% homologous to the amino acids sequences of the CO2 importer/exporters described herein].

Bioproduction Methods

In some applications of the invention the host cell is genetically modified for increased malonyl-CoA flux by at least one heterologous ACCase complex, such as Table 4 to further increase chemical bio-production in host cell. In some applications of the invention the host cell is genetically modified with heterologous salt tolerant enzymes, such as Table 5 to increase chemical bio-production in a host cell. In some applications of the invention the host cell is genetically modified with heterologous 3-HP exporters to further increase chemical bio-production in a host cell.

In some applications of the invention the host cell is genetically modified by at least one heterologous gene and/or salt tolerant heterologous gene of FIG. 1 or Table 5 and at least one 3-HP exporter provided herein to further increase chemical bioproduction in a host cell.

In some applications of the invention the host cell is genetically modified with a heterologous gene for increased malonyl-CoA flux, 3-HP export, at least one heterologous and/or salt tolerant heterologous gene, as provided herein, to increase chemical bio-production in a host cell. In some applications of the invention the host cell is genetically modified for increased malonyl-CoA flux, 3-HP export, at least one heterologous gene and/or salt tolerant heterologous gene and the host cell is genetically modified by at least one gene, as provided herein to increase chemical bioproduction in a host cell.

When utilizing certain organisms to create certain products, it may be advantageous to control each phase discretely. For example, depending on the pathway involved, reactions, reactants, intermediates and byproducts created during cell growth can inhibit enzyme induction and/or the organism's ability to produce the desired chemical product. Similarly, reactions, reactants, intermediates and byproducts created as part of the production pathway can impact cell growth, and even the increased concentration of the chemical product as it is produced can impede cell replication.

Table. 5

VI. Multi-Phase Fermentation

In accordance with another aspect of the present invention, there is provided a method of producing a chemical product from a carbon source through a bioproduction process that comprises a controlled multi-phase production process. The multi-phase production process includes an initiation and/or completion. of one or more phases of the production process is controlled by genetic modifications to the organism producing the chemical product and/or is controlled by changes made to the cell environment.

In accordance with this aspect of the invention, the bioproduction process may include two or more of the following phases: (1) growth phase; (2) induction phase; and (3) production phase. During the growth phase, the organism replicates itself and the biocatalyst needed to produce the chemical product is built up. During the induction phase, expression of key enzymes critical to the production of the chemical is induced and the enzymes accumulate within the biocatalyst to carry out the reactions required to produce the product. During the production phase organism produces the desired chemical product.

The initiation and/or completion of the growth, induction and/or production phases are controlled. In accordance with the present invention, the growth phase is dependent on the presence of a critical external reactant that will initiate growth. The initiation and completion of the growth phase is controlled by the addition and amount of the initiating reactant added to the reaction vessel.

In accordance with certain preferred embodiments of the present invention, the chemical product is 3-HP and the production organism is E. coli or yeast. The critical external reactant may be phosphate, which is needed for replication of E. coli cells. In accordance with a preferred embodiment, the growth phase is initiated by the addition of phosphate to a reaction vessel (together with a carbon source such as sugar and the E. coli cells), and the duration of the growth phase is controlled by the amount of phosphate added to the system.

The induction phase is controlled by genetic modifications to the producing organism. The key enzymes triggered during this phase are engineered into the organism using promoters that are sensitive to (e.g., activated by) the depletion of the initiating reactant. As a result, once the initiating reactant is depleted, the growth phase ends, e key enzymes are activated and the induction phase begins.

In accordance with a preferred embodiment, the induction phase is controlled by key genes that encode for enzymes in the biosynthetic pathway for the product into the production organism using promoters that are activated by phosphate depletion. In one embodiment where the chemical product is 3-HP and the production organism is E. coli, the key genetic modifications may include one or more of the following: mcr, mmsB, ydfG, rutE, nemA and NDSD; genes that encode individual or fused subunits of ACCase, such as accA, accB, accC, accD, accDA fusion, and accCB fusion, and the promoters may include one or more of the promoters that direct expression of the following E. coli genes: amn, tktB, xasA, yibD, ytfK, pstS, phoH, phnC, or other phosphate-regulated genes as described in [Back and Lee, FEMS Microbiol Lett 264: 104-109, 2006]. In accordance with this embodiment, once the phosphate is depleted, expression of the key enzymes is activated by their promoters and the induction phase begins.

The production phase may also be controlled by genetic modifications. For example, the organism can be engineered to included mutated forms of enzymes critical to the initiation of production of the chemical product. These initiation enzymes may facilitate. initiation of production either by: (1) becoming active and serving a key function in the production pathway; and/or (2) becoming inactive and thereby turning off a branch pathway or other competitive pathway that prevents or limits the production pathway leading to the chemical product. In accordance with a preferred erribodiment, initiation enzymes are mutated to form temperature sensitive variants of the enzymes that are either activated by or deactivated at certain temperatures. As a result, the production phase is initiated by changing the changing the temperature within the reaction vessel.

In one embodiment, the production phase is controlled by genetically modifying the microorganism with a heterologous nucleotide sequence encoding i one or more of the following temperature sensitive enzymes: fabI^(ts) (SEQ ID NO, 27), fabB^(ts) (SEQ NO.28) and fabD^(ts) (SEQ NO. 29). These enzymes are deactivated or shut-off at the desired temperature for production of the chemical product. These enzymes play a key role shuttling carbon atoms into the fatty acid synthesis pathway. Although fatty acid synthesis pathway is critical during the growth phase, it inhibits production of the chemical product. Once the reaction vessel temperature is changed, the temperature sensitive enzymes are deactivated and the fatty acid synthesis pathway shuts down thereby allowing the production pathway of the chemical product to ramp up.

In accordance with the present invention, the growth phase can last be between 10 to 40 hours, or about 15 to about 35 hours, or about 20 to about 30 hours. The induction phase may be for about 1 to about 6 hours, about 1 to about hours, or about 2 to about 4 hours. The production phase may be greater than 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 100 hours depending on the amount of chemical product that is desired.

In accordance with the present invention, the growth phase and induction phase are conducted at a temperature of about 25° C. to about 35° C., about 28° C. to about 32° C., or about 30° C. The production phase is conducted at a temperature of about 35° C. to about 45° C., about 3520 C. to about 40° C., or about 36° C. to about 38° C. Preferably, the production phase temperature is higher than the induction phase temperature, and the increase in temperature that initiates the production phase occurs over a period of about 1 to about 5 hours, about 1 to about 3 hours, about 2 hours, or about 1 hour.

In accordance with the present invention, there is provided a method of producing a chemical product from a renewable carbon source through a bioproduction process comprising:

-   -   (1) constructing a genetically modified organism capable of         converting said renewable carbon source to said chemical         product, wherein said genetically modified organism requires         inorganic phosphate for growth and comprises: (a) at least one         heterologous gene whose expression is regulated by a promoter         sensitive to inorganic phosphate levels within a culture system,         wherein said gene provides a critical function in converting         said carbon source to said chemical product and is not required         for the genetically modified organism to replicate; and (b) a         gene encoding a temperature-sensitive enzyme;     -   (2) forming a culture system comprising said carbon source in an         aqueous medium and said genetically modified microorganism;     -   (3) maintaining the culture system under conditions that allow         the genetically modified microorganism to replicate comprising         maintaining a sufficient level of inorganic phosphate within         said culture system;     -   (4) allowing the inorganic phosphate to deplete thereby         triggering the expression of the gene regulated by a promoter         sensitive to inorganic phosphate levels; and     -   (5) changing the temperature of the culture system thereby         activating or deactivating said temperature-sensitive enzyme and         initiating the production of said chemical product.

In accordance with the present invention, there is provided a method of producing 3-hydropropionic acid (3-HP) from a renewable carbon source, comprising:

-   -   (1) constructing a genetically modified organism capable of         converting said renewable carbon source to 3-HP, wherein said         genetically modified organism requires inorganic phosphate for         growth and comprises: (a) at least one heterologous gene whose         expression is regulated by a promoter sensitive to inorganic         phosphate levels within a culture system, wherein said gene is         selected from the group consisting of mcr, mmsB, ydfG, rutE,         nemA, NDSD, accA, accB, accC, accD, accDA fusion, and accCB         fusion; and (b) a gene encoding a temperature-sensitive enzyme         selected from the group consisting of fahI, fabB and fabD;     -   (2) forming a culture system comprising said carbon source in an         aqueous medium, phosphate and said genetically modified         microorganism, and thereby initiating a growth phase during         which the genetically modified microorganism replicates;     -   (3) maintaining a sufficient level of inorganic phosphate within         said culture system until the desired level of cell growth is         achieved;     -   (4) allowing the inorganic phosphate to deplete thereby         initiating an induction phase which begins the expression of         said gene regulated by a promoter sensitive to inorganic         phosphate levels; and     -   (5) changing the temperature of the culture system thereby         activating or deactivating said temperature-sensitive enzyme and         initiating a growth phase during which said genetically modified         microorganism produces 3-HP.

Fermentation Conditions

Depending on the host cell fermentation may be performed under aerobic, microaerobic, or anaerobic conditions, with or without agitation. The operation of culture systems to achieve aerobic, microaerobic and anaerobic conditions are well known to those of ordinary skill in the art.

Suitable pH ranges for fermentation depend on the multiple factors such as the host cell. In some applications of the invention fermentation can occur between various pH ranges for example, pH 3.0 to pH 4.0, pH 4.0 to pH 5.0, pH 5.0 to pH 6.0, pH 6.0 to pH 7.0, pH 7.0 to pH 8.0 pH 8.0 to pH 9.0, or pH 9.0 to pH 10.0. However, the actual pH conditions for a particular application are not meant to be limited by these ranges and can be between the expressed pH ranges if it provides more optimal production of the fermentation process, such as increased 3-HP production.

VII. Genes and Proteins for the Bioproduction of Chemicals

An overview of the engineered pathways provided by the invention in a host cell is shown in FIG. 1. Various combinations of the pathways shown can be carried out by various combinations of genetic modifications to key enzymes either in the intrinsic pathways or supplied through the transformation of a heterologous gene.

In some applications of the genetically modified microorganism of the invention may comprise a single genetic modification, or one or more genetic modifications. Various types of genetic modifications that can be used with the invention are disclosed herein.

In some embodiments the genetic modified organism of the invention can comprise a genetic modification to the following gene/proteins or a homolog with at least 80% identity to or a functional homolog of: bifunctional malonyl-CoA reductase (MCR from Chloroflexus aurantiacus), monofunctional malonyl-CoA reductase (caMCR from Chloroflexus aurantiacus), malonyl-CoA reductase (stMCR from Sulfolobus tokodaii), Enzyme: malonyl-CoA reductase (cgMCR from Chloroflexus aggregans), Enzyme: malonyl-CoA reductase (otMCR from Oscillochloris trichoides), Polypeptide: host restriction; endonuclease R (hsdR from E. coli), lactose metabolism (lac from E. coli), L-rhamnulose kinase (rhaB from E. coli), rhamnulose-1-phosphate aldolase (rhaD from E. coli), Enzyme: β-galactosidase (lacZ from E. coli), L-ribulose 5-phosphate 4-epimerase (araD from E. coli), L-ribulokinase (araB from E. coli), Enzyme: D-lactate dehydrogenase-fermentative (IdhA from E. coli), enzyme: pyruvate formate-lyase (pflB from E. coli), Enzyme: phosphate acetyltransferase/phosphate propionyltransferase (pta from E. coli), Enzyme: pyruvate oxidase (poxB from E. coli), Enzyme: methylglyoxal synthase (mgsA from E. coli), enzyme: Acetate kinase (ackA from E. coli), enzymes: phosphotransacetylase-acetate kinase (pta-ack from E. coli), Enzyme: enoyl-[acyl-carrier-protein] reductase (fabI from E. coli), Protein: zeocin binding protein (zeoR from Streptoalloteichus Hindustanus), Enzyme: carboxytransferase moiety of acetyl-CoA carboxylase (accAD from E. coli), Enzyme: triose phosphate isomerase (tpiA from E. coli), Enzyme: biotoin carboxylase moiety of acetyl-CoA carboxylase (accBC from E. coli), Enzyme: transhydrogenase (pntAB from E. coli), Polypeptide: Lael DNA-binding transcriptional repressor (lacl from E. coli), Enzyme: β-ketoacyl-ACP synthases I (fabB from E. coli), Enzyme: β-ketoacyl-ACP synthases II (fabF from E. coli), Enzyme: malonyl-CoA-ACP transacylase (fabD from E. coli), Enzyme: pantothenate kinase (coaA from E. coli), Enzyme: pyruvate dehydrogenase complex (aceEF from E. coli), Enzyme: 3-hydroxyisobutyrate/3-HP dehydrogenase (mmsB from Pseudomonas aeruginosa), Enzyme: lipoamide dehydrogenase (lpd from E. coli), Enzyme: γ-glutamyl-γ-aminobutyraldehyde dehydrogenase (puuC from E. coli), Enzyme: malate synthase A (aceB from E. coli), Enzyme: isocitrate lyase (aceA from E. coli), Enzyme: isocitrate dehydrogenase phosphatase/kinase (aceK from E. coli), Enzyme: 3-hydroxy acid dehydrogenase (ydfG from E. coli), Enzyme: acetyl CoA carboxylase (accADBC from E. coli), Polypeptide: predicted transcriptional regulator (yieP from E. coli), Blastocyin resistance gene (BSD from Schizosaccharomyces pombe), Enzyme: pyridine nucleotide transhydrogenase (udha from E. coli), Protein: Cra DNA-binding transcriptional dual regulator (fruR from E. coli), (SCB from E. coli), enzyme: aldehyde dehydrogenase B (aldB from E. coli), Enzyme: carbonic anhydrase (cynT from E. coli), Enzyme: cyanase (cynS from E. coli), DNA gyrase toxin-antitoxin system (ccdAB from E. coli), Enzyme: phosphoglycerate mutase (pgi from E. coli), ArcA transcriptional dual regulator or Aerobic respiration control (arcA from E. coli), Enzyme: 6-phosphofructokinase (pfk from E. coli), Enzyme: glyceraldehyde :3-phosphate dehydrogenase-A complex (gapA from E. coli), aldehyde dehydrogenase A (alda from E. coli), Enzyme: glutamate dehydrogenase (gdhA from E. coli), Enzyme: NADH-dependent serine dehydrogenase (NDSD from Pseudomonas aeruginosa), Protein: threonine/homoserine efflux transporter (rhtA from E. coli), Enzyme: glyceraldehyde 3-phosphate dehydrogenase (gapN from E. coli), Phosphotransferase system (pts from E. coli), Enzyme: 6-phosphofructokinase II (pfkB from E. coli), Enzyme: methylmalonate-semialdehyde dehydrogenase (mmsA from Pseudomonas aeruginosa), Oxaloacetate:beta-alanine aminotransferase (OAT-1 from Bacillus cereus), Enzyme: aspartate 1-decarboxylase (panD from E. coli), Gene that confers resistance to valine (ValR from E. coli), Enzyme: glucokinase (glk from E. coli), Polypeptide: 30 S ribosomal sununit protein S12 (rpsL from E. coli), Polypeptide: CynR DNA-binding transcriptional repressor (cynR from E. coli), Transporter: galactose:H+ symporter (galP from E. coli), aspartate aminotransferase (aspC from E. coli), Enzyme: alpha-ketoglutarate reductase (serA from E. coli), Enzyme: 6-phosphofructokinase I (pfkA from E. co;li), Enzyme: phosphoenolpyruvate carboxylase (ppc from E. coli), Enzyme: succinate-semialdehyde dehydrogenase (NADP+) (gabD from E. coli), Enzyme: pyruvate kinase (pyk from E. coli), Enzyme: oxaloacetate 4-decarboxylase (OAD from Leuconostoc mesenteroides), Enzyme: trigger factor; a molecular chaperone involved in cell division (tig from E. coli), Transcription Unit (ptsHIcrr from E. coli), Enzyme: acetyl-CoA acetaldehyde dehydrogenase/alcohol dehydrogenase (adhE from E. coli), Enzyme: fattyacyl thioesterase I (tesA from E. coli), Enzyme: guanosine 3′-diphosphate 5′-triphosphate 3′-diphosphatase (spoT from E. coli), combination of genes encoding accABCD subunits (from E. coli and Halomonas elongata), pol (from E. coli), Enzyme: GDP pyrophosphokinase/GTP pyrophosphokinase (relA from E. coli), [Enzyme Name] (me from E. coli), Enzyme: citrate synthase (gltA from E. coli), Polypeptide: DNA gyrase, subunit A (gyrA from E. coli),En/you: multifunctional 2-keto-3-deoxygluconate 6-phosphate aldolase and 2-keto-4-hydroxyglu(arate aldolase and oxaloacetate decarboxylase (eda from E. coli), thiamin biosynthesis (thi from E. coli), Polypeptide: acetolactate synthase II (ilvG from E. coli), acetyl CoA carboxylase (accDACB from E. coli), Citrate synthase (ArCS from Arthrobacter aurescens), Acetyl-CoA carboxylase from Corynebacter glutamicum (CgACC from Corynebacter glutatnicum), Polypeptide: ferrichrome/phage/antibiotic outer membrane porin FhuA (fhuA from E. coli), Transporter: phosphate:H+ symporter PitA (pitA from E. coli), Transporter: uracil:H+ symporter (uraA from E. coli), Enzyne: uracil phosphoribosyltransferase (upp from E. coli), Enzyme: acylphosphatase (yccX from E. coli), acetyl-CoA synthetase acsA from E. coli), Polypeptide: restriction of methylated adenine (mrr from E. coli), Protein: TrpR transcriptional repressor (trpR from E. coli), Enzymes: glutamate 5-semialdehyde dehydrogenase/gamma-glutamyl kinase (proAB from E. coli), methylcytosine restriction system (mcrBC from E. coli), Protein: citrate lyase, citrate-ACP transferase component (citf from E. coli), Enzyme: thioesterase II (tesB from E. coli), Enzyme: DNA-specific endonuclease I (endA from E. coli), Enzyme: phosphate acetyltransferase (cutD from E. coli), Enzyme: propionate kinase (tdcD from E. coli), tRNA: tRNA glnV (supE from E. coli), Enzyme: DNA-binding, ATP-dependent protease La (Ion from E. coli), Polypeptide: DNA strand exchange and recombination protein with protease and nuclease activity (recA from E. coli), Transcription Unit: restriction endonulease component of EcolKI restriction-modification system (hsdRMS from E. coli), Enzyme: restriction of DNA at 5-methylcytosine residues (mcrA from E. coli) araD (from E. coli), araB (from E. coli), rhaD (from E. coli), rhaB (from E. coli), ack (from E. coli), fruR (from E. coli), gapA (from E. coli), lad (from E. coli), lacZ (from E. coli), ldhA (from E. coli), mgsA (from E. coli), pfkA (from E. coli), pflB (from E. coli), pgi (from E. coli), poxB (from E. coli), pta-ack (from E. coli), ptsH (from E. coli), glut 1 (from E. coli) and/or ack (from E. coli) or any combination thereof.

The use of genetic modifications in genetic elements, genes, proteins or the use of compounds, such as siRNA technology, anti-sense technology, and small molecule inhibitors supplied to the host cell that modulate the expression of gene and proteins provided b the present invention are also contemplated.

In some embodiments the genetic modified organism of the invention uses genetic elements such as siRNA ect, genes, proteins or compounds supplied to the host cell to modulate one or more of the following: bifunctional rnalonyl-CoA reductase (MCR from Chloroflexus aurantiacus), monofunctional malonyl-CoA reductase (caMCR from Chloroflexus aurantiacus), malonyl-CoA reductase (stMCR from Sulfolobus tokodaii), Enzyme: malonyl-CoA reductase (cgMCR from Chloroflexus aggregans), Enzyme: malonyl-CoA reductase (otMCR from Oscillochloris trichoides), Polypeptide: host restriction; endonuclease R (hsdR from E. coli), lactose metabolism (lac from E. coli), L-rhamnulose kinase (rhaB from E. coli), rhamnulose-1-phosphate aldolase (rhaD from E. coli), Enzyme: β-galactosidase (lacZ from E. coli), L-ribulose 5-phosphate 4-epimerase (araD from E. coli), L-ribulokinase (araB from E. coli), Enzyme: D-lactate dehydrogenase-fermentative (IdhA from E. coli), enzyme: pyruvate formate-lyase (pflB from E. coli), Enzyme: phosphate acetyltransferase/phosphate propionyltransferase (pta from E. coli), Enzyme: pyruvate oxidase (poxB from E. coli), Enzyme: methylglyoxal synthase (mgsA from E. coli). enzyme: Acetate kinase (ackA from E. coli), enzymes: phosphotransacetylase-acetate kinase (pta-ack from E. coli), Enzyme: enoyl-[acyl-carrier-protein] reductase (fabI from E. coli), Protein: zeocin binding protein (zeoR from Streptoalloteichus Hindustanus), Enzyme: carboxytransferase moiety of acetyl-CoA carboxylase (accAD from E. coli), Enzyme: triose phosphate isomerase (tpiA from E. coli), Enzyme: biotoin carboxylase moiety of acetyl-CoA carboxylase (accBC from E. coli), Enzyme: transhydrogenase (pntAB front E. coli), Polypeptide: LacI DNA-binding transcriptional repressor (lacI from E. coli), Enzyme: β-ketoacyl-ACP synthases I (fabB from E. coli), Enzyme: β-ketoacyl-ACP synthases II (fabF front E. coli), Enzyme: malonyl-CoA-ACP transacylase (fabD from E. coli), Enzyme: pantothenate kinase (coaA from E. coli), Enzyme: pyruvate dehydrogenase complex (aceEF from E. coli), Enzyme: 3-hydroxyisobutyrate/3-HP dehydrogenase (mmsB from Pseudomonas aeruginosa), Enzyme: lipoamide dehydrogenase (Ipd from E. coli), Enzyme: γ-glutamyl-γ-aminobutyraldehyde dehydrogenase (puuC from E. coli), Enzyme: malate synthase A (aceB from E. coli), Enzyme: isocitrate lyase (aceA from E. coli), Enzyme: isocitrate dehydrogenase phosphatase/kinase (aceK from E. coli), Enzyme: 3-hydroxy acid dehydrogenase (ydfG from E. coli), Enzyme: acetyl CoA carboxylase (accADBC from E. coli), Polypeptide: predicted transcriptional regulator (yieP from E. coli). Blastocyin resistance gene (BSD from Schizosaccharomyces pombe), Enzyme: pyridine nucleotide transhydrogenase (udha from E. coli), Protein: Cra DNA-binding transcriptional dual regulator (fruR from E. coli), (SCB from E. coli), enzyme: aldehyde dehydrogenase B (aldB from E. coli), Enzyme: carbonic anhydrase (cynT from E. coli), Enzyme: cyanase (cynS from E. coli), DNA gyrase toxin-antitoxin system (ccdAB from E. coli), Enzyme: phosphoglycerate mutase (pgi from E. coli), ArcA transcriptional dual regulator or Aerobic respiration control (arcA from E. coli), Enzyme: 6-phosphofructokinase (pfk from E. coli), Enzyme: glyceraldehyde 3-phosphate dehydrogenase-A complex (gapA from E. coli), aldehyde dehydrogenase A (alda from E. coli), Enxyune: glutamate dehydrogenase (gdhA from E. coli), Enzyme: NADH-dependent serine dehydrogenase (NDSD from Pseudomonas aeruginosa), Protein: threonine/homoserine efflux transporter (rhtA from E. coli), Enzyme: glyceraldehyde 3-phosphate dehydrogenase (gapN from E. coli), Phosphotransferase system (pts from E. coli), Enzyme: 6-phosphofructokinase II (pfkB from E. coli), Enzyme: methylmalonate-semialdehyde dehydrogenase (mmsA from Pseudomonas aeruginosa), Oxaloacetate:beta-alanine aminotransferase (OAT-1 from Bacillus cereus), Enzyme: aspartate 1-decarboxylase (panD from E. coli), Gene that confers resistance to valine (VaIR from E. coli), Enzyme: glucokinase (glk from E. coli), Polypeptide: 30 S ribosomal sununit protein S12 (rpsL from E. coli), Polypeptide: CynR DNA-binding transcriptional repressor (cynR, from E. coli), Transporter: galactose:H+ symporter (galP from E. coli), aspartate aminotransferase (aspC from E. coli), Enzyme: alpha-ketoglutarate reductase (serA from E. coli), Enzyme: 6-phosphofructokinase I (pfkA from E. coli), Enzyme: phosphoenolpyruvate carboxylase (ppc from E. coli), Enzyme: succinate-semialdehyde dehydrogenase (NADP+) (gabD from E. coli), Enzyme: pyruvate kinase (pyk from E. coli), Enzyme: oxaloacetate 4-decarboxylase (OAD from Leuconostoc mesenteroides), Enzyme: trigger factor; a molecular chaperone involved in cell division (tig from E. coli), Transcription Unit (ptsHIcrr from E. coli), Enzyme: acetyl-CoA acetaldehyde dehydrogenase/alcohol dehydrogenase (adhE from E. coli), Enzyme: fattyacyl thioesterase I (tesA from E. coli), Enzyme: guanosine 3′-diphosphate 5′-triphosphate 3′-diphosphatase (spoT from E. coli), combination of genes encoding aceABCD subunits (from E. coli and Halomonas elongata), pol (from E. coli), Enzyme: GDP pyrophosphokinase/GTP pyrophosphokinase (relA from E. coli), [Enzyme Name] (me from E. coli), Enxyme: citrate synthase (gitA from E. coli), Polypeptide: DNA gyrase, subunit A (gyrA from E. coli), Enzyme: multifunctional 2-keto-3-deoxygluconate 6-phosphate aldolase and 2-keto-4-hydroxygiutarate aldolase and oxaloacetate decarboxylase (eda from E. coli), thiamin biosynthesis (thi front E. coli), Polypeptide: acetolactate synthase II (ilvG from E. coli), acetyl CoA carboxylase (accDACB from E. coli), Citrate synthase (ArCS from Arthrobacter aurescens), Acetyl-CoA carboxylase from Corynebacter glutamicum (CgACC from Corynebacter glutamicum), Polypeptide: ferrichrome/phage/antibiotic outer membrane porin FhuA (fhuA from E. coli), Transporter: phosphate:H+ symporter PitA (pitA from E. coli), Transporter: uracil:H+ symporter (uraA from E. coli), Enzyme: uracil phosphoribosyltransferase (upp from E. coli), Enzyme: acylphosphatase (yccX from E. coli), acetyl-CoA synthetase (acsA from E. coli:), Polypeptide: restriction of methylated adenine (mrr from E. coli.), Protein: TrpR transcriptional repressor (trpR from E. coli), Enzymes: glutamate 5-semialdehyde dehydrogenase/gamma-glutamyl kinase (proAB from E. coli), methylcytosine restriction system (mcrBC from E. coli), Protein: citrate lyase, citrate-ACP transferase component (citF from E. coli), Enzyme: thioesterase II (tesB from E. coli), Enzyme: DNA-specific endonuclease I (endA from E. coli), Enzyme: phosphate acetyltransferase (eutD from E. coli), Enzyme: propionate kinase (tdcD from E. coli), tRNA: tRNA ginV (supE from E. coli), Enzyme: DNA-binding, ATP-dependent protease La (lon from E. coli), Polypeptide: DNA strand exchange and recombination protein with protease and nuclease activity (recA from E. coli), Transcription Unit: restriction endonulease component of EcoKI restriction-modification system (hsdRMS from E. coli), Enzyme: restriction of DNA at 5-methylcytosine residues (mcrA from E. coli). In some embodiment the genetic modifications listed above are modified further with the genetic modules provided herein.

in some embodiment the genetic modification of the genes, proteins and enzymes of the invention can be for the method of bioproduction of various chemicals which can be used to make various consumer products described herein.

In some embodiment the genetic modification of the genes, proteins and enzymes of the invention can be for the bioproduction of 1,4-butanediol (1,4-BDO) (U.S. Pub. No. 20110190513). In some embodiment the genetic modification of the genes, proteins and enzymes of the invention can be for the bioproduction of butanol (U.S. app. Ser. No. 13/057,359). In some embodiment the genetic modification of the genes, proteins and enzymes of the invention can be for the bioproduction of isobutanol (U.S. app. Ser. No. 13/057,359)

in some embodiment the genetic modification of the genes, proteins and enzymes of the invention can be for the bioproduction of 3-HP such and its aldehyde metabolites (U.S. app. Ser. No. 13/062,917).

In some embodiment the genetic modification of the genes, proteins and enzymes of the invention can be for the bioproduction of polyketide chemical products (U.S. app. Ser. No. 13/575,581).

In some embodiment the genetic modification of the genes, proteins and enzymes of the invention can be for the bioproduction of fatty acid methyl esters (U.S. Pub. No. 20110124063). In some embodiment the genetic modification of the genes, proteins and enzymes of the invention can be for the bioproduction of C4-C18 fatty acids (U.S. app Ser. No. 61/682,127).

Genetic Modifications

Various methods to achieve such genetic modification in a host strain are well known to one skilled in the art. Example of genetic modification that can be used by the claimed invention include, but are not limited to, increasing expression of an endogenous genetic element; increasing expression of an exogenous genetic element; decreasing functionality of a repressor gene; increasing functionality of a repressor gene; increasing functionality of a activator gene; decreasing functionality of a activator gene; introducing a genetic change or element integrated in the host genome, introducing a heterologous genetic element permanently, by integration into the genome or transiently by transformation with plasmid; increasing copy number of a nucleic acid sequence encoding a polypeptide catalyzing an enzymatic conversion step; mutating a genetic element to provide a mutated protein to increase specific enzymatic activity; mutating a genetic element to provide a mutated protein to decrease specific enzymatic activity; over-expressing of gene; reduced the expression of a gene; knocking out or deleting a gene; altering or modifying feedback inhibition; providing an enzyme variant comprising one or more of an impaired binding sites or active sites; increasing functionality of a siRNA, decreasing functionality of a siRNA, increasing functionality of a antisense molecule, decreasing functionality of a antisense molecule, addition of genetic modules such as RBS, ′3 UTR elements to increase mRNA stability or translation; deletion of genetic modules such as RBS, ′3 UTR elements to decrease mRNA stability or translation; addition or modification of genetic modules such as '5 UTR elements to increase transcription; deletion or modification of genetic modules such as ′5 uTR and elements to increase transcription. In addition other genetic modules, provide herein, such a multicopy plasmids and various promoters can be used to further modify of the genetic modifications provide herein. Additionally, as known to those of ordinarily skill in the art compounds such as siRNA technology, anti-sense technology, and small molecule in inhibitors can be used to alter gene expression in the same manner as a genetic modification.

Screening methods, such as SCALE in combination with random mutagenesis may be practiced to provide genetic modifications that provide a benefit to increased production of 3-HP in a host cell. Examples of random mutagenesis can include insertions, deletions and substitutions of one or more nucleic acids in a nucleic acid of interest. In various embodiments a genetic modification results in improved enzymatic specific activity and/or turnover number of an enzyme. Without being limited, changes may be measured by one or more of the following: KM; Kcat, Kavidity, gene expression level, protein expression level, level of a product known to be produced by the enzyme, 3-HP tolerance, or by 3-HP production or by other means.

Host Cells

In some applications of the invention the host cell can be a gram-negative bacterium. In some applications of the invention the host cell can be from the genera Zymomonas, Escherichia, Pseudomonas, Alcaligenes or Klebsiella. In some applications of the invention the host cell can be Escherichia coli, Cupriavidus necator, Oligotropha carboxidovorans, or Pseudomonas putida. In some applications of the invention the host cell is one or more an E. coli strains.

In some applications of the invention the host cell can be a gram-positive bacterium. In some applications of the invention the host cell can be from the genera Clostridium, Salmonella, Rhodococcus, Bacillus, Lactobacillus, Enterococcus, Paenibacillus, Arthrobacter, Corynebacterium, or Brevibacterium, in some applications of the invention the host cell is Bacillus licheniformis, Paenibacillus macerans, Rhodococcus erythropolis, Lactobacillus plantarum, Enterococcus faecium, Enterococcus gallinarium, Enterococcus aecalis, or Bacillus subtilis, In some applications of the invention the host cell is 1B. subtilis strain.

In some applications of the invention the host cell is yeast. In some applications of the invention the host cell can be from the genera Pichia, Candida, Hansenula or Sacchammyces. In some applications of the invention the host cell is Saccharomyces cerevisiae. In some applications of the invention the host cell is Saccharomyces pombe.

In some applications of the invention the host cell is an alga. In some applications of the invention the host cell is a halophile. In some applications of the invention the host cell is an alga, in some applications of the invention the host cell is a chemolithotrophic bacterium.

In some applications of the invention the host cell is comprised of multiple host cell types. In some applications of the invention the host cell is comprised of one host cell type. In some applications of the invention the host cell is comprised of one more species or strain of a host cell type.

Downstream Consumer Products Chemicals

3-HP purified according to the methods provided in this disclosure may be converted to various other products having industrial uses including, but not limited to, acrylarnide, acrylic acid, esters of acrylic acid, 1,3-propanediol, and other chemicals, collectively referred to as “downstream chemical products” or “downstream products.” In some instances the conversion is associated with the separation and/or purification steps. These downstream chemical products are useful for producing a variety of consumer products which are described in more detail below. The methods of the present invention include steps to produce downstream products of 3-HP.

As a C3 building block, 3-HP offers much potential in a variety of chemical conversions o commercially important intermediates, industrial end products, and consumer products. For example, 3-HP may be converted to acrylic acid, acrylates (e.g., acrylic acid salts and es(ers), 1,3-propanediol, malonic acid, ethyl-3-hydroxypropionate, ethyl ethoxy propionate, propiolactone, acrylamide, or acrylonitrile.

Additionally, 3-HP may be oligomerized or polymerized to form poly(3-hydroxypropionate) homopolymers, or co-polymerized with one or more other monomers to form various co-polymers. Because 3-HP has a single stereoisomer, polymerization of 3-HP is not complicated by the stereo-specificity of monomers during chain growth. This is in contrast to (S)-2-hydroxypropanoic acid (also known as lactic acid), which has two (D, L) stereoisomers that should be considered during its polymerizations,

As will be further described, 3-HP can be converted into derivatives starting (i) substantially as the protonated form of 3-hydroxypropionic acid; (ii) substantially as the deprotonated form, 3-hydroxypropionate; or (iii) as mixtures of the protonated and deprotonated forms. Generally, the fraction of 3-HP present as the acid versus the salt will depend on the pH, the presence of other ionic species in solution, temperature (which changes the equilibrium constant relating the acid and salt forms), and, to some extent, pressure. Many chemical conversions may be carried out from either of the 3-HP forms, and overall process economics will typically dictate the form of 3-HP for downstream conversion.

Acrylic acid obtained from 3-HP purified by the methods described in this disclosure may be further converted to various polymers. For example, the free-radical polymerization of acrylic acid takes place by polymerization methods known to the skilled worker and can be carried out, for example, in an emulsion or suspension in aqueous solution or another solvent. Initiators, such as but not limited to organic peroxides, are often added to aid in the polymerization. Among the classes of organic peroxides that may be used as initiators are diacyls, peroxydicarbonates, monoperoxycarbonates, peroxyketals, peroxyesters, dialkyls, and hydroperoxides. Another class of initiators is azo initiators, which may be used for acrylate polymerization as well as co-polymerization with other monomers. U.S. Pat. Nos. 5,470,928; 5,510,307; 6,709,919; and 7,678,869 teach various approaches to polymerization using a number of initiators, including organic peroxides, azo compounds, and other chemical types, and are incorporated by reference for such teachings as applicable to the polymers described herein.

Accordingly, it is further possible for co-monomers, such as crosslinkers, to be present during the polymerization. The free-radical polymerization of the acrylic acid obtained from dehydration of 3-HP, as produced herein, in at least partly neutralized form and in the presence of crosslinkers is practiced in certain embodiments. This polymerization may result in hydrogels which can then be communicated, ground and, where appropriate, surface-modified, by known techniques.

An important commercial use of polyacrylic acid is for superabsorbent polymers. This specification hereby incorporates by reference Modern Superabsorbent Polymer Technology, Buchholz and Graham (Editors), Wiley-VCH, 1997, in its entirety for its teachings regarding superabsorbent polymers components, manufacture, properties and uses. Superabsorbent polymers are primarily used as absorbents for water and aqueous solutions for diapers, adult incontinence products, feminine hygiene products, and similar consumer products. In such consumer products, superabsorbent materials can replace traditional absorbent materials such as cloth, cotton, paper wadding, and cellulose fiber. Superabsorbent polymers absorb, and retain under a slight mechanical pressure, up to 25 times or more their weight in liquid. The swollen gel holds the liquid in a solid, rubbery state and prevents the liquid from leaking. Superabsorbent polymer particles can be surface-modified to produce a shell structure with the shell being more highly cross-linked than the rest of the particle. This technique improves the balance of absorption, absorption under load, and resistance to gel-blocking. It is recognized that superabsorbent polymers have uses in fields other than consumer products, including agriculture, horticulture, and medicine.

Superabsorbent polymers are prepared from acrylic acid (such as acrylic acid derived from 3-HP provided herein) and a crosslinker, by solution or suspension polymerization. Exemplary methods include those provided in U.S. Pat. Nos. 5,145,906; 5,350,799; 5,342,899; 4,857,610; 4,985,518; 4,708, 997; 5,180,798; 4,666,983; 4,734,478; and 5,331,059, each incorporated by reference for their teachings relating to superabsorbent polymers.

Among consumer products, a diaper, a feminine hygiene product, and an adult incontinence product are made with superabsorbent polymer that itself is made substantially from acrylic acid converted from 3-HP made in accordance with the present invention.

Diapers and other personal hygiene products may be produced that incorporate superabsorbent polymers made from acrylic acid made from 3-HP which is produced and purified by the teachings of the present application. The following provides general guidance for making a diaper that incorporates such superabsorbent polymer. The superabsorbent polymer first is molded into an absorbent pad that may be vacuum formed, and in which other materials, such as a fibrous material (e.g., wood pulp) are added. The absorbent pad then is assembled with sheet(s) of fabric, generally a nonwoven fabric (e.g., made from one or more of nylon, polyester, polyethylene, and polypropylene plastics) to form diapers.

More particularly, in one non-limiting process, multiple pressurized nozzles, located above a conveyer belt, spray superabsorbent polymer particles (e.g., about 400 micron size or larger), fibrous material, and/or a combination of these onto the conveyer belt at designated spaces/intervals. The conveyor belt is perforated and under vacuum from below, no that the sprayed on materials are pulled toward the belt surface to form a flat pad. In various embodiments, fibrous material is applied first on the belt, followed by a mixture of fibrous material and the superabsorbent polymer particles, followed by fibrous material, so that the superabsorbent polymer is concentrated in the middle of the pad. A leveling roller may be used toward the end of the belt path to yield pads of uniform thickness. Each pad thereafter may be further processed, such as to cut it to a proper shape for the diaper, or the pad may be in the form of a long roll sufficient for multiple diapers. Thereafter, the pad is sandwiched between a top sheet and a bottom sheet of fabric (one generally being liquid pervious, the other liquid impervious), for example on a conveyor belt, and these are attached together, for example by gluing, heating or ultrasonic welding, and cut into diaper-sized units (if not previously so cut). Additional features may be provided, such as elastic components, strips of tape, etc., for fit and ease of wearing by a person.

The ratio of the fibrous material to polymer particles is known to affect performance characteristics. In some cases, this ratio is between 75:25 and 90:10 (see e.g., U.S. Pat. No. 4,685,915, incorporated by reference for its teachings of diaper manufacture). Other disposable absorbent articles may be constructed in a similar fashion, such as absorbent articles for adult incontinence, feminine hygiene (sanitary napkins), tampons, etc. (see, for example, U.S. Pat. Nos. 5,009,653; 5,558,656; and 5,827,255 incorporated by reference for their teachings of sanitary napkin manufacture).

Low molecular weight polyacrylic acid has uses for water treatment, and as a flocculant and thickener for various applications including cosmetics and pharmaceutical preparations. For these applications, the polymer may be uncrosslinked or lightly cross-linked, depending on the specific application. The molecular weights are typically from about 200 to about 1,000,000 g/mol. Preparation of these low molecular weight polyacrylic acid polymers is described in U.S. Pat. Nos. 3,904,685; 4,301,266; 2,798,053; and 5,093,472, each of which is incorporated by reference for its teachings relating to methods to produce these polymers.

Acrylic acid may be co-polymerized with one or more other monomers selected from acrylamide, 2-acrylamido-2-methylpropanesulfonic acid, N,N-dimethylacrylamide, N-isopropylacrylamide, methacrylic acid, and methacrylamide, to name a few. The relative reactivities of the monomers affect the microstructure and thus the physical properties of the polymer. Co-monomers may be derived from 3-HP, or otherwise provided, to produce co-polymers. Ullmann's Encyclopedia of Industrial Chemistry, Polyacrylamides and Poly(Acrylic Acids), Wiley VCH Verlag GmbH, Wienham (2005), is incorporated by reference herein for its teachings of polymer and co-polymer processing.

Acrylic acid can in principle be copolymerized with almost any free-radically polymerizable monomers including styrene, butadiene, acrylonitrile, acrylic esters, maleic acid, maleic anhydride, vinyl chloride, acrylamide, itaconic acid, and so on. End-use applications typically dictate the co-polymer composition, which influences properties. Acrylic acid also may have a number of optional substitutions and, after such substitutions, may be used as a monomer for polymerization, or co-polymerization reactions. As a general rule, acrylic acid (or one of its co-polymerization monomers) may be substituted by any substituent that does not interfere with the polymerization process, such as alkyl, alkoxy, aryl, heteroaryl, benzyl, vinyl, allyl, hydroxy, epoxy, amide, ethers, esters, ketones, maleimides, succinimides, sulfoxides, glycidyl and silyl (see e.g., U.S. Pat. No. 7,678,869, incorporated by reference above, for further discussion). The following paragraphs provide a few non-limiting examples of copolymerization applications.

Paints that comprise polymers and copolymers of acrylic acid and its esters are in wide use as industrial and consumer products. Aspects of the technology for making such paints can be found in e.g., U.S. Pat. Nos. 3,687,885 and 3,891,591, incorporated by reference for their teachings of such paint manufacture. Generally, acrylic acid and its esters may form homopolymers or copolymers among themselves or with other monomers, such as amides, methacrylates, acrylonitrile, vinyl, styrene and butadiene. A desired mixture of homopolymers and/or copolymers, referred to in the paint industry as “vehicle” (or “binder”) are added to an aqueous solution and agitated sufficiently to form an aqueous dispersion that includes sub-micrometer sized polymer particles. The paint cures by coalescence of these vehicle particles as the water and any other solvent evaporate. Other additives to the aqueous dispersion may include pigment, filler (e.g., calcium carbonate, aluminum silicate), solvent (e.g., acetone, benzol, alcohols, etc., although these are not found in certain no VOC paints), thickener, and additional additives depending on the conditions, applications, intended surfaces, etc. In many paints, the weight percent of the vehicle portion may range from about nine to about 26 percent, but for other paints the weight percent may vary beyond this range.

Acrylic-based polymers are used for many coatings in addition to paints. For example, for paper coating latexes, acrylic acid is used from 0.1-5.0%, along with styrene and butadiene, to enhance binding to the paper and modify rheology, freeze-thaw stability and shear stability. In this context, U.S. Pat. Nos. 3,875,101 and 3,872,037 are incorporated by reference for their teachings regarding such latexes. Acrylate-based polymers also are used in many inks, particularly UV curable printing inks. For water treatment, acrylamide and/or hydroxy ethyl acrylate are commonly co-polymerized with acrylic acid to produce low molecular-weight linear polymers. In this context, U.S. Pat. Nos. 4,431,547 and 4,029,577 are incorporated by reference for their teachings of such polymers. Co-polymers of acrylic acid with maleic acid or itaconic acid are also produced for water-treatment applications, as described in U.S. Pat. No. 5,135,677, incorporated by reference for that teaching. Sodium acrylate (the sodium salt of glacial acrylic acid) can be co-polymerized with acrylamide (which may be derived from acrylic acid via amidation chemistry) to make an anionic co-polymer that is used as a flocculant in water treatment.

For thickening agents, a variety of co-monomers can be used, such as those described in U.S. Pat. Nos. 4,268,641 and 3,915,921, incorporated by reference for their description of these co-monomers. U.S. Pat. No. 5,135,677 describes a number of co-monomers that can be used with acrylic acid to produce water-soluble polymers, and is incorporated by reference for such description.

In some cases, conversion to downstream products may be made enzymatically. For example, 3-HP may be converted to 3-HP-CoA, which then may be converted into polymerized 3-HP with an enzyme having polyhydroxy acid synthase activity (EC 2.3.1.-). Also, 1,3-propanediol can be made using polypeptides having oxidoreductase activity or reductase activity (e.g., enzymes in the EC 1.1.1.—class of enzymes). Alternatively, when creating 1,3-propanediol from 3-HP, a combination of (1) a polypeptide having aldehyde dehydrogenase activity (e.g., an enzyme from the 1.1.1.34 class) and (2) a polypeptide having alcohol dehydrogenase activity (e.g., an enzyme front the 1.1.1.32 class) can be used. Polypeptides having lipase activity may be used to form esters. Enzymatic reactions such as these may be conducted in vitro, such as using cell-free extracts, or in vivo.

Thus, various embodiments described in this disclosure, such as methods of making a chemical, include conversion steps to any downstream products of microbially produced 3-HP, including but not limited to those chemicals described herein, in the incorporated references, and known in the art. For example, in some cases, 3-HP is produced and converted to polymerized-3-HP (poly-3-HP) or acrylic acid. In some cases, 3-HP or acrylic acid can be used to produce polyacrylic acid (polymerized acrylic acid, in various forms), methyl acrylate, acrylamide, acrylonitrile, propiolactone, ethyl 3-HP, malonic acid, 1,3-propanediol, ethyl acrylate, n-butyl acrylate, hydroxypropyl acrylate, hydroxyethyl acrylate, isobutyl acrylate, 2-ethylhexyl acrylate, and acrylic acid or an acrylic acid ester to which an alkyl or aryl addition may be made, and/or to which halogens, aromatic amines or amides, and aromatic hydrocarbons may be added.

a) Reactions that form downstream compounds such as acrylates or acrylamides can be conducted in conjunction with use of suitable stabilizing agents or inhibiting agents reducing the likelihood of polymer formation. See, for example, U.S. Publication No. 2007/0219390, incorporated by reference in its entirety. Stabilizing agents and/or inhibiting agents include, but are not limited to, e.g., phenolic compounds (e.g., dimethoxyphenol (DMP) or alkylated phenolic compounds such as di-tert-butyl phenol), quinones (e.g., t-butyl hydroquinone or the monomethyl ether of hydroquinone (MEHQ)), and/or metallic copper or copper salts (e.g., copper sulfate, copper chloride, or copper acetate). Inhibitors and/or stabilizers can be used individually or in combinations as will be known by those of skill in the art.

In some cases, the one or more downstream compounds are recovered at a molar yield of up to about 100 percent, or a molar yield in the range from about 70 percent to about 90 percent, or a molar yield in the range from about 80 percent to about 100 percent, or a molar yield in the range from about 90 percent to about 100 percent. Such yields may be the result of single-pass (batch or continuous) or iterative separation and purification steps in a particular process.

The methods described in this disclosure can also be used to produce downstream compounds derived from 3-HP, such as but not limited to, polymerized-3-HP (poly-3-HP), acrylic acid, polyacrylic acid (polymerized acrylic acid, in various forms), copolymers of acrylic acid and. acrylic esters, acrylamide, acrylonitrile, propiolactone, ethyl 3-HP, malonic acid, and 1,3-propanediol. Also, among esters that are formed are methyl acrylate, ethyl acrylate, n-butyl acrylate, hydroxypropyl acrylate, hydroxyethyl acrylate, isobutyl acrylate, and 2-ethylhexyl acrylate. These and/or other acrylic acid and/or other acrylate esters may be combined, including with other compounds, to form various known acrylic acid-based polymers. Numerous approaches may be employed for such downstream conversions, generally falling into enzymatic, catalytic (chemical conversion process using a catalyst), thermal, and combinations thereof (including some wherein a desired pressure is applied to accelerate a reaction). For example, without being limiting, acrylic acid may be made from 3-HP via a dehydration reaction, methyl acrylate may be made from 3-HP via dehydration and esterification, the latter to add a methyl group (such as using methanol), acrylamide may be made from 3-HP via dehydration and amidation reactions, acrylonitrile may be made via a dehydration reaction and forming a nitrile moiety, propiolactone may be made from 3-HP via a ring-forming internal esterification reaction, ethyl-3-HP may be made from 3-HP via esterification with ethanol, malonic acid may be made from 3-HP via an oxidation reaction, and 1,3-propanediol may be made from 3-HP via a reduction reaction. Additionally, it is appreciated that various derivatives of the derivatives of 3-HP and acrylic acid may be made, such as the various known polymers of acrylic acid and its derivatives. Production of such polymers is considered within the scope of the present invention. Copolymers containing acrylic acid and/or esters have been widely used in the pharmaceutical formulation to achieve extended or sustained release of active ingredients, for example as coating material. Downstream compounds may also be converted to consumer products such as diapers, carpet, paint, and adhesives.

Another important product, acrylamide, has been used in a number of industrial applications. Acrylamide may be produced from 3-HP, for example, without being limiting, via an esterification-amidation-dehydration sequence. Refluxing an alcohol solution of 3-HP in the presence of an acid or Lewis acid catalyst described herein would lead to a 3-HP ester. Treatment of the 3-HP ester with either an ammonia gas or an ammonium ion could yield 3-HP amide. Finally, dehydration of the 3-HP amide with dehydration reagents described elsewhere in this disclosure could produce acrylamide. The steps mentioned herein may be rearranged to produce the same final product acrylamide. Polymerization of acrylamide can be achieved, for example, and without being limiting, by radical polymerization. Polyacrylamide polymers have been widely used as additives for treating municipal drinking water and waste water. In addition, they have found applications in gel electrophoresis, oil-drilling, papermaking, ore processing, and the manufacture of permanent press fabrics.

VIII. Expression Systems General Concepts

The following general concepts are applicable to embodiments of the invention described above.

Multicopy Plasmids

The researcher is faced with a myriad of genetic module options when designing a plasmid for expression of a heterologous protein in a host cell. How to optimize an expression plasmid system often depends on the downstream use of the expressed protein.

Different cloning vectors or plasmids are maintained at different copy numbers, dependent on the replicon of the plasmid. Most general cloning plasmids can carry a DNA insert up to around 15 kb in size.

Multicopy plasmids can be used for the expression of recombinant genes in Escherichia coli. Examples of include multicopy plasmids include high-copy, medium-copy and low-copy plasmids (see FIG. 8). The high copy number is generally desired for maximum gene expression. However, the metabolic burden effects can result from multiple plasmid copies could prove to be detrimental for maximum productivity in certain metabolic engineering applications by adding significant metabolic burden to the system.

The low-copy plasmids for example, pBR322 is based on the original ColE1 replicon and thus has a copy number of 15-20. The pACYC series of plasmids are based on the p15A replicon, which has a copy number of 18-22, whereas pSC101 has even a lower copy number around 5, and BACs are maintained at one copy per cell. Such low copy plasmids may be useful in metabolic engineering applications, particularly when one or more of the substrates used in the recombinant pathway are required for normal cellular metabolism and can be toxic to the cell at high levels.

However, the used of high-copy plasmids may be useful in enhanced cellular metabolism contexts. The mutant ColE1 replicon, as found in the pUC series of plasmids produces a copy number of 500-700 as a result of a point mutation within the RNAII regulatory molecule.

There are transcription and translation vectors. Transcription vectors are utilized when the DNA to be cloned has an ATG start codon and a prokaryotic ribosome -binding site. Translation vectors contain an efficient ribosome-binding site and, therefore, it is not necessary for the target DNA to contain one. This is particularly useful in cases where the initial portion of the gene may be cleaved in an effort to improve solubility. Another consideration when choosing a transcription or translation vector is the source of the DNA to be expressed. Prokaryotic genes usually have a ribosome-binding site that is compatible with the host E. coli translation machinery, whereas eukaryotic genes do not. Normal prokaryotic gene expression may be enhanced by use of an engineered promoter and ribosome-binding site.

Promoters

A promoter is a region of DNA that initiates transcription of a particular gene. In bacteria, transcription is initiated by the promoter being recognized by RNA polymerase and an associated sigma factor, which are often brought to the promoter site by an activator protein's binding to its own DNA binding site located by the promoter.

Promoter selection is an important factor when designing an expression plasmid system. A promoter is located upstream of the ribosome-binding site. Owing to the fact that many heterologous protein products are toxic to the cell, the promoter can be regulated so that the heterologous protein is expressed at the appropriate amount and time to reduced the burden on the cell host.

Historically, the most commonly used promoters have been the lactose (lac) and tryptophan (trp) promoters. These two promoters were combined to create the hybrid promoters lac and trc that are also commonly used. Other common promoters are the phage lambda promoters, the phage T7 promoter (T7), and the alkaline phosphatase promoter (phoA).

Promoters can be constitutive and inducible. Constitutive promoter is active in all circumstances in the cell, while regulated or inducible promoter become active in response to specific stimuli. In addition the strength of the promoter can also differ. A strong promoter has a high frequency of transcription and generates the heterologous protein as 10-30% of the total cellular protein production (for examples see FIG. 8). Chemically-inducible promoters that can be used in various aspects of the invention include but are not limited to promoters whose transcriptional activity is regulated by the presence or absence of alcohol, tetracycline, steroids, metal and other compounds. Physically-inducible promoters that can be used in various aspects of the invention include but are not limited to including promoters whose transcriptional activity is regulated by the presence or absence of light and low or high temperatures.

In order to be an inducible promoter, the promoter should be initially be completely repressed to transcription and then transcription induced with the addition of an inducer to allow expression at the time that expression is desired in the host cell. Alternatively, an inducible promoter may be responsive to the lack of a substance, such as inorganic phosphate, such that the absence of inorganic phosphate will allow expression at the time that expression is desired in the host cell (for examples see FIG. 8).

Ribosome Binding Sites

A Ribosome Binding Sites (RBS) is an RNA sequence upstream of the start codon that affects the rate at which a particular gene or open reading frame (ORF) is translated. One can tailor an RBS site to a particular gene. Ribosome Binding Sites (RBSs) are typically short sequences, often less than 20 base pairs. Various aspects of RBS design are known to affect the rate at which the gene is translated in the cell. The RBS module can influences the translation rate of a gene largely by two known mechanisms. First, the rate at which ribosomes are recruited to the mRNA and initiate translation is dependent on the sequence of the RBS. Secondly, the sequence of the RBS can also affect the stability of the mRNA in the cell, which in turn affects the number of proteins. Through the use of genetic expression modules the expression of desired genes, such as genes encoding enzymes in the biosynthetic pathway for 3-HP, can be tailored activity either at the transcriptional and translational level.

One can access the registry RBS collection as a starting point for designing an RBS <<http://partsregistry.org/Ribosome_Binding_Sites/Catalog>>. The Registry has collections of RBSs that are recommended for general protein expression in E. coli and other prokaryotic hosts. In addition, each family of RBSs has multiple members covering a range of translation initiation rates. There are also several consensus RBS sequence for E. coli have been described. However, it is important to keep in mind the known RBS functions and mechanisms in a larger context. For example, in certain contexts the RBS can interact with upstream sequences, such as sequence that comprise the promoter or an upstream ORF. In other contexts, the RBS may interact with downstream sequences, for example the ribosome enzyme binds jointly to the RBS and start codon at about the same time. These potential interactions should be considered in the overall RBS sequence design. The degree of secondary structure near the RBS can affect the translation initiation rate. This fact can be used to produce regulated translation initiation rates.

The Shine-Dalgarno portion of the RBS is critical to the strength of the RBS. The Shine-Dalgarno is found at the end of the 16s rRNA and is the portion that binds with the mRNA and includes the sequence 5′ACCUCC-3′. RBSs will commonly include a portion of the Shine-Dalgarno sequence. One of the ribosomal proteins, S1, is known to bind to adenine bases upstream from the Shine-Dalgarno sequence. As a result, the RBS can be made stronger by adding more adenines in the sequence upstream of the RBS.

When considering the design of the spacing between the RBS and the start codon, it is important to think of the aligned spacing rather than just the absolute spacing. While the Shine-Dalgarno portion of the RBS is critical to the strength of the RBS, the sequence upstream of the Shine-Dalgarno sequence is also important. Note that the promoter may add some bases onto the start of the mRNA that may affect the strength of the RBS by affecting S1 binding. Computer programs that design RBS sequence to match protein coding sequences, desired upstream sequences including regulatory mRNA sequences, and account of secondary structure are known [Salis, Mirsky, and Voight, Nature Biotechnology 27: 946-950, 2009] and were used to optimize RBSs for the ACCase subunit genes as described in(see EXAMPLE 3).

While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.

EXAMPLES Example 1 Salt Inhibition Studies in E. COLI

The activity of ACCase complex, a critical enzyme in the conversion of acetyl-CoA to malonyl-CoA, the immediate precursor for 3-HP, is severely inhibited by salt. Dose-dependent effects on ACCase activity was observed in the presence of NaCl, Na₄Cl, Na-3-HP, or NH₄₋3-HP such that salt levels near 0.44M resulted in decreasing the activity of the ACCase enzyme by approximately 80%, while salts of 3-HP levels near 0.66M decreased the activity of the ACCase enzyme by approximately 80% relative to control (FIG. 4). Levels of greater than 0.66M (60 g/L) are expected to be present for commercially viable commercial production of 3-HP.

Example 2 ACCase from Halophilic Organism

Halophilic organisms, such as Halomonas elongata, are found in environments with high salt concentrations and, in general, have a salt internal concentration>2.5-3M. It is hypothesized that enzymes derived from any salt-tolerant species should be more resistant to enzyme inhibition by salts, such as 3-HP. Further, these enzymes that have greater salt tolerance should in turn have extended production under high salt conditions than enzymes with lower salt tolerance.

Accordingly, the genes encoding the accA, accB, accC, accD of H. elongata described in Table 1 were synthesized for expression in E. coli using codons optimized for this organism and supplied individually on pUC57 plasmids without promoters. Synthetic operons comprising the subunits were assembled using the Gibson assembly method

TABLE 1 Accession numbers for genes encoding ACCase subunits from Halomonas elongata Gene Accession number SEQ ID NO. accA YP_003898857.1 SEQ ID NO. 1, 2 accB YP_003897250.1 SEQ ID NO. 3, 4 accC YP_003897249.1 SEQ ID NO. 5, 6 accD YP_003897309.1 SEQ ID NO. 7, 8 Each gene was amplified by PCRs with Pfu Ultra II HS using the manufacturer's instructions, and the PCR products were purified using the Zymo PCR Cleanup kit. Concentrations of products were measured using the Nanodrop spectophotometer. The Gibson Assembly kit (NEB) was used to construct plasmids expressing the ACCase subunit genes as directed by the manufacturer. The effect of NH₄₋3-HP and NH4Cl on H. elongata ACCase was tested and compared to the E. coli ACCase. As shown in FIG. 4, whereas the E. coli ACCase is significantly inhibited by the salts, the ACCase from the halophile is less affected by either NH₄₋3-HP or by NH₄Cl. This result indicated that use of the H. elongata ACCase in 3-HP production strains would in beneficial in relieving 3-HP inhibition of the conversion of acetyl-CoA to malonyl-CoA, a critical step in the pathway.

Example 3 RBS-Optimized Genes

Enzyme expression is regulated at transcriptional and translational levels in prokaryotes. Ribosome Binding Sites (RBS) are 15 nucleotide segments which are known to control the level of protein expression in microorganisms. To enhance H. elongata ACCase expression various customized RBS were constructed and optimized for E. coli translation expression. Table 2 shows the RBS sequences used to increase expression of the individual subunits.

TABLE 2 RBS sequences used to enhance expression of H. elongate ACCase subunits. H. elongata ACC expression Modified RBS sequences preceeding ATG (underlined) plasmid He_accD He_accA He_accC He_accB Parent 2-4 5′- 5′- 5′- 5′- GCGTAGTAAAGGA CAATTTATTTAAGGA GAAATTTCATACC GGAAGAACAAGGG GGTAACATATG GGACTCTTAAGATG ACAGGCGAAGGAG GTGTACATG GAAAAACCATG B2 Same as 2-4 Same as 2-4 Same as 2-4 5′- ggaagaattaagg gggacaaggggga ataATG 13A 5′- Same as 2-4 Same as 2-4 gcgtagtagccggg tgataaggagccgt aacATG 14C 5′- Same as 2-4 Same as 2-4 Same as 2-4 gcgtagtagctgat ataaaaggaggtaa cggATG 15C Same as 2-4 5′- Same as 2-4 Same as 2-4 caatttatttttgtt cacccaaggagtatt gctaATG 17C Same as 2-4 5′- Same as 2-4 Same as 2-4 caatttatttaccga aataaaaggagggat gcgaATG 35C 5′- 5′- Same as 2-4 Same as 2-4 gcgtagtagccggg caatttatttttgtt tgataaggagccgt cacccaaggagtatt aacATG gctaATG 36C 5′- 5′- Same as 2-4 Same as 2-4 gcgtagtagccggg caatttatttaccga tgataaggagccgt aataaaaggagggat aacATG gcgaATG 36C-8 5′- 5′- Same as 2-4 5′- gcgtagtagccggg caatttatttaccga ggaagaattaagg tgataaggagccgt aataaaaggagggat gggacaaggggga aacATG gcgaATG ataATG 72B 5′- 5′- 5′- 5′- gcgtagtagccggg caatttatttaccga TCTTCCCACAACA GAAATTTCATACC tgataaggagccgt aataaaaggagggat CTGGCGGACTCCA ACAGGCGAAGGAG aacATG gcgaATG TCATG GAAAAACCATG 105F 5′- 5′- 5′- 5′- gcgtagtagccggg caatttatttttgtt TCTTCCCACAACA GAAATTTCATACC tgataaggagccgt cacccaaggagtatt CTGGCGGACTCCA ACAGGCGAAGGAG aacATG gctaATG TCATG GAAAAACCATG

The expression performance of the RBS-optimized H. elongata ACCases was evaluated by 3-HP production in a 96-well format, each in triplicate wells, and the averaged results shown in Table 3. Specific 3HP production is shown as g/L per OD_(600.) As may be seen in Table 3, enhancing the efficiency of the RBS in strains B2, 35C, and 72 B clearly resulted in increased malonyl-CoA production leading to increased 3-HP production. It is evident from these results that combinations of enhanced RBS's before each of the individual genes accA, accB, accC, and accD may result in strains with even higher ACCase expression and activity.

TABLE 3 Improvement in 3-HP production by RBS-optimized expression of H. elongata ACCase subunits. H. elongata ACCase 3HP expression plasmid (g/l · OD) Parent 2-4 0.06 B2 0.81 13A 0.01 14C 0.54 15C 0.14 17C 0.08 35C 0.68 36C 0.31 36C-8 0.31 72B 0.57 105F 0.19

EXAMPLE 4 Coordinated Expression by Subunit Fusions

In nature ACCase subunit genes from prokaryotes such as E. coli and H. elongata have been shown to have a quaternary structure: accA_(2:)accD_(2:)accB_(4:)accC_(2.) However, the intrinsic levels of the ACCase subunit genes are too low for optimal production. Therefore, for optimal production it is ideal to have overexpression to be coordinated in a similar manner.

Expression of the genes encoding each ACCase subunit is regulated at transcriptional and translational levels. Coordinated overexpression of the AC:Case subunit genes, accA, accB, accC, accD should give better ACCase activity. Examples of fusions of accC-B proteins exist in bacteria. It is hypothesized that coordinated overexpression may be achieved by fusion of subunit genes should ensures equimolar expression of the subunit genes at the optimal time.

The following ACCase subunit gene fusion were constructed and the constructs overexpressed in E. coli: (A) Control ABCD, (B) fusion of accC-B (SEQ ID NOs 9, 10) subunit genes as seen in bacteria, (C) fusion of accD-A subunit genes using a flexible 15-amino acid linker (Linker sequence LSGGGGSGGGGSGGGGSGGGGSAAA; SEQ ID NOs 11, 12) as depicted in FIG. 5.

The performance of the ACC fusions were tested for their ACCase activity and for various 3-HP production metrics in Table 4. ACCase activity was determined in cell lysates using an assay for malonyl-CoA production as described in [Kroeger, Zarzycki, and Fuchs, Analytical Biochem. 411: 100-105, 2011]. Production of 3-HP was determined in cells co-transformed with a plasmid bearing the genes encoding the malonyl-CoA reductase from S. tokadaii and E. coli ydfG providing a 3-HP dehydrogenase to complete the metabolic pathway from malonyl-CoA to 3HP. These results show that the strain with the fused accDA genes had higher average specific productivity of 3-HP compared to the parental strain in which the overexpressed ACCase is not fused. FIG. 6 shows that the benefit of the accDA fusion were also manifested in 3-HP production in fermentors with environmental controls of nutrient feed, pH, aeration, and temperature.

Table 4:

TABLE 4 ACC Fusions and ACCase activity Avg specific Avg specific ACCase Strain prodn rate prodn rate specific activity desig- (g/gDCW · h) (g/gDCW · hr) at TS + 6 nation Plasmid at TS + 6 at TS + 20 (U/mg) BX3_783 Parent 0.160 0.146 0.057 (unfused ACCase) BX3_829 No ACC 0.069 0.062 0.000 BX3_837 EC ACC 0.209 0.201 0.054 DA fusion

Example 5 3-HP Exporter

Growth inhibition has been demonstrated for E. coli strains grown in the presence of 3-HP at levels as low as 20 g/L. To produce high titers of 3-1-IP the production host is required to balance production with overcoming inhibition. A known chemical exporter from E. coli that has been previously characterized for homoserine transport, rhtA, was evaluated for increased production of 3-HP. A mutant version of the exporter, rhtA(P2S) (SEQ ID NO. 30 nucleic acid, SEQ ID NO. 31 protein) was synthesized behind the PtpiA promoter and inserted into the pTRC-PyibD-MCR plasmid behind a terminator using the Gibson Assemply kit (NEB) according to manufacturer's instructions. The effects of overexpression of rhtA were evaluated in IL fermentation compared to the control plasmid without rhtA. As shown in FIG. 7, overexpression of rhtA resulted in a significant improvement in 3HP titer compared to the control production strain. Construction of plasmids expressing another putative transporter, ydcO (SEQ ID NO. 32 nucleic acid, SEQ ID NO. 33 protein) is carried out in the same manner.

Example 6 Bicarbonate Importer Prophetic

Increased import of bicarbonate to increase availability of bicarbonate for the ACCase reaction will increase production of inalonyl-CoA and hence products derived metabolically from malonyl-CoA, such as 3-HP. The gene encoding the bicA bicarbonate transporter (SEQ lD NO. 13) of Synechococcus sp. was synthesized using codons optimized for expression in E. coli (SEQ ID NO. 14) and expressed using the E. coli tal promoter in a strain cotransformed with plasmids encoding ACCase and MCR functions. Production of 3-HP by this strain is compared to that achieved by a control strain without overexpressed bicA.

SEQUENCE LISTING SEQ ID NO. 1: ACCA PROTEIN, HALOMONAS ELONGATA MNPNYLDFEQPIAELQAKIEELRMVGNDSQVNLSDEIGRLEEKSRKLTES IFKDLSAWQVSQLSRHPQRPYTLDYLEHVETDFDELHGDRRFADDAAIVG GVARLDDKPVMVIGHQKGRDVHEKVRRNEGMPRPEGYRKACRLMEMAERF HMPVLTFIDTPGAYPGIDAEERGQSEAIAYNLGVMSRLKTPIISTVVGEG GSGGALAIGVCDELAMLQYSTYSVISPEGCASILWKSADKASEAAQAMGI TAERLKELGFVDTLIPEPLGGAHRQPSATAERIKTALLESLDRLETMETD ALLERRYERLMSYGAPV SEQ ID NO, 2: ACCA NUCLEIC ACID, HALOMONAS ELONGATA (SYNTHETIC, CODON OPTIMIZE FOR E. COLI EXPRESSION) ATGAATCCGAACTATCTGGACTTTGAACAACCGATCGCTGAACTGCAAGC CAAAATCGAAGAACTGCGTATGGTGGGCAACGACTCACAGGTGAACCTGT CTGATGAAATTGGCCGTCTGGAAGAAAAAAGTCGCAAACTGACCGAATCC ATCTTTAAAGACCTGTCAGCGTGGCAAGTTAGCCAACTGTCTCGTCATCC GCAACGCCCGTATACCCTGGATTACCTGGAACATGTCTTTACGGATTTCG ACGAACTGCACGGTGACCGTCGCTTTGCAGATGACGCGGCCATTGTTGGC GGTGTCGCTCGTCTGGATGACAAACCGGTCATGGTGATCGGCCATCAGAA AGGTCGTGATGTGCACGAAAAAGTTCGTCGCAACTTCGGCATGCCGCGCC CGGAAGGTTATCGTAAAGCGTGCCGCCTGATGGAAATGGCCGAACGCTTT CACATGCCGGTGCTGACCTTCATTGATACGCCGGGCGCATATCCGGGTAT CGACGCTGAAGAACGTGGCCAAAGCGAAGCGATTGCCTACAATCTGGGTG TTATGTCGCGCCTGAAAACCCCGATTATCAGCACGGTGGTTGGCGAAGGC GGTTCTGGCGGTGCACTGGCTATCGGTGTCTGCGATGAACTGGCGATGCT GCAATATAGTACCTACTCCGTGATTTCACCGGAAGGCTGTGCCTCGATCC TGTGGAAAAGCGCAGATAAAGCTTCTGAAGCAGCTCAAGCGATGGGCATT ACCGCCGAACGTCTGAAAGAACTGGGTTTCGTTGACACGCTGATCCCGGA ACCGCTGGGCGGTGCACATCGTCAGCCGAGTGCGACCGCCGAACGCATTA AAACGGCCCTGCTGGAAAGCCTGGATCGCCTGGAAACGATGGAAACGGAT GCCCTGCTGGAACGCCGCTATGAACGCCTGATGTCTTACGGTGCCCCGGT CTGA SEQ ID NO. 3: ACCB PROTEIN, HALOMONAS ELONGATA MDIRKVKKLIELLEESNISEIEIQEGEESVRISRHPNGTEHPQPAAPAWP ATAAAPAPQPAAAPVESPAEVDEGPAYQGQPIVSPMVGTFYRAPAPGAKA FVELGQSVKKGETVCIVEAMKMMNQIEADRDGVVEAILVEDGEPVEFEQP MVVIS SEQ ID NO. 4: ACCB NUCLEIC ACID HALOMONAS ELONGATA (SYNTHETIC, CODON OPTIMIZE FOR E. COLI EXPRESSION)  ATGGACATCCGCAAAGTGAAAAAACTGATCGAACTGCTGGAAGAAAGTAA CATCTCTGAAATTGAAATCCAAGAAGGCGAAGAAAGCGTGCGTATTAGTC GCCATCCGAACGGCACCGAACACCCGCAGCCGGCGGCACCGGCATGGCCG GCCACGGCAGCTGCGCCGGCGCCGCAACCGGCCGCAGCTCCGGTGGAAAG CCCGGCAGAAGTTGATGAAGGCCCGGCTTATCAGGGTCAACCGATCGTTT CTCCGATGGTCGGCACCTTTTACCGTGCGCCGGCACCGGGTGCAAAAGCT TTCGTCGAACTGGGCCAGAGCGTTAAAAAAGGTGAAACGGTCTGCATTGT GGAAGCCATGAAAATGATGAATCAAATCGAAGCCGATCGCGACGGTGTGG TTGAAGCAATCCTGGTGGAAGATGGTGAACCGGTGGAATTTGAACAGCCG ATGGTGGTGATTAGTTAA SEQ ID NO. 5: ACCC PROTEIN, HALOMONAS ELONGATA MLKKVLIANRGEIALRILRACKELGIRTVAVHSKADRELMHVRLADEAVC IGPASSAQSYLNIPALISAAEVTDTSAIHPGYGFLSENADFAEQVERSGF TFIGPSAETIRLMGDKVSAINAMKEAGVPTVPGSNGPLGDDEGEILATAR RIGYPVIIKAAAGGGGRGMRVVHAEGHLLSAVNVTRTEAHSSFGDGTVYM EKFLENPRHVEVQVLADGQGNAIHLYDRDCSLQRRHQKVLEEAPAPGLDQ QAREQVFKACRDACVKIGYRGAGTFEFLYENGEFFFIEMNTRVQVEHPVT EMVTGVDIVREQLRIASGLPLSIRQEDVELSGHAFECRINAEDSRTFMPS PGRVTLYHPPGGLGVRMDSHVYTGYTVPPHYDSLIGKLITWGDDRETALI RMRNALDELLVEGIKTNTDLHKDLVRDGYFQQGGVNIHYLEKKLGL SEQ ID NO. 6: ACCC NUCLEIC ACID, HALOMONAS ELONGATA (SYNTHETIC, CODON OPTIMIZE FOR E. COLI EXPRESSION) ATGCTGGACAAAGTGCTGATTGCGAATCGTGGCGAAATTGCGCTGCGTAT CCTGCGTGCGTGTAAAGAACTGGGTATCCGTACCGTCGCTGTTCATTCAA AAGCGGACCGTGAACTGATGCACGTCCGCCTGGCCGATGAAGCAGTGTGC ATTGGTCCGGCTAGCTCTGCGCAGTCGTATCTGAACATTCCGGCACTGAT CAGTGCGGCCGAAGTGACCGACACGTCCGCGATCCATCCGGGCTACGGTT TCCTGAGCGAAAATGCCGATTTTGCAGAACAAGTCGAACGTTCAGGTTTC ACCTTTATTGGCCCGTCGGCCGAAACGATCCGCCTGATGGGTGATAAAGT TAGTGCTATTAACGCGATGAAAGAAGCAGGCGTGCCGACCGTTCCGGGTT CCAATGGTCCGCTGGGTGATGACGAAGGTGAAATTCTGGCCACCGCACGT CGCATCGGCTATCCGGTTATTATCAAAGCAGCTGCGGGCGGTGGCGGTCG TGGTATGCGTGTGGTTCATGCTGAAGGCCACCTGCTGAGCGCGGTCAACG TGACCCGTACGGAAGCGCATAGTTCCTTCGGCGATGGCACCGTTTATATG GAAAAATTTCTGGAAAACCCGCGTCACGTTGAAGTCCAGGTGCTGGCCGA TGGCCAGGGTAATGCAATTCATCTGTACGATCGCGACTGCTCTCTGCAAC GTCGCCACCAAAAAGTGCTGGAAGAAGCTCCGGCACCGGGTCTGGACCAG CAAGCACGTGAACAGGTTTTTAAAGCCTGCCGCGATGCATGTGTCAAAAT TGGTTATCGTGGCGCGGGCACCTTCGAATTTCTGTACGAAAACGGCGAAT TTTTCTTTATCGAAATGAATACGCGCGTTCAGGTCGAACATCCGGTGACC GAAATGGTCACGGGTGTGGATATTGTTCGTGAACAGCTGCGTATCGCATC AGGTCTGCCGCTGTCGATTCGCCAAGAAGACGTTGAACTGAGCGGTCATG CCTTCGAATGTCGTATCAATGCAGAAGATAGCCGCACCTTTATGCCGTCT CCGGGTCGTGTCACGCTGTATCACCCGCCGGGCGGTCTGGGTGTCCGTAT GGACAGCCATGTGTATACCGGCTACACGGTTCCGCCGCACTACGATTCTC TGATTGGTAAACTGATCACCTGGGGCGATGACCGTGAAACGGCTCTGATT CGTATGCGCAACGCCCTGGATGAACTGCTGGTTGAAGGCATCAAAACCAA TACGGATCTGCACAAAGACCTGGTTCGCGATGGCTACTTTCAGCAAGGCG GTGTCAACATTCACTACCTGGAAAAAAAACTGGGTCTGTAA SEQ ID NO. 7: ACCD PROTEIN, HALOMONAS ELONGATA MSWLDKIVPSVGRIQRKERRTSVPDGLWRKCPKCESVLYLPELEKHHNVC PKCDHHLRLTARKRLDWFLDKEGREEIAADLEPVDRLKFRDSKKYKDRLS AAQKATGEKDGLVAMRGTLEGLPVVAVAFEFTFMGGSMGAVVGEKFVRAA TQALDEGVPLVCFSASGGARMQEALFSLMQMAKTSAALEKLKQAGVPYIS VLTDPVFGGVSASLAMLGDLNIAEPNALIGFAGPRVIEQTVREQLPEGFQ RSEFLLEHGAVDMIVHRQQIRERLGGVLRKLTHQPASGPAVVENDEPDLV DAAEQAEPQPEAPEAVETSESEAPTEKGVEADSEETDESPRSGDNR SEQ ID NO. 8: ACCD NUCLEIC ACID, HALOMONAS ELONGATA (SYNTHETIC, CODON OPTIMIZE FOR E. COLI EXPRESSION) ATGTCTTGGTTAGATAAAATCGTCCCGTCAGTGGGTCGCATTCAACGCAA AGAACGTCGCACCTCGGTCCCGGATGGTCTGTGGCGTAAATGCCCGAAAT GTGAATCAGTTCTGTATCTGCCGGAACTGGAAAAACATCACAACGTCTGC CCGAAATGTGATCATCACCTGCGTCTGACCGCGCGTAAACGCCTGGACTG GTTCCTGGATAAAGAAGGCCGCGAAGAAATTGCGGCCGACCTGGAACCGG TGGATCGTCTGAAATTTCGCGACAGCAAAAAATACAAAGATCGTCTGAGC GCGGCGCAGAAAGCAACCGGTGAAAAAGACGGTCTGGTGGCCATGCGTGG CACGCTGGAAGGTCTGCCGGTGGTTGCAGTTGCTTTTGAATTTACCTTTA TGGGCGGTAGCATGGGCGCAGTCGTGGGTGAAAAATTCGTTCGTGCGGCC ACGCAGGCTCTGGATGAAGGTGTGCCGCTGGTTTGCTTCAGCGCATCTGG CGGTGCCCGCATGCAGGAAGCACTGTTTAGTCTGATGCAAATGGCTAAAA CCTCCGCAGCTCTGGAAAAACTGAAACAGGCGGGCGTGCCGTATATTTCT GTTCTGACGGACCCGGTCTTCGGCGGTGTGAGTGCGTCCCTGGCCATGCT GGGTGATCTGAACATTGCAGAACCGAATGCTCTGATCGGCTTTGCGGGTC CGCGTGTCATCGAACAGACCGTGCGCGAACAACTGCCGGAAGGCTTCCAG CGTTCAGAATTTCTGCTGGAACATGGTGCCGTTGATATGATTGTCCACCG TCAGCAAATCCGTGAACGCCTGGGCGGTGTGCTGCGCAAACTGACGCATC AACCGGCATCGGGTCCGGCCGTTGTCGAAAATGATGAACCGGACCTGGTC GATGCGGCCGAACAGGCAGAACCGCAACCGGAAGCACCGGAAGCTGTTGA AACCTCAGAATCGGAAGCACCGACGGAAAAAGGCGTGGAAGCAGACTCGG AAGAAACGGATGAATCACCGCGCTCAGGCGACAACCGCTAA SEQ ID NO. 9: FUSION ACCCB PROTEIN, E. COLI MLDKIVIANRGEIALRILRACKELGIKTVAVHSSADRDLKHVLLADETVC IGPAPSVKSYLNIPAIISAAEITGAVAIHPGYGFLSENANFAEQVERSGF IFIGPKAETIRLMGDKVSAIAAMKKAGVPCVPGSDGPLGDDMDKNRAIAK RIGYPVIIKASGGGGGRGMRVVRGDAELAQSISMTRAEAKAAFSNDMVYM EKYLENPRHVEIQVLADGQGNAIYLAERDCSMQRRHQKVVEEAPAPGITP ELRRYIGERCAKACVDIGYRGAGTFEFLFENGEFYFIEMNTRIQVEHPVT EMITGVDLIKEQLRIAAGQPLSIKQEEVHVRGHAVECRINAEDPNTFLPS PGKITRFHAPGGFGVRWESHIYAGYTVPPYYDSMIGKLICYGENRDVAIA RMKNALQELIIDGIKTNVDLQIRIMNDENFQHGGTNIHYLEKKLGLQEKD IRKIKKLIELVEESGISELEISEGEESVRISRAAPAASFPVMQQAYAAPM MQQPAQSNAAAPATVPSMEAPAAAEISGHIVRSPMVGTFYRTPSPDAKAF IEVGQKVNVGDTLCIVEAMKMMNQIEADKSGTVKAILVESGQPVEFDEPL VVIE SEQ ID NO. 10: FUSION ACCCB NUCLEIC ACID, E. COLI ATGCTGGACAAGATCGTCATCGCCAACCGCGGCGAAATCGCCCTGCGCAT CTTGCGCGCGTGTAAAGAGCTGGGCATTAAGACTGTTGCCGTGCATTCCA GCGCAGACCGCGACCTGAAGCATGTTCTGCTGGCCGACGAAACGGTTTGC ATCGGTCCGGCACCGAGCGTGAAAAGCTATCTGAACATCCCGGCCATCAT CTCTGCGGCAGAGATCACCGGTGCAGTGGCGATTCATCCGGGCTACGGTT TCCTGAGCGAGAACGCTAACTTTGCTGAACAAGTGGAGCGTAGCGGTTTC ATCTTCATTGGCCCTAAGGCGGAGACGATTCGCCTGATGGGCGACAAAGT GAGCGCCATTGCAGCGATGAAAAAGGCCGGTGTGCCGTGTGTTCCGGGCA GCGATGGTCCGCTGGGTGACGATATGGACAAGAACCGTGCCATCGCTAAA CGTATTGGCTACCCGGTCATTATCAAAGCCTCTGGTGGTGGCGGTGGCCG TGGTATGCGTGTCGTCCGTGGTGATGCGGAACTGGCGCAAAGCATCAGCA TGACCCGTGCGGAAGCCAAAGCGGCGTTCTCTAACGATATGGTGTATATG GAGAAGTATCTGGAGAATCCGCGCCACGTTGAAATCCAAGTTCTGGCGGA TGGTCAGGGCAATGCGATCTACTTGGCAGAACGTGATTGCTCCATGCAAC GCCGTCATCAGAAGGTGGTGGAAGAGGCACCGGCTCCGGGTATTACGCCG GAACTGCGTCGCTACATCGGTGAGCGCTGTGCGAAAGCGTGTGTGGACAT TGGTTACCGTGGTGCGGGTACGTTTGAGTTCCTGTTCGAAAATGGTGAGT TTTACTTCATTGAAATGAATACCCGCATCCAGGTTGAGCACCCGGTGACC GAGATGATTACTGGCGTTGATCTGATCAAAGAGCAACTGCGCATTGCGGC TGGTCAGCCGCTGTCGATCAAGCAAGAAGAGGTGCACGTTCGTGGTCACG CGGTCGAGTGCCGTATCAATGCGGAGGACCCGAATACCTTTCTGCCGAGC CCTGGTAAGATCACTCGTTTTCACGCGCCAGGTGGTTTTGGCGTTCGTTG GGAGTCTCACATCTACGCCGGTTACACCGTGCCGCCGTACTATGACAGCA TGATTGGTAAACTGATCTGCTATGGCGAAAATCGTGATGTCGCGATCGCC CGCATGAAAAACGCGCTGCAAGAGCTGATCATTGATGGCATTAAGACCAA TGTGGATTTGCAGATCCGCATTATGAACGACGAGAATTTCCAGCACGGCG GTACGAACATTCACTACCTGGAAAAGAAACTGGGCCTGCAAGAGAAAGAC ATCCGCAAGATCAAGAAGCTGATCGAACTGGTGGAAGAGTCTGGCATCAG CGAGCTGGAGATCAGCGAAGGTGAAGAGAGCGTCCGTATTTCCCGTGCGG CACCGGCAGCGAGCTTTCCGGTTATGCAGCAAGCATACGCCGCTCCGATG ATGCAACAGCCGGCACAGAGCAACGCCGCTGCACCGGCGACCGTTCCAAG CATGGAGGCACCGGCAGCGGCCGAGATTTCGGGTCATATCGTGCGTAGCC CGATGGTGGGCACCTTCTATCGCACGCCGTCGCCGGACGCAAAAGCCTTC ATCGAAGTCGGCCAGAAGGTCAATGTCGGCGACACGCTGTGTATCGTTGA GGCAATGAAAATGATGAACCAGATTGAAGCGGATAAGAGCGGTACTGTTA AAGCGATCCTGGTGGAATCCGGCCAGCCTGTTGAGTTCGATGAACCGCTG GTTGTGATCGAGTAA SEQ ID NO. 11: FUSION ACCDA PROTEIN, E. COLI MSWIERIKSNITPTRKASIPEGWVTKCDSCGQVLYRAELERNLEVCPKCD  HHMRMTARNRLHSLLDEGSLVELGSELEPKDVLKFRDSKKYKDRLASAQK ETGEKDALVVMKGTLYGMPVVAAAFEFAFMGGSMGSVVGARFVRAVEQAL EDNCPLICFSASGGARMQEALMSLMQMAKTSAALAKMQERGLPYISVLTD PTMGGVSASFAMLGDLNIAEPKALIGFAGPRVIEQTVREKLPPGFQRSEF LIEKGAIDMIVRRPEMRLKLASILAKLMNLPAPNPEAPREGVVVPPVPDQ EPEALSGGGGSGGGGSGGGGSGGGGSAAASLNFLDFEQPIAELEAKIDSL TAVSRQDEKLDINIDEEVHRLREKSVELTRKIFADLGAWQIAQLARHPQR PYTLDYVRLAFDEFDELAGDRAYADDKAIVGGIARLDGRPVMIIGHQKGR ETKEKIRRNFGMPAPEGYRKALRLMQMAERFKMPIITFIDTPGAYPGVGA EERGQSEAIARNLREMSRLGVPVVCTVIGEGGSGGALAIGVGDKVNMLQY STYSVISPEGCASILWKSADKAPLAAEAMGIIAPRLKELKLIDSIIPEPL GGAHRNPEAMAASLKAQLLADLADLDVLSTEDLKNRRYQRLMSYGYA SEQ ID NO. 12: FUSION ACCDA NUCLEIC ACID; E. COLI ATGAGCTGGATCGAGCGCATCAAGAGCAACATCACCCCGACCCGCAAGGC GAGCATCCCTGAAGGCGTCTGGACCAAATGCGATAGCTGCGGTCAGGTTT TGTATCGTGCGGAGCTGGAGCGTAACCTGGAAGTGTGCCCGAAATGCGAC CATCACATGCGTATGACCGCTCGTAATCGTCTGCATAGCCTGCTGGATGA GGGCAGCCTGGTCGAGCTGGGTAGCGAACTGGAACCGAAAGATGTTCTGA AATTCCGTGATTCCAAGAAGTATAAGGATCGTTTGGCATCTGCACAAAAA GAAACCGGTGAGAAGGACGCACTGGTTGTTATGAAAGGCACCCTGTATGG TATGCCGGTTGTTGCTGCGGCGTTCGAGTTTGCGTTTATGGGTGGCAGCA TGGGTTCCGTGGTGGGCGCACGCTTTGTGCGTGCCGTGGAGCAGGCGCTG GAGGATAACTGTCCTCTGATTTGTTTCAGCGCGAGCGGTGGTGCGCGTAT GCAAGAGGCCCTGATGAGCCTGATGCAGATGGCAAAAACCTCGGCAGCCC TGGCGAAGATGCAAGAACGCGGCCTGCCGTACATTTCCGTCCTGACCGAC CCTACGATGGGCGGTGTCAGCGCCAGCTTTGCGATGCTGGGTGATTTGAA CATCGCAGAGCCGAAGGCTCTGATTGGTTTTGCTGGTCCGCGTGTTATTG AACAGACGGTTCGCGAAAAGTTGCCGCCTGGTTTCCAGCGCAGCGAGTTC CTGATTGAGAAAGGTGCCATCGACATGATCGTTCGCCGTCCAGAAATGCG TCTGAAACTGGCGAGCATTCTGGCGAAATTGATGAATCTGCCGGCTCCGA ATCCTGAAGCACCGCGTGAGGGTGTCGTGGTTCCGCCGGTCCCGGACCAA GAGCCGGAGGCTCTGAGCGGCGGAGGTGGCTCTGGTGGAGGCGGTTCAGG AGGCGGTGGCAGTGGTGGCGGCGGATCTGCGGCAGCTTCTCTGAACTTCC TGGACTTCGAGCAGCCGATCGCCGAACTGGAGGCGAAGATTGACAGCCTG ACCGCGGTTAGCCGTCAAGATGAGAAACTGGACATTAACATCGACGAAGA GGTCCACCGTTTGCGTGAGAAGTCTGTTGAACTGACTCGCAAAATCTTTG CTGATTTGGGCGCATGGCAGATTGCCCAGTTGGCTCGCCACCCACAACGC CCATATACCCTGGACTACGTGCGCCTGGCGTTTGACGAGTTCGACGAACT GGCAGGCGACCGCGCCTATGCGGACGATAAAGCAATTGTCGGCGGTATTG CTCGTTTGGATGGCCGTCCGGTGATGATTATCGGCCATCAAAAAGGCCGC GAGACAAAGGAAAAGATTCGTCGTAATTTCGGAATGCCGGCACCGGAGGG CTACCGCAAGGCCCTGCGTCTGATGCAAATGGCCGAACGCTTTAAGATGC CGATTATCACGTTCATTGATACGCCTGGTGCGTACCCAGGCGTTGGTGCG GAAGAGCGTGGTCAGAGCGAGGCCATCGCACGTAACCTGCGTGAGATGTC TCGTCTGGGTGTGCCGGTCGTTTGCACCGTGATTGGCGAGGGCGGTAGCG GTGGTGCGTTGGCGATCGGTGTCGGTGATAAGGTCAACATGCTGCAATAC AGCACGTACAGCGTCATTAGCCCGGAAGGTTGCGCTTCCATTCTGTGGAA GAGCGCGGATAAAGCACCATTGGCAGCGGAAGCGATGGGTATCATCGCAC CGCGTCTGAAAGAACTGAAGTTGATTGATTCTATCATCCCGGAACCGCTG GGCGGTGCTCACCGTAATCCGGAGGCGATGGCAGCCAGCCTGAAGGCCCA GCTGCTGGCGGACCTGGCGGATCTGGACGTGCTGAGCACGGAGGATCTGA AAAACCGTCGCTATCAGCGCTTGATGAGCTATGGCTACGCTTAA SEQ ID NO. 13: BICA PROTEIN, SYNECHOCOCCUS SP. MQITNKIHFRNIRGDIFGGLTAAVIALPMALAFGVASGAGAEAGLWGAVL VGFFAALFGGTPTLISEPTGPMTVVMTAVIAHFTASAATPEEGLAIAFTV VMMAGVGQIIFGSLKLGKYVTMMPYTVISGFMSGIGIILVILQLAPFLGQ ASPGGGVIGTLQNLPTLLSNIQPGETALALGTVAIIWFMPEKFKKVIPPQ LVALVLGTVIAFFVFPPEVSDLRRIGEIRAGFPELVRPSESPVEFQRMIL DAAVLGMLGCIDALLTSVVADSLTRTEHNSNKELIGQGLGNLFSGLFGGI AGAGATMGTVVNIQSGGRTALSGLVRAFVLLVVILGAASLTATIPLAVLA GIAFKVGVDIIDWSFLKRAHEISPKGALIMYGVILLTVLVDLIVAVGVGV FVANVLTIERMSNLQSEKVQTVSDADDNIRLTTTEKRWLDEGQGRVLLFQ LSGPMIFGVAKAIAREHNAMGDCDALVFDIGEVPHMGVTASLALENAIEE ALDKERQVYIVGAAGQTRRRLEKLKLFKRVPPDKCLMSREEALKNAVLGI YPHLADGVTAPSSEMG SEQ ID NO. 14: BICA NUCLEIC ACID, SYNECHOCOCCUS SP. ATGCAGATTACCAACAAGATCCATTTCCGTAACATTCGTGGCGACATTTT TGGTGGCCTGACCGCTGCTGTGATTGCGCTGCCGATGGCACTGGCTTTTG GTGTGGCAAGTGGTGCAGGTGCAGAAGCAGGTCTGTGGGGTGCAGTTCTG GTGGGCTTTTTCGCAGCACTGTTCGGTGGTACGCCGACCCTGATTTCAGA ACCGACGGGCCCGATGACCGTGGTTATGACGGCCGTGATCGCACATTTTA CCGCATCGGCAGCTACGCCGGAAGAAGGCCTGGCTATTGCGTTCACCGTC GTGATGATGGCCGGTGTTTTTCAGATTATCTTCGGCAGCCTGAAACTGGG CAAGTATGTTACCATGATGCCGTACACGGTCATCAGTGGTTTTATGTCCG GTATTGGCATTATCCTGGTGATCCTGCAGCTGGCACCGTTCCTGGGTCAA GCCAGTCCGGGCGGTGGCGTTATTGGCACCCTGCAGAACCTGCCGACGCT GCTGTCCAATATCCAACCGGGTGAAACCGCCCTGGCACTGGGTACGGTCG CGATTATCTGGTTCATGCCGGAAAAGTTCAAGAAGGTTATCCCGCCGCAG CTGGTTGCGCTGGTTCTGGGCACCGTCATCGCGTTTTTCGTGTTTCCGCC GGAAGTTAGCGATCTGCGTCGCATTGGCGAAATCCGTGCAGGTTTCCCGG AACTGGTGCGTCCGAGCTTTTCTCCGGTTGAATTTCAGCGCATGATTCTG GATGCGGCCGTGCTGGGCATGCTGGGTTGCATCGATGCGCTGCTGACCAG CGTTGTCGCCGACTCTCTGACGCGTACCGAACATAACAGCAATAAAGAAC TGATTGGTCAGGGCCTGGGTAACCTGTTTTCTGGCCTGTTCGGTGGTATT GCTGGTGCAGGTGCAACGATGGGCACCGTGGTTAATATCCAAAGTGGTGG CCGTACCGCACTGTCCGGTCTGGTGCGTGCTTTTGTTCTGCTGGTCGTGA TTCTGGGTGCAGCTTCTCTGACGGCAACCATTCCGCTGGCTGTGCTGGCA GGCATCGCCTTTAAAGTGGGTGTTGATATTATCGACTGGTCATTCCTGAA ACGCGCCCACGAAATCTCGCCGAAGGGCGCACTGATTATGTATGGTGTGA TCCTGCTGACCGTCCTGGTGGATCTGATTGTTGCGGTCGGCGTGGGTGTT TTTGTCGCCAACGTTCTGACCATCGAACGTATGTCAAATCTGCAGTCGGA AAAAGTCCAAACCGTGAGCGATGCGGATGACAACATTCGCCTGACCACGA CCGAAAAGCGTTGGCTGGACGAGGGTCAGGGTCGTGTGCTGCTGTTTCAA CTGTCTGGCCCGATGATTTTCGGTGTTGCAAAAGCTATCGCGCGTGAACA TAACGCAATGGGTGATTGCGACGCTCTGGTGTTTGATATTGGCGAAGTCC CGCACATGGGTGTGACCGCAAGTCTGGCTCTGGAAAATGCGATTGAAGAA GCCCTGGACAAAGAACGCCAGGTTTACATCGTCGGTGCAGCAGGTCAAAC CCGTCGCCGTCTGGAAAAACTGAAGCTGTTTAAACGCGTGCCGCCGGATA AGTGTCTGATGTCCCGTGAAGAAGCACTGAAGAATGCTGTTCTGGGTATC TATCCGCATCTGGCTGACGGTGTTACGGCTCCGAGTTCCGAAATGGGCTA A SEQ ID NO. 15: MCR DNA ORGANISM NAME: SULFOLOBUS TOKODAII ATGTCTCGTC GCACCCTGAA AGCGGCTATC CTGGGCGCCA CCGGCCTGGT TGGTATCGAA   60 TATGTCCGTA TGCTGTCAAA TCATCCGTAT ATCAAACCGG CGTATCTGGC CGGCAAAGGT  120 TCAGTTGGCA AACCGTACGG TGAAGTGGTT CGTTGGCAGA CCGTTGGCCA AGTCCCGAAA  180 GAAATCGCCG ATATGGAAAT TAAACCGACG GACCCGAAAC TGATGGATGA CGTGGATATT  240 ATCTTTTCGC CGCTGCCGCA GGGTGCGGCC GGTCCGGTTG AAGAACAATT TGCAAAAGAA  300 GGCTTCCCGG TCATCAGCAA CTCTCCGGAT CATCGTTTCG ATCCGGACGT CCCGCTGCTG  360 GTGCCGGAAC TGAATCCGCA CACCATTAGT CTGATCGATG AACAGCGCAA ACGTCGCGAA  420 TGGAAAGGTT TTATTGTTAC CACGCCGCTG TGCACGGCAC AAGGTGCAGC TATCCCGCTG  480 GGTGCTATCT TCAAAGATTA CAAAATGGAC GGCGCGTTCA TTACCACGAT CCAGAGTCTG  540 TCCGGTGCAG GTTACCCGGG TATCCCGTCT CTGGATGTCG TGGACAACAT TCTGCCGCTG  600 GGCGATGGTT ATGACGCGAA AACCATTAAA GAAATCTTCC GTATTCTGTC AGAAGTTAAA  660 CGCAATGTCG ATGAACCGAA ACTGGAAGAC GTTTCGCTGG CGGCCACCAC GCATCGTATC  720 GCCACCATTC ATGGCCACTA TGAAGTGCTG TACGTTAGTT TTAAAGAAGA AACCGCAGCT  780 GAAAAAGTGA AAGAAACGCT GGAAAACTTC CGCGGTGAAC CGCAGGATCT GAAACTGCCG  840 ACCGCACCGT CCAAACCGAT TATCGTCATG AATGAAGATA CGCGTCCGCA AGTGTACTTT  900 GATCGCTGGG CTGGCGACAT TCCGGGTATG AGCGTTGTCG TGGGCCGTCT GAAACAGGTG  960 AACAAACGTA TGATCCGCCT GGTGTCTCTG ATTCACAATA CCGTTCGCGG TGCGGCGGGC 1020 GGTGGCATCC TGGCTGCTGA ACTGCTGGTT GAAAAAGGTT ACATTGAAAA A 1071 <212> TYPE: DNA <211> LENGTH: 1071 SEQUENCENAME: SULFOLOBUS TOKODAII MCR DNA SEQ ID NO. 16: MCR PROTEIN ORGANISM NAME: SULFOLOBUS TOKODAII MSRRTLKAAI LGATGLVGIE YVRMLSNHPY IKPAYLAGKG SVGKPYGEVV RWQTVGQVPK   60 EIADMEIKPT DPKLMDDVDI IFSPLPQGAA GPVEEQFAKE GFPVISNSPD HRFDPDVPLL  120 VPELNPHTIS LIDEQRKRRE WKGFIVTTPL CTAQGAAIPL GAIFKDYKMD GAFITTIQSL  180 SGAGYPGIPS LDVVDNILPL DGDYDAKTIK EIFRILSEVK RNVDEPKLED VSLAATTHRI  240 ATIHGHYEVL YVSFKEETAA EKVKETLENF RGEPQDLKLP TAPSKPIIVM NEDTRPQVFY  300 DRWAGDIPGM SVVVGRLKQV NKRMIRLVSL IHNTVRGAAG GGILAAELLV EKGYIEK  357 <212> TYPE: PRT <211> LENGTH: 357 SEQUENCENAME: SULFOLOBUS TOKODAII MCR PROTEIN SEQ ID NO. 17 : NEMA DNA ORGANISM NAME: ESCHERICHIA COLI ATGTCATCTG AAAAACTGTA TTCCCCACTG AAAGTGGGCG CGATCACGGC GGCAAACCGT   60 ATTTTTATGG CACCGCTGAC GCGTCTGCGC AGTATTGAAC CGGGTGACAT TCCTACCCCG  120 TTGATGGCGG AATACTATCG CCAACGTGCC AGTGCCGGTT TGATTATTAG TGAAGCCACG  180 CAAATTTCTG CCCAGGCAAA AGGATATGCA GGTGCGCCTG GCATCCATAG TCCGGAGCAA  240 ATTGCCGCAT GGAAAAAAAT CACCGCTGGC GTTCATGCTG AAAATGGTCA TATGGCCGTG  300 CAGCTGTGGC ACACCGGACG CATTTCTCAC GCCAGCCTGC AACCTGGCGG TCAGGCACCG  360 GTAGCGCCTT CAGCACTTAG CGCGGGAACA CGTACTTCTC TGCGCGATGA AAATGGTCAG  420 GCGATCCGTG TTGAAACATC CATGCCGCGT GCGCTTGAAC TGGAAGAGAT TCCAGGTATC  480 GTCAATGATT TCCGTCAGGC CATTGCTAAC GCGCGTGAAG CCGGTTTTGA TCTGGTAGAG  540 CTCCACTCTG CTCACGGTTA TTTGCTGCAT CAGTTCCTTT CTCCTTCTTC AAACCATCGT  600 ACCGATCAGT ACGGCGGCAG CGTGGAAAAT CGCGCACGTT TGGTACTGGA AGTGGTCGAT  660 GCCGGGATTG AAGAATGGGG TGCCGATCGC ATTGGCATTC GCGTTTCACC AATCGGTACT  720 TTCCAGAACA CAGATAACGG CCCGAATGAA GAAGCCGATG CACTGTATCT GATTGAACAA  780 CTGGGTAAAC GCGGCATTGC TTATCTGCAT ATGTCAGAAC CAGATTGGGC GGGGGGTGAA  840 CCGTATACTG ATGCGTTCCG CGAAAAAGTA CGCGCCCGTT TCCACGGTCC GATTATCGGC  900 GCAGGTGCAT ACACAGTAGA AAAAGCTGAA ACGCTGATCG GCAAAGGGTT AATTGATGCG  960 GTGGCATTTG GTCGTGACTG GATTGCGAAC CCGGATCTGG TCGCCCGCTT GCAGCGCAAA 1020 GCTGAGCTTA ACCCACAGCG TGCCGAAAGT TTCTACGGTG GCGGCGCGGA AGGCTATACC 1080 GATTACCCGA CGTTGTAA 1098 <212> TYPE: DNA <211> LENGTH: 1098 SEQUENCENAME: ESCHERICHIA COLI NEMA DNA SEQ ID NO. 18: NEMA PROTEIN ORGANISM NAME: ESCHERICHIA COLI MSSEKLYSPL KVGAITAANR IFMAPLTRLR SIEPGDIPTP LMAEYYRQRA SAGLIISEAT   60 QISAQAKGYA GAPGIHSPEQ IAAWKKITAG VHAENGHMAV QLWHTGRISH ASLQPGGQAP  120 VAPSALSAGT RTSLRDENGQ AIRVETSMPR ALELEEIPGI VNDFRQAIAN AREAGFDLVE  180 LHSAHGYLLH QFLSPSSNHR TDQYGGSVEN RARLVLEVVD AGIEEWGADR IGIRVSPIGT  240 FQNTDNGPNE EADALYLIEQ LGKRGIAYLH MSEPDWAGGE PYTDAFREKV RARFHGPIIG  300 AGAYTVEKAE TLIGKGLIDA VAFGRDWIAN PDLVARLQRK AELNPQRAES FYGGGAEGYT  360 DYPTL  365 <212> TYPE: PRT <211> LENGTH: 365 SEQUENCENAME: ESCHERICHIA COLI NEMA PROTEIN SEQ ID NO. 19: RUTE DNA ORGANISM NAME: ESCHERICHIA COLI ATGAACGAAG CCGTTAGCCC AGGTGCGCTT AGCACCCTGT TCACCGATGC CCGCACTCAC   60 AACGGCTGGC GGGAGACACC CGTCAGCGAT GAGACGTTAC GGGAGATTTA TGCCCTGATG  120 AAATGGGGGC CGACATCAGC TAACTGTTCT CCGGCACGGA TCGTGTTTAC CCGCACGGCA  180 GAAGGAAAAG AACGTCTGCG CCCGGCACTT TCCAGCGGCA ATCTGCAAAA AACCCTGACC  240 GCGCCCGTCA CCGCTATCGT CGCCTGGGAC AGTGAATTTT ATGAACGGTT ACCACTACTG  300 TTTCCCCACG GTGATGCCCG CAGTTGGTTT ACCTCCAGCC CACAACTTGC CGAAGAAACA  360 GCGTTTCGCA ACAGTTCCAT GCAGGCGGCC TATCTGATCG TCGCCTGCCG GGCGCTGGGA  420 CTGGATACCG GCCCGATGTC GGGCTTTGAC CGTCAACACG TGGACGACGC CTTTTTTACG  480 GGCAGCACGC TGAAGAGCAA TCTGCTGATT AATATCGGCT ATGGCGATAG CAGCAAGCTT  540 TATGCGCGCC TGCCACGTCT GTCCTTTGAA GAAGCCTGCG GGCTGTTGTA A  591 <212> TYPE: DNA <211> LENGTH: 591 SEQUENCENAME: ESCHERICHIA COLI RUTE DNA SEQ ID NO. 20 RUTE PROTEIN ORGANISM NAME: ESCHERICHIA COLI MNEAVSPGAL STLFTDARTH NGWRETPVSD ETLREIYALM KWGPTSANCS PARIVFTRTA   60 EGKERLRPAL SSGNLQKTLT APVTAIVAWD SEFYERLPLL FPHGDARSWF TSSPQLAEET  120 AFRNSSMQAA YLIVACRALG LDTGPMSGED RQHVDDAFFT GSTLKSNLLI NIGYGDSSKL  180 YARLPRLSFE EACGLL  196 <212> TYPE: PRT <211> LENGTH: 196 SEQUENCENAME: ESCHERICHIA COLI RUTE PROTEIN SEQ ID NO. 21: YDFG DNA ORGANISM NAME: ESCHERICHIA COLI ATGGTCGTTT TAGTAACTGG AGCAACGGCA GGTTTTGGTG AATGCATTAC TCGTCGTTTT   60 ATTCAACAAG GGCATAAAGT TATCGCCACT GGCCGTCGCC AGGAACGGTT GCAGGAGTTA  120 AAAGACGAAC TGGGAGATAA TCTGTATATC GCCCAACTGG ACGTTCGCAA CCGCGCCGCT  180 ATTGAAGAGA TGCTGGCATC GCTTCCTGCC GAGTGGTGCA ATATTGATAT CCTGGTAAAT  240 AATGCCGGCC TGGCGTTGGG CATGGAGCCT GCGCATAAAG CCAGCGTTGA AGACTGGGAA  300 ACGATGATTG ATACCAACAA CAAAGGCCTG GTATATATGA CGCGCGCCGT CTTACCGGGT  360 ATGGTTGAAC GTAATCATGG TCATATTATT AACATTGGCT CAACGGCAGG TAGCTGGCCG  420 TATGCCGGTG GTAACGTTTA CGGTGCGACG AAAGCGTTTG TTCGTCAGTT TAGCCTGAAT  480 CTGCGTACGG ATCTGCATGG TACGGCGGTG CGCGTCACCG ACATCGAACC GGGTCTGGTG  540 GGTGGTACCG AGTTTTCCAA TGTCCGCTTT AAAGGCGATG ACGGTAAAGC AGAAAAAACC  600 TATCAAAATA CCGTTGCATT GACGCCAGAA GATGTCAGCG AAGCCGTCTG GTGGGTGTCA  660 ACGCTGCCTG CTCACGTCAA TATCAATACC CTGGAAATGA TGCCGGTTAC CCAAAGCTAT  720 GCCGGACTGA ATGTCCACCG TCAGTAA  747 <212> TYPE: DNA <211> LENGTH: 747 SEQUENCENAME: ESCHERICHIA COLI YDEG DNA SEQ ID NO. 22: YDFG PROTEIN ORGANISM NAME: ESCHERICH A COLI MVVLVTGATA GFGECITRRE IQQGHKVIAT GRRQERLQEL KDELGDNLYI AQLDVRNRAA   60 IEEMLASLPA EWCNIDILVN NAGLALGMEP AHKASVEDWE TMIDTNNKGL VYMTRAVLPG  120 MVERNHGHII NIGSTAGSWP YAGGNVYGAT KAFVRQESLN LRTDLHGTAV RVTDIEPGLV  180 GGTEESNVRE KGDDGKAEKT YQNTVALTPE DVSEAVWWVS TLPAHVNINT LEMMPVTQSY  240 AGLNVHRQ  248 <212> TYPE: PRT <211> LENGTH: 248 SEQUENCENAME: ESCHERICHIA COLI YDFG PROTEIN SEQ ID NO. 23: MMSB DNA ORGANISM NAME: P. AERUGINOSA ATGGCCGACA TTGCGTTTCT GGGTCTGGGC AATATGGGCG GTCCGATGGC CGCGAACCTG   60 CTGAAAGCCG GCCACCGTGT GAATGTGTTC GACCTGCAAC CAAAAGCGGT CCTGGGCTTG  120 GTTGAGCAAG GCGCGCAGGG CGCAGACTCT GCTCTGCAAT GTTGTGAGGG TGCGGAGGTC  180 GTGATTTCTA TGCTGCCAGC AGGCCAGCAT GTGGAAAGCC TGTACCTGGG CGATGATGGT  240 CTGCTGGCAC GCGTGGCGGG CAAGCCTTTG CTGATTGACT GTAGCACCAT CGCACCGGAA  300 ACGGCGCGTA AGGTGGCGGA GGCAGCCGCA GCAAAGGGCC TGACGCTGCT GGATGCCCCG  360 GTTTCGGGCG GTGTCGGTGG TGCCCGTGCA GGTACGCTGT CGTTTATCGT GGGTGGTCCG  420 GCGGAGGGTT TTGCGCGTGC GCGTCCGGTT CTGGAGAATA TGGGTCGCAA CATTTTCCAC  480 GCGGGTGATC ACGGCGCTGG TCAGGTGGCG AAAATCTGTA ACAACATGCT GCTGGGTATC  540 TTGATGGCGG GCACCGCCGA AGCCTTGGCG CTGGGCGTCA AAAACGGTCT GGACCCGGCA  600 GTGCTGTCCG AAGTGATGAA ACAGAGCAGC GGTGGTAACT GGGCGCTGAA TCTGTACAAT  660 CCGTGGCCGG GTGTGATGCC GCAGGCCCCA GCCTCTAATG GCTACGCAGG CGGCTTCCAA  720 GTGCGCCTGA TGAACAAAGA CCTGGGCCTG GCGCTGGCGA ATGCGCAAGC GGTCCAAGCG  780 AGCACCCCGC TGGGCGCACT GGCCCGTAAC CTGTTTAGCC TGCACGCTCA AGCCGACGCC  840 GAGCACGAAG GTCTGGACTT CAGCTCTATT CAAAAACTGT ATCGCGGTAA GGATTAG  897 <212> TYPE: DNA <211> LENGTH: 897 SEQUENCE NAME: P. AERUGINOSA MMSB DNA SEQ ID NO. 24: MMSB PROTEIN ORGANISM NAME: P. AERUGINOSA MADIAELGLG NMGGPMAANL LKAGHRVNVF DLQPKAVLGL VEQGAQGADS ALQCCEGAEV   60 VISMLPAGQH VESLYLGDDG LLARVAGKPL LIDCSTIAPE TARKVAEAAA AKGLTLLDAP  120 VSGGVGGARA GTLSFIVGGP AEGFARARPV LENMGRNIFH AGDHGAGQVA KICNNMLLGI  180 LMAGTAEALA LGVKNGLDPA VLSEVMKQSS GGNWALNLYN PWPGVMPQAP ASNGYAGGFQ  240 VRLMNKDLGL ALANAQAVQA STPLGALARN LFSLHAQADA EHEGLDFSSI QKLYRGKD  298 <212> TYPE: PRT <211> LENGTH: 298 SEQUENCENAME: P. AERUGINOSA MMSB PROTEIN SEQ ID NO. 25: NDSD DNA ORGANISMNAME: PSEUDOMONAS AERUGINOSA ATGGGCAAAC AGATCGCCTT CATCGGCCTG GGCCATATGG GCGCACCTAT GGCCACCAAC   60 CTGCTGAAGG CCGGCTACCT GCTGAATGTG TTCGACCTGG TGCAGAGCGC CGTGGATGGT  120 TTAGTGGCCG CAGGTGCAAG TGCAGCACGC AGTGCACGCG ATGCCGTTCA GGGTGCCGAC  180 GTGGTGATCA GCATGCTGCC TGCCAGCCAA CACGTGGAGG GTCTGTACCT GGACGACGAT  240 GGTCTGCTGG CCCACATTGC CCCTGGCACC TTAGTGCTGG AGTGCAGCAC AATCGCCCCG  300 ACCAGTGCAC GCAAGATTCA TGCAGCAGCC CGCGAGCGTG GTCTGGCAAT GCTGGACGCA  360 CCGGTTAGCG GTGGTACAGC AGGTGCCGCA GCAGGCACCC TGACCTTCAT GGTGGGCGGT  420 GACGCCGAAG CCCTGGAAAA AGCACGCCCG CTGTTTGAGG CAATGGGCCG TAACATCTTC  480 CATGCCGGCC CTGATGGCGC AGGTCAGGTG GCCAAAGTGT GCAATAACCA GCTGCTGGCA  540 GTGCTGATGA TCGGTACCGC CGAGGCAATG GCACTGGGCG TGGCAAACGG CTTAGAGGCC  600 AAGGTGCTGG CAGAAATCAT GCGCCGTAGT AGCGGCGGTA ACTGGGCCCT GGAGGTGTAC  660 AACCCGTGGC CTGGCGTGAT GGAGAATGCA CCGGCCAGTC GTGACTACAG CGGCGGTTTC  720 ATGGCACAGC TGATGGCCAA GGACCTGGGC TTAGCCCAAG AGGCAGCCCA AGCCAGCGCC  780 AGTAGTACCC CGATGGGCAG CTTAGCCCTG AGTCTGTACC GCTTACTGCT GAAGCAGGGC  840 TACGCCGAAC GCGACTTCAG CGTGGTGCAG AAGCTGTTCG ACCCGACCCA AGGCCAGTAA  900 <212> TYPE: DNA <211> LENGTH: 900 SEQUENCENAME: P. AERUGINOSA NDSD DNA SEQ ID NO. 26: NDSD PROTEIN PSEUDOMONAS AERUGINOSA MGKQIAFIGL GHMGAPMATN LLKAGYLLNV FDLVQSAVDG LVAAGASAAR SARDAVQGAD   60 VVISMLPASQ HVEGLYLDDD GLLAHIAPGT LVLECSTIAP TSARKIHAAA RERGLAMLDA  120 PVSGGTAGAA AGTLTFMVGG DAEALEKARP LFEAMGRNIF HAGPDGAGQV AKVCNNQLLA  180 VLMIGTAEAM ALGVANGLEA KVLAEIMRRS SGGNWALEVY NPWPGVMENA PASRDYSGGF  240 MAQLMAKDLG LAQEAAQASA SSTPMGSLAL SLYRLLLKQG YAERDFSVVQ KLFDPTQGQ  299 <212> TYPE: PRT <211> LENGTH: 299 SEQUENCENAME: P. AERUGINOSA NDSD PROTEIN SEQ ID NO. 27: FABI(TS) PROTEIN ORGANISM NAME: ESCHERICHIA COLI MGFLSGKRIL VTGVASKLSI AYGIAQAMHR EGAELAFTYQ NDKLKGRVEE FAAQLGSDIV   60 LQCDVAEDAS IDTMFAELGK VWPKEDGFVH SIGFAPGDQL DGDYVNAVTR EGFKIAHDIS  120 SYSFVAMAKA CRSMLNPGSA LLTLSYLGAE RAIPNYNVMG LAKASLEANV RYMANAMGPE  180 GVRVNAISAG PIRTLAASGI KDFRKMLAHC EAVTPIRRTV TIEDVGNSAA FLCSDLSAGI  240 FGEVVHVDGG FSIAAMNELE LK  262 <212> TYPE: PRT <211> LENGTH: 262 SEQUENCENAME: ESCHERICHIA COLI FABI(TS) PROTEIN SEQ ID NO. 28: FABB(TS) PROTEIN ORGANISM NAME: ESCHERICHIA COLI MKRAVITGLG IVSSIGNNQQ EVLASLREGR SGITFSQELK DSGMRSHVWG NVKLDTTGLI   60 DRKVVRFMSD ASIYAELSME QAIADAGLSP EAYQNNPRVG LIAGSGGGSP RFQVFGADAM  120 RGPRGLKAVG PYVVTKAMAS GVSACLATPF KIHGVNYSIS SACATSAHCI GNAVEQIQLG  180 KQDIVFAGGG EELCWEMACE FDAMGALSTK YNDTPEKASR TYDAHRDGFV IAGGGGMVVV  240 EELEHALARG AHIYAEIVGY GATSDGADMV APSGEGAVRC MKMAMHGVDT PIDYLNSHGT  300 STPVGDVKEL AAIREVFGDK SPAISATKVM TGHSLGAAGV QEAIYSLLML EHGFIAPSIN  360 TEELDEQAAG LNIVTETTDR ELTTVMSNSF GFGGTNATLV MRKLKD  406 <212> TYPE: PRT <211> LENGTH: 406 SEQUENCENAME: ESCHERICHIA COLI FABB(TS) PROTEIN SEQ ID NO. 29: FABD(TS) PROTEIN ORGANISM NAME: ESCHERICHIA COLI MTQFAFVFPG QGSQTVGMLA DMAASYPIVE ETFAEASAAL GYDLWALTQQ GPAEELNKTW   60 QTQPALLTAS VALYRVWQQQ GGKAPAMMAG HSLGEYSALV CAGVIDFADA VRLVEMRGKF  120 MQEAVPEGTG AMAAIIGLDD ASIAKACEEA AEGQVVSPVN FNSPGQVVIA GHKEAVERAG  180 AACKAAGAKR ALPLPVSVPS HCALMKPAAD KLAVELAKIT FNAPTVPVVN NVDVKCETNG  240 DAIRDALVRQ LYNPVQQTKS VEYMAAQGVE HLYEVGPGKV LTGLIKRIVD TLTASALNEP  300 SAMAAALEL  309 <212> TYPE: PRT <211> LENGTH: 309 SEQUENCENAME: ESCHERICHIA COLI FABD(TS) PROTEIN SEQ ID NO. 30: RHTA DNA ORGANISM NAME: ESCHERICHIA COLA ATGAGCGGTT CATTACGTAA AATGCCGGTC TGGTTACCAA TAGTCATATT GCTCGTTGCC   60 ATGGCGTCTA TTCAGGGTGG AGCCTCGTTA GCTAAGTCAC TTTTTCCTCT GGTGGGCGCA  120 CCGGGTGTCA CTGCGCTGCG TCTGGCATTA GGAACGCTGA TCCTCATCGC GTTCTTTAAG  180 CCATGGCGAC TGCGCTTTGC CAAAGAGCAA CGGTTACCGC TGTTGTTTTA CGGCGTTTCG  240 CTGGGTGGGA TGAATTATCT TTTTTATCTT TCTATTCAGA CAGTACCGCT GGGTATTGCG  300 GTGGCGCTGG AGTTCACCGG ACCACTGGCG GTGGCGCTGT TCTCTTCTCG TCGCCCGGTA  360 GATTTCGTCT GGGTTGTGCT GGCGGTTCTT GGTCTGTGGT TCCTGCTACC GCTGGGGCAA  420 GACGTTTCCC ATGTCGATTT AACCGGCTGT GCGCTGGCAC TGGGGGCCGG GGCTTGTTGG  480 GCTATTTACA TTTTAAGTGG GCAACGCGCA GGAGCGGAAC ATGGCCCTGC GACGGTGGCA  540 ATTGGTTCGT TGATTGCAGC GTTAATTTTC GTGCCAATTG GAGCGCTTCA GGCTGGTGAA  600 GCACTCTGGC ACTGGTCGGT TATTCCATTG GGTCTGGCTG TCGCTATTCT CTCGACCGCT  660 CTGCCTTATT CGCTGGAAAT GATTGCCCTC ACCCGTTTGC CAACACGGAC ATTTGGTACG  720 CTGATGAGCA TGGAACCGGC GCTGGCTGCC GTTTCCGGGA TGATTTTCCT CGGAGAAACA  780 CTGACACCCA TACAGCTACT GGCGCTCGGC GCTATCATCG CCGCTTCAAT GGGGTCTACG  840 CTGACAGTAC GCAAAGAGAG CAAAATAAAA GAATTAGACA TTAATTAA  888 <212> TYPE: DNA <211> LENGTH: 888 SEQUENCENAME: ESCHERICHIA COLI RHTA DNA SEQ ID NO. 31: RHTA PROTEIN ORGANISM NAME: ESCHERICHIA COLI MSGSLRKMPV WLPIVILLVA MASIQGGASL AKSLFPLVGA PGVTALRLAL GTLILIAFFK   60 PWRLRFAKEQ RLPLLFYGVS LGGMNYLFYL SIQTVPLGIA VALEFTGPLA VALFSSRRPV  120 DFVWVVLAVL GLWFLLPLGQ DVSHVDLTGC ALALGAGACW AIYILSGQRA GAEHGPATVA  180 IGSLIAALIF VPIGALQAGE ALWHWSVIPL GLAVAILSTA LPYSLEMIAL TRLPTRTFGT  240 LMSMEPALAA VSGMIFLGET LTPIQLLALG AIIAASMGST LTVRKESKIK ELDIN  295 <212> TYPE: PRT <211> LENGTH: 295 SEQUENCENAME: ESCHERICHIA COLI RHTA PROTEIN SEQ ID NO. 32: YDCO DNA ORGANISM NAME: ESCHERICHIA COLI ATGCGACTCC TCCGGCAAAA CGGAAGTTTA TCACTTGTGC GTTATAACGG ACAAATGCTA   60 CGGTGCCTGT ACGCTATAAC GCACGAGGTG ACTATGCGTC TGTTTTCTAT TCCTCCACCC  120 ACGCTACTGG CGGGGTTTCT GGCGGTATTA ATTGGCTACG CCAGTTCAGC GGCAATAATC  180 TGGCAAGCAG CGATTGTCGC CGGAGCCACC ACTGCACAAA TCTCTGGCTG GATGACGGCG  240 CTGGGGCTGG CAATGGGCGT CAGTACGCTG ACTCTGACAT TATGGTATCG CGTACCTGTT  300 CTCACCGCAT GGTCAACGCC TGGCGCGGCT TTGTTGGTCA CCGGATTGCA GGGACTAACA  360 CTTAACGAAG CCATCGGCGT TTTTATTGTC ACCAACGCGC TAATAGTCCT CTGCGGCATA  420 ACGGGACTCT TTGCTCGTCT GATGCGCATT ATTCCGCACT CGCTTGCGGC GGCAATGCTT  480 GCCGGGATTT TATTACGCTT TGGTTTACAG GCGTTTGCCA GTCTGGACGG TCAATTTACG  540 TTGTGTGGAA GTATGTTGCT GGTATGGCTG GCAACCAAGG CCGTTGCGCC GCGCTATGCG  600 GTAATTGCCG CGATGATTAT TGGGATCGTG ATCGTCATCG CGCAAGGTGA CGTTGTCACA  660 ACTGATGTTG TCTTTAAACC CGTTCTCCCC ACTTATATTA CCCCTGATTT TTCGTTTGCT  720 CACAGCCTGA GCGTTGCACT CCCCCTTTTT CTGGTGACGA TGGCATCGCA AAACGCACCG  780 GGTATCGCAG CAATGAAAGC AGCTGGATAT TCGGCTCCTG TTTCGCCATT AATTGTATTT  840 ACTGGATTGC TGGCACTGGT TTTTTCCCCT TTCGGCGTTT ATTCCGTCGG TATTGCGGCA  900 ATCACCGCGG CTATTTGCCA AAGCCCGGAA GCGCATCCGG ATAAAGATCA ACGTTGGCTG  960 GCCGCTGCCG TTGCAGGCAT TTTCTATTTG CTCGCAGGTC TGTTTGGTAG TGCCATTACC 1020 GGGATGATGG CTGCCCTGCC CGTAAGTTGG ATCCAGATGC TGGCAGGTCT GGCGCTGTTA 1080 AGTACCATCG GCGGCAGTTT GTATCAGGCG CTGCATAATG AGCGTGAGCG AGACGCGGCG 1140 GTGGTGGCAT TTCTGGTAAC GGCAAGTGGA TTGACGCTGG TCGGGATTGG TTCTGCGTTT 1200 TGGGGATTAA TTGCCGGAGG CGTTTGTTAC GTGGTGTTGA ATTTAATCGC TGACAGAAAC 1260 CGATATTGA 1269 <212> TYPE: DNA <211> LENGTH: 1269 SEQUENCENAME: ESCHERICHIA COLI YDCO DNA SEQ ID NO. 33: YDCO PROTEIN ORGANISM NAME: ESCHERICHIA COLI MRLLRQNGSL SLVRYNGQML RCLYAITHEV TMRLFSIPPP TLLAGFLAVL IGYASSAAII   60 WQAAIVAGAT TAQISGWMTA LGLAMGVSTL TLTLWYRVPV LTAWSTPGAA LLVTGLQGLT  120 LNEAIGVFIV TNALIVLCGI TGLFARLMRI IPHSLAAAML AGILLRFGLQ AFASLDGQFT  180 LCGSMLLVWL ATKAVAPRYA VIAAMIIGIV IVIAQGDVVT TDVVFKPVLP TYITPDFSFA  240 HSLSVALPLF LVTMASQNAP GIAAMKAAGY SAPVSPLIVF TGLLALVFSP FGVYSVGIAA  300 ITAAICQSPE AHPDKDQRWL AAAVAGIFYL LAGLFGSAIT GMMAALPVSW IQMLAGLALL  360 STIGGSLYQA LHNERERDAA VVAFLVTASG LTLVGIGSAF WGLIAGGVCY VVLNLIADRN  420 RY  422 <212> TYPE: PRT <211> LENGTH: 422 SEQUENCENAME: ESCHERICHIA COLI YDCO PROTEIN SEQ ID NO. 34: ACRD ORGANISM NAME: ESCHERICHIA COLI MANFFIDRPI FAWVLAILLC LTGTLAIFSL PVEQYPDLAP PNVRVTANYP GASAQTLENT VTQVIEQNMT GLDNLMYMSS QSSGTGQASV TLSFKAGTDP DEAVQQVQNQ LQSAMRKLPQ AVQNQGVTVR KTGDTNILTI AFVSTDGSMD KQDIADYVAS NIQDPLSRVN GVGDIDAYGS QYSMRIWLDP AKLNSFQMTA KDVTDAIESQ NAQIAVGQLG GTPSVDKQAL NATINAQSLL QTPEQFRDIT LRVNQDGSEV RLGDVATVEM GAEKYDYLSR FNGKPASGLG VKLASGANEM ATAELVLNRL DELAQYFPHG LEYKVAYETT SFVKASIEDV VKTLLEAIAL VFLVMYLFLQ NFRATLIPTI AVPVVLMGTF SVLYAFGYSV NTLTMFAMVL AIGLLVDDAI VVVENVERIM SEEGLTPREA TRKSMGQIQG ALVGIAMVLS AVFVPMAFFG GTTGAIYRQF SITIVAAMVL SVLVAMILTP ALCATLLKPL KKGEHHGQKG FFAWFNQMFN RNAERYEKGV AKILHRSLRW IVIYVLLLGG MVFLFLRLPT SFLPLEDRGM FTTSVQLPSG STQQQTLKVV EQIEKYYFTH EKDNIMSVFA TVGSGPGGNG QNVARMFIRL KDWSERDSKT GTSFAIIERA TKAFNQIKEA RVIASSPPAI SGLGSSAGFD MELQDHAGAG HDALMAARNQ LLALAAENPE LTRVRHNGLD DSPQLQIDID QRKAQALGVA IDDINDTLQT AWGSSYVNDF MDRGRVKKVY VQAAAPYRML PDDINLWYVR NKDGGMVPFS AFATSRWETG SPRLERYNGY SAVEIVGEAA PGVSTGTAMD IMESLVKQLP NGFGLEWTAM SYQERLSGAQ APALYAISLL VVFLCLAALY ESWSVPFSVM LVVPLGVIGA LLATWMRGLE NDVYFQVGLL TVIGLSAKNA ILIVEFANEM NQKGHDLFEA TLHACRQRLR PILMTSLAFI FGVLPMATST GAGSGGQHAV GTGVMGGMIS ATILAIYFVP LFFVLVRRRF PLKPRPE SEQ ID NO. 35: ATTA ORGANISM NAME: ESCHERICHIA COLI MAHPPLLHLQ DITLSLGGNP LLDGAGFAVG RGERLCLVGR NGSGKSTLLK IAAGVIQPDS GSVFVQPGAS LRYLPQEPDL SAYATTADYV VGQIGDPDMA WRATPLLDAL GLTGRESTQN LSGGEGRRCA IAGVLAAAPD VLLLDEPTNH LDMPTIEWLE RELLSLGAMV IISHDRRLLS TLSRSVVWLD RGVTRRLDEG FGRFEAWREE VLEQEERDAH KLDRKIAREE DWMRYGVTAR RKRNVRRVRE LADLRTARKE AIRAPGTLTL NTQLRPHRKL VAVAEDISKA WGEKQVVRHL DLRILRGDRL GIVGANGAGK TTLLRMLTGL DQPDSGTISL GPSLNMVTLD QQRRTLNPER TLADTLTEGG GDMVQVGTEK RHVVGYMKDF LFRPEQARTP VSALSGGERG RLMLACALAK PSNLLVLDEP TNDLDLETLD ILQDMLASCE GTVLLVSHDR DFLDRVATSV LATEGDGNWI EYAGGYSDML AQRHQKPLII ASVVENEPTK PKETTAARGP TKKLSYKDQF ALDNLPKEME KLEAQAANCV KNWQIQIYME KTPRSLRNFR LIYRSSKQSW QNLKNAGWNW K SEQ ID NO. 36: BCR ORGANISM NAME: ESCHERICHIA COLI MTTRQHSSFA IVFILGLLAM LMPLSIDMYL PALPVISAQF GVPAGSTQMT LSTYILGFAL GOLIYGPMAD SFGRKPVVLG GTLVFAAAAV ACALANTIDQ LIVMRFFHGL AAAAASVVIN ALMRDIYPKE EFSRMMSFVM LVTTIAPLMA PIVGGWVLVW LSWHYIFWIL ALAAILASAM IFFLIKETLP PERRQPFHIR TTIGNFAALF RHKRVLSYML ASGFSFAGMF SELSAGPFVY IEINHVAPEN FGYYFALNIV FLEVMTIENS RFVRRIGALN MFRSGLWIQF IMAAWMVISA LLGLGFWSLV VGVAAFVGCV SMVSSNAMAV ILDEFPHMAG TASSLAGTFR FGIGAIVGAL LSLATFNSAW PMIWSIAFCA TSSILFCLYA SRPKKR SEQ ID NO. 37: CUSA ORGANISM NAME: ESCHERICHIA COLI MIEWIIRRSV ANRFLVLMGA LFLSIWGTWT IINTPVDALP DLSDVQVIIK TSYPGQAPQI VENQVTYPLT TTMLSVPGAK TVRGFSQFGD SYVYVIFEDG TDPYWARSRV LEYLNQVQGK LPAGVSAELG PDATGVGWIY EYALVDRSGK HDLADLRSLQ DWFLKYELKT IPDVAEVASV GGVVKEYQVV IDPQRLAQYG ISLAEVKSAL DASNQEAGGS SIELAEAEYM VRASGYLQTL DDFNHIVLKA SENGVPVYLR DVAKVQIGPE MRRGIAELNG EGEVAGGVVI LRSGKNAREV IAAVKDKLET LKSSLPEGVE IVITYDRSQL IDRAIDNLSG KLLEEFIVVA VVCALFLWHV RSALVAIISL PLGLCIAFIV MHFQGLNANI MSLGGIAIAV GAMVDAAIVM IENAHKRLEE WQHQHPDATL DNKTRWQVIT DASVEVGPAL FISLLIITLS FIPIFTLEGQ EGRLFGPLAF TKTYAMAGAA LLAIVVIPIL MGYWIRGKIP PESSNPLNRF LIRVYHPLLL KVLHWPKTTL LVAALSVLTV LWPLNKVGGE FLPQINEGDL LYMPSTLPGI SAAEAASMLQ KTDKLIMSVP EVARVFGKTG KAETATDSAP LEMVETTIQL KPQEQWRPGM TMDKIIEELD NTVRLPGLAN LWVPPIRNRI DMLSTGIKSP IGIKVSGTVL ADIDAMAEQI EEVARTVPGV ASALAERLEG GRYINVEINR EKAARYGMTV ADVQLEVTSA VGGAMVGETV EGIARYPINL RYPQSWRDSP QALRQLPILT PMKQQITLAD VADIKVSTGP SMLKTENARP TSWIYIDARD RDMVSVVHDL QKAIAEKVQL KPGTSVAFSG QFELLERANH KLKLMVPMTL MIIFVLLYLA FRRVGEALLI ISSVPFALVG GIWLLWWMGF HLSVATGTGF IALAGVAAEF GVVMLMYLRH AIEAVPSLNN PQTESEQKLD EALYHGAVLR VRPKAMTVAV IIAGLLPILW GTGAGSEVMS RIAAPMIGGM ITAPLLSLFI IPAAYKLMWL FIRFIRVRK SEQ ID NO. 38: CYNX ORGANISM NAME: ESCHERICHIA COLI MLLVLVLIGL NMRPLLTSVG PLLPQLRQAS GMSFSVAALL TALPVVTMGG LALAGSWLHQ HVSERRSVAI SLLLIAVGAL MRELYPQSAL LLSSALLGGV GIGIIQAVMP SVIKRRFQQR TPLVMGLWSA ALMGGGGLGA AITPWLVQHS ETWYQTLAWW ALPAVVALFA WWWQSAREVA SSHKTTTTPV RVVFTPRAWT LGVYFGLING GYASLIAWLP AFYIEIGASA QYSGSLLALM TLGQAAGALL MPAMARHQDR RKLLMLALVL QLVGFCGFIW LPMQLPVLWA MVCGLGLGGA FPLCLLLALD HSVQPAIAGK LVAFMQGIGF IIAGLAPWFS GVLRSISGNY LMDWAFHALC VVGLMIITLR FAPVRFPQLW VIKEA SEQ ID NO. 39: DEDA ORGANISM NAME: ESCHERICHIA COLI MDLIYFLIDF ILHIDVHLAE LVAEYGVWVY AILFLILFCE TGLVVTPFLP GDSLLFVAGA LASLETNDLN VHMMVVLMLI AAIVGDAVNY TIGRLFGEKL FSNPNSKIFR RSYLDKTHQF YEKHGGKTII LARFVPIVRT FAPFVAGMGH MSYRHFAAYN VIGALLWVLL FTYAGYFFGT IPMVQDNLKL LIVGIIVVSI LPGVIEIIRH KRAAARAAK SEQ ID NO. 40: EAMA ORGANISM NAME: ESCHERICHIA COLI MSRKDGVLAL LVVVVWGLNF VVIKVGLHNM PPLMLAGLRF MLVAFPAIFF VARPKVPLNL LLGYGLTISF AQFAFLFCAI NFGMPAGLAS LVLQAQAFFT IMLGAFTFGE RLHGKOLAGI ALAIFGVLVL IEDSLNGQHV AMLGFMLTLA AAFSWACGNI FNKKIMSHST RPAVMSLVIW SALIPIIPFF VASLILDGSA TMIHSLVTID MTTTLSLMYL AFVATIVGYG IWGTLLGRYE TWRVAPLSLL VPVVGLASAA LLLDERLTGL QFLGAVLIMT GLYINVFGLR WRKAVKVGS SEQ ID NO. 41: EAMB ORGANISM NAME: ESCHERICHIA COLI MTPTLLSAFW TYTLITAMTP GPNNILALSS ATSHGFRQST RVLAGMSLGF LIVMLLCAGI SFSLAVIDPA AVHLLSWAGA AYIVWLAWKI ATSPTKEDGL QAKPISFWAS FALQFVNVKI ILYGVTALST FVLPQTQALS WVVGVSVLLA MIGTFGNVCW ALAGHLFQRL FRQYGRQLNI VLALLLVYCA VRIFY SEQ ID NO. 42: EMRB ORGANISM NAME: ESCHERICHIA COLI MQQQKPLEGA QLVIMTIALS LATFMQVLDS TIANVAIPTI AGNLGSSLSQ GTWVITSFGV ANAISIPLTG WLAKRVGEVK LFLWSTIAFA IASWACGVSS SLNMLIFFRV IQGIVAGPLI PLSQSLLLNN YPPAKRSIAL ALWSMTVIVA PICGPILGGY ISDNYHWGWI FFINVPIGVA VVLMTLQTLR GRETRTERRR IDAVGLALLV IGIGSLQIML DRGKELDWFS SQEIIILTVV AVVAICFLIV WELTDDNPIV DLSLFKSRNF TIGCLCISLA YMLYFGAIVL LPQLLQEVYG YTATWAGLAS APVGIIPVIL SPIIGRFAHK LDMRRLVTFS FIMYAVCFYW RAYTFEPGMD FGASAWPQFI QGFAVACFFM PLTTITLSGL PPERLAAASS LSNFTRTLAG SIGTSITTTM WTNRESMHHA QLTESVNPFN PNAQAMYSQL EGLGMTQQQA SGWIAQQITN QGLIISANEI FWMSAGIFLV LLGLVWFAKP PFGAGGGGGG AH SEQ ID NO. 43: EMRD ORGANISM NAME: ESCHERICHIA COLI MKRQRNVNLL LMLVLLVAVG QMAQTIYIPA IADMARDLNV REGAVQSVMG AYLLTYGVSQ LFYGPISDRV GRRPVILVGM SIFMLATLVA VTTSSLTVLI AASAMQGMGT GVGGVMARTL PRDLYERTQL RHANSLLNMG ILVSPLLAPL IGGLLDTMWN WRACYLFLLV LCAGVTFSMA RWMPETRPVD APRTRLLTSY KTLFGNSGFN CYLLMLIGGL AGIAAFEACS GVLMGAVLGL SSMTVSILFI LPIPAAFFGA WFAGRPNKRF STLMWQSVIC CLLAGLLMWI PDWFGVMNVW TLLVPAALFF FGAGMLFPLA TSGAMEPFPF LAGTAGALVG GLQNIGSGVL ASLSAMLPQT GQGSLGLLMT LMGLLIVLON LPLATRMSHQ GQPV SEQ ID NO. 44: EMRKY ORGANISM NAME: ESCHERICHIA COLI MAITKSTPAP LTGGTLWCVT IALSLATFMQ MLDSTISNVA IPTISGFLGA STDEGTWVIT SFGVANAIAI PVTGRLAQRI GELRLFLLSV TFFSLSSLMC SLSTNLDVLI FFRVVQGLMA GPLIPLSQSL LLRNYPPEKR TFALALWSMT VIIAPICGPI LGGYICDNFS WGWIFLINVP MGIIVLTLCL TLLKGRETET SPVKMNLPGL TLLVLGVGGL QIMLDKGRDL DWFNSSTIII LTVVSVISLI SLVIWESTSE NPILDLSLFK SRNFTIGIVS ITCAYLFYSG AIVLMPQLLQ ETMGYNAIWA GLAYAPIGIM PLLISPLIGR YGNKIDMRLL VTFSFLMYAV CYYWRSVTFM PTIDFTGIIL PQFFQGFAVA CFFLPLTTIS FSGLPDNKFA NASSMSNFFR TLSGSVGTSL TMTLWGRRES LHHSQLTATI DQFNPVFNSS SQIMDKYYGS LSGVLNEINN EITQQSLSIS ANEIFRMAAI AFILLTVLVW FAKPPFTAKG VG SEQ ID NO. 45: EMRY ORGANISM NAME: ESCHERICHIA COLI MAITKSTPAP LTGGTLWCVT IALSLATFMQ MLDSTISNVA IPTISGFLGA STDEGTWVIT SFGVANAIAI PVTGRLAQRI GELRLFLLSV TFFSLSSLMC SLSTNLDVLI FFRVVQGLMA GPLIPLSQSL LLRNYPPEKR TFALALWSMT VIIAPICGPI LGGYICDNFS WGWIFLINVP MGIIVLTLCL TLLKGRETET SPVKMNLPGL TLLVLGVGGL QIMLDKGRDL DWFNSSTIII LTVVSVISLI SLVIWESTSE NPILDLSLFK SRNFTIGIVS ITCAYLFYSG AIVLMPQLLQ ETMGYNAIWA GLAYAPIGIM PLLISPLIGR YGNKIDMRLL VTFSFLMYAV CYYWRSVTFM PTIDFTGIIL PQFFQGFAVA CFFLPLTTIS FSGLPDNKFA NASSMSNFFR ILSGSVGISL TMTLWGRRES LHHSQLTATI DQFNPVFNSS SQIMDKYYGS LSGVLNEINN EITQQSLSIS ANEIFRMAAI AFILLTVLVW FAKPPFTAKG VG SEQ ID NO. 46: GARP ORGANISM NAME: ESCHERICHIA COLI MILDTVDEKK KGVHTRYLIL LIIFIVTAVN YADRATLSIA GTEVAKELQL SAVSMGYIFS AFGWAYLLMQ IPGGWLLDKF GSKKVYTYSL FFWSLFTFLQ GFVDMFPLAW AGISMFFMRF MLGFSEAPSF PANARIVAAW FPTKERGTAS AIFNSAQYFS LALFSPLLGW LTFAWGWEHV FTVMGVIGFV LTALWIKLIH NPTDHPRMSA EELKFISENG AVVDMDHKKP GSAAASGPKL HYIKQLLSNR MMLGVFFGQY FINTITWFFL TWFPIYLVQE KGMSILKVGL VASIPALCGF AGGVLGGVFS DYLIKRGLSL TLARKLPIVL GMLLASTIIL CNYTNNTTLV VMLMALAFFG KGFGALGWPV ISDTAPKEIV GLCGGVFNVF GNVASIVTPL VIGYLVSELH SFNAALVFVG CSALMAMVCY LFVVGDIKRM ELQK SEQ ID NO. 47: GUDP ORGANISM NAME: ESCHERICHIA COLI MSSLSQAASS VEKRTNARYW IVVMLFIVTS FNYGDRATLS IAGSEMAKDI GLDPVGMGYV FSAFSWAYVI GQIPGGWLLD RFGSKRVYFW SIFIWSMFTL LQGFVDIFSG FGIIVALFTL RFLVGLAEAP SFPGNSRIVA AWFPAQERGT AVSIFNSAQY FATVIFAPIM GWLTHEVGWS HVFFFMGGLG IVISFIWLKV IHEPNQHPGV NKKELEYIAA GGALINMDQQ NTKVKVPFSV KWGQIKQLLG SRMMIGVYIG QYCINALTYF FITWFPVYLV QARGMSILKA GFVASVPAVC GFIGGVLGGI ISDWLMRRTG SLNIARKTPI VMGMLLSMVM VFCNYVNVEW MIIGFMALAF FGKGIGALGW AVMADTAPKE ISGLSGGLFN MFGNISGIVT PIAIGYIVGT TGSFNGALIY VGVHALIAVL SYLVLVGDIK RIELKPVAGQ  SEQ ID NO. 48: HSRA ORGANISM NAME: ESCHERICHIA COLI MSDKKKRSMA GLPWIAAMAF FMQALDATIL NTALPAIAHS LNRSPLAMQS AIISYTLIVA MLIPVSGWLA DRFGTRRIFT LAVSLFTLGS LACALSNSLP QLVVFRVIQG IGGAMMMPVA RLALLRAYPR NELLPVLNFV AMPGLVGPIL GPVLGGVLVT WATWHWIFLI NIPIGIAGLL YARKHMPNFT TARRRFDITG FLLFGLSLVL FSSGIELFGE KIVASWIALT VIVTSIGLLL LYILHARRTP NPLISLDLFK TRTFSIGIVG NIATRLGTGC VPFLMPLMLQ VGFGYQAFIA GCMMAPTALG SIIAKSMVTQ VLRRLGYRHT LVGITVIIGL MIAQFSLQSP AMAIWMLILP LFILGMAMST QFTAMNTITL ADLTDDNASS GNSVLAVTQQ LSISLGVAVS AAVLRVYEGM EGTTTVEQFH YTFITMGIIT VASAAMFMLL KTTDGNNLIK RQRKSKPNRV PSESE SEQ ID NO. 49: LEUE ORGANISM NAME: ESCHERICHIA COLI MFAEYGVLNY WTYLVGAIFI VLVPGPNTLF VLKNSVSSGM KGGYLAACGV FIGDAVLMFL AWAGVATLIK TTPILFNIVR YLGAFYLLYL GSKILYATLK GKNSEAKSDE PQYGAIFKRA LILSLTNPKA ILFYVSFFVQ FIDVNAPHTG ISFFILAATL ELVSFCYLSF LIISGAFVTQ YIRTKKKLAK VGNSLIGLMF VGFAARLATL QS SEQ ID NO. 50: MDLB ORGANISM NAME: ESCHERICHIA COLI MRSFSQLWPT LKRLLAYGSP WRKPLGIAVL MMWVAAAAEV SGPLLISYFI DNMVAKNNLP LKVVAGLAAA YVGLQLFAAG LHYAQSLLFN RAAVGVVQQL RTDVMDAALR QPLSEFDTQP VGQVISRVTN DTEVIRDLYV TVVATVLRSA ALVGAMLVAM FSLDWRMALV AIMIFPVVLV VMVIYQRYST PIVRRVRAYL ADINDGFNEI INGMSVIQQF RQQARFGERM GEASRSHYMA RMQTLRLDGF LLRPLLSLFS SLILCGLLML FGFSASGTIE VGVLYAFISY LGRLNEPLIE LTTQQAMLQQ AVVAGERVFE LMDGPRQQYG NDDRPLQSGT IEVDNVSFAY RDDNLVLKNI NLSVPSRNFV ALVGHTGSGK STLASLLMGY YPLTEGEIRL DGRPLSSLSH SALRQGVAMV QQDPVVLADT FLANVTLGRD ISEERVWQAL ETVQLAELAR SMSDGIYTPL GEQGNNLSVG QKQLLALARV LVETPQILIL DEATASIDSG TEQAIQHALA AVREHTTLVV IAHRLSTIVD ADTILVLHRG QAVEQGTHQQ LLAAQGRYWQ MYQLQLAGEE LAASVREEES LSA SEQ ID NO. 51: MDTD ORGANISM NAME: ESCHERICHIA COLI MTDLPDSTRW QLWIVAFGFF MQSLDTTIVN TALPSMAQSL GESPLHMHMV IVSYVLTVAV MLPASGWLAD KVGVRNIFFT AIVLFTLGSL FCALSGTLNE LLLARALQGV GGAMMVPVGR LTVMKIVPRE QYMAAMTFVT LPGQVGPLLG PALGGLLVEY ASWHWIFLIN IPVGIIGAIA TLLLMPNYTM QTRRFDLSGF LLLAVGMAVL TLALDGSKGT GLSPLTIAGL VAVGVVALVL YLLHARNNNR ALFSLKLFRT RTFSLGLAGS FAGRIGSGML PFMTPVFLQI GLGFSPFHAG LMMIPMVLGS MGMKRIVVQV VNRFGYRRVL VATTLGLSLV TLLFMTTALL GWYYVLPFVL FLQGMVNSTR FSSMNTLTLK DLPDNLASSG NSLLSMIMQL SMSIGVTIAG LLLGLFGSQH VSVDSGTTQT VFMYTWLSMA LIIALPAFIF ARVPNDTHQN VAISRRKRSA Q SEQ ID NO. 52: MDTG ORGANISM NAME: ESCHERICHIA COLI MSPCENDTPI NWKRNLIVAW LGCFLTGAAF SLVMPFLPLY VEQLGVTGHS ALNMWSGIVF SITFLFSAIA SPFWGGLADR KGRKLMLLRS ALGMGIVMVL MGLAQNIWQF LILRALLGLL GGFVPNANAL IATQVPRNKS GWALGTLSTG GVSGALLGPM AGGLLADSYG LRPVFFITAS VLILCFFVTL FCIREKFQPV SKKEMLHMRE VVTSLKNPKL VLSLFVTTLI IQVATGSIAP ILTLYVRELA GNVSNVAFIS GMIASVPGVA ALLSAPRLGK LGDRIGPEKI LITALIFSVL LLIPMSYVQT PLQLGILRFL LGAADGALLP AVQTLLVYNS SNQIAGRIFS YNQSFRDIGN VTGPLMGAAI SANYGFRAVF LVTAGVVIIN AVYSWNSLRR RRIPQVSN SEQ ID NO. 53: MDTL ORGANISM NAME: ESCHERICHIA COLI MSRFLICSFA LVLLYPAGID MYLVGLPRIA ADLNASEAQL HIAFSVYLAG MAAAMLFAGK VADRSGRKPV AIPGAALFII ASVFCSLAET STLFLAGRFL QGLGAGCCYV VAFAILRDTL DDRRRAKVLS LLNGITCIIP VLAPVLGHLI MLKFPWQSLF WAMAMMGIAV LMLSLFILKE TRPAAPAASD KPRENSESLL NRFFLSRVVI TTLSVSVILT FVNTSPVLLM EIMGFERGEY ATIMALTAGV SMTVSFSTPF ALGIFKPRTL MITSQVLFLA AGITLAVSPS HAVSLFGITL ICAGFSVGFG VAMSQALGPF SLRAGVASST LGIAQVCGSS LWIWLAAVVG IGAWNMLIGI LIACSIVSLL LIMFVAPGRP VAAHEEIHHH A SEQ ID NO. 54: MDTM ORGANISM NAME: ESCHERICHIA COLI MPRFFTRHAA TLFFPMALIL YDFAAYLSTD LIQPGIINVV RDFNADVSLA PAAVSLYLAG GMALQWLLGP LSDRIGRRPV LITGALIFTL ACAATMFTTS MTQFLIARAI QGTSICFIAT VGYVTVQEAF GQTKGIKLMA IITSIVLIAP IIGPLSGAAL MHFMHWKVLF AIIAVMGFIS FVGLLLAMPE TVKRGAVPFS AKSVLRDFRN VFCNRLFLFG AATISLSYIP MMSWVAVSPV ILIDAGSLTT SQFAWTQVPV FGAVIVANAI VARFVKDPTE PRFIWRAVPI QLVGLSLLIV GNLLSPHVWL WSVLGTSLYA FGIGLIFPTL FRFTLFSNKL PKGTVSASLN MVILMVMSVS VEIGRWLWFN GGRLPFHLLA VVAGVIVVFT LAGLLNRVRQ HQAAELVEEQ  SEQ ID NO. 55: MHPT ORGANISM NAME: ESCHERICHIA COLI MSTRTPSSSS SRLMLTIGLC FLVALMEGLD LQAAGIAAGG IAQAFALDKM QMGWIFSAGI LGLLPGALVG GMLADRYGRK RILIGSVALF GLFSLATAIA WDFPSLVFAR LMTGVGLGAA LPNLIALTSE AAGPRFRGTA VSLMYCGVPI GAALAATLGF AGANLAWQTV FWVGGVVPLI LVPLLMRWLP ESAVFAGEKQ SAPPLRALFA PETATATLLL WLCYFFTLLV VYMLINWLPL LLVEQGFQPS QAAGVMFALQ MGAASGTLML GALMDKLRPV TMSLLIYSGM LASLLALGTV SSFNGMLLAG FVAGLFATGG QSVLYALAPL FYSSQIRATG VGTAVAVGRL GAMSGPLLAG KMLALGTGTV GVMAASAPGI LVAGLAVFIL MSRRSRIQPC ADA SEQ ID NO. 56: RHTA ORGANISM NAME: ESCHERICHIA COLI MPGSLRKMPV WLPIVILLVA MASIQGGASL AKSLFPLVGA PGVTALRLAL GTLILIAFFK PWRLRFAKEQ RLPLLFYGVS LGGMNYLFYL SIQTVPLGIA VALEFTGPLA VALFSSRRPV DFVWVVLAVL GLWFLLPLGQ DVSHVDLTGC ALALGAGACW AIYILSGQRA GAEHGPATVA IGSLIAALIF VPIGALQAGE ALWHWSVIPL GLAVAILSTA LPYSLEMIAL TRLPTRTFGT LMSMEPALAA VSGMIFLGET LTPIQLLALG AIIAASMGST LTVRKESKIK ELDIN SEQ ID NO. 57: RHTB ORGANISM NAME: ESCHERICHIA COLI MTLEWWFAYL LTSIILSLSP GSGAINTMTT SLNHGYRGAV ASIAGLQTGL AIHIVLVGVG LGTLFSRSVI AFEVLKWAGA AYLIWLGIQQ WRAAGAIDLK SLASTQSRRH LFQRAVFVNL TNPKSIVFLA ALFPQFIMPQ QPQLMQYIVL GVITIVVDII VMIGYATLAQ RIALWIKGPK QMKALNKIFG SLFMLVGALL ASARHA SEQ ID NO. 58: RHTC ORGANISM NAME: ESCHERICHIA COLI MLMLFLTVAM VHIVALMSPG PDFFTVSQTA VSRSRKEAMM GVLGITCGVM VWAGIALLGL HLIIEKMAWL HTLIMVGGGL YLCWMGYQML RGALKKEAVS APAPQVELAK SGRSFLKGLL TNLANPKAII YFGSVFSLFV GDNVGTTARW GIFALIIVET LAWFTVVASL FALPQMRRGY QRLAKWIDGF AGALFAGFGI HLIISR SEQ ID NO. 59: YAHN ORGANISM NAME: ESCHERICHIA COLI MMQLVHLFMD EITMDPLHAV YLTVGLFVIT FFNPGANLFV VVQTSLASGR RAGVLTGLGV ALGDAFYSGL GLFGLATLIT QCEEIFSLIR IVGGAYLLWF AWCSMRRQST PQMSTLQQPI SAPWYVFFRR GLITDLSNPQ TVLFFISIFS VTLNAETPTW ARLMAWAGIV LASIIWRVFL SQAFSLPAVR RAYGRMQRVA SRVIGAIIGV FALRLIYEGV TQR SEQ ID NO. 60: YAJR ORGANISM NAME: ESCHERICHIA COLI MNDYKMTPGE RRATWGLGTV FSLRMLGMFM VLPVLTTYGM ALQGASEALI GIAIGIYGLT QAVFQIPFGL LSDRIGRKPL IVGGLAVFAA GSVIAALSDS IWGIILGRAL QGSGAIAAAV MALLSDLTRE QNRTKAMAFI GVSFGITFAI AMVLGPIITH KLGLHALFWM IAILATTGIA LTIWVVPNSS THVLNRESGM VKGSFSKVLA EPRLLKLNFG IMCLHILLMS TFVALPGQLA DAGFPAAEHW KVYLATMLIA FGSVVPFIIY AEVKRKMKQV FVFCVGLIVV AEIVLWNAQT QFWQLVVGVQ LFFVAFNLME ALLPSLISKE SPAGYKGTAM GVYSTSQFLG VAIGGSLGGW INGMFDGQGV FLAGAMLAAV WLTVASTMKE PPYVSSLRIE IPANIAANEA LKVRLLETEG IKEVLIAEEE HSAYVKIDSK VTNRFEIEQA IRQA SEQ ID NO. 61: YBBP ORGANISM NAME: ESCHERICHIA COLI MIARWFWREW RSPSLLIVWL ALSLAVACVL ALGNISDRME KGLSQQSREF MAGDRALRSS REVPQAWLEE AQKRGLKVGK QLTFATMTFA GDTPOLANVK AVDDIYPMYG DLQTNPPGLK PQAGSVLLAP RLMALLNLKT GDTIDVGDAT LRIAGEVIQE PDSGFNPFQM APRLMMNLAD VDKTGAVQPG SRVTWRYKFG GNENQLDGYE KWLLPQLKPE QRWYGLEQDE GALGRSMERS QQFLLLSALL TLLLAVAAVA VAMNHYCRSR YDLVAILKTL GAGRAQLRKL IVGQWLMVLT LSAVTGGAIG LLFENVLMVL LKPVLPAALP PASLWPWLWA LGTMTVISLL VGLRPYRLLL ATQPLRVLRN DVVANVWPLK FYLPIVSVVV VLLLAGLMGG SMLLWAVLAG AVVLALLCGV LGWMLLNVLR RMTLKSLPLR LAVSRLLRQP WSTLSQLSAF SLSFMLLALL LVLRGDLLDR WQQQLPPESP NYFLINIATE QVAPLKAFLA EHQIVPESFY PVVRARLTAI NDKPTEGNED EALNRELNLT WQNTRPDHNP IVAGNWPPKA DEVSMEEGLA KRLNVALGDT VTFMGDTQEF RAKVTSLRKV DWESLRPNFY FIFPEGALDG QPQSWLTSFR WENGNGMLTQ LNRQFPTISL LDIGAILKQV GQVLEQVSRA LEVMVVLVTA CGMLLLLAQV QVGMRQRHOE LVVWRTLGAG KKLLRTTLWC EFAMLGFVSG LVAAIGAETA LAVLQAKVED FPWEPDWRLW IVLPCSGALL LSLFGGWLGA RLVKGKALFR QFAG SEQ ID NO. 62: YBIF (RHTA) ORGANISM NAME: ESCHERICHIA COLI MPGSLRKMPV WLPIVILLVA MASIQGGASL AKSLFPLVGA PGVTALRLAL GTLILIAFFK PWRLRFAKEQ RLPLLFYGVS LGGMNYLFYL SIQTVPLGIA VALEFTGPLA VALFSSRRPV DFVWVVLAVL GLWFLLPLGQ DVSHVDLTGC ALALGAGACW AIYILSGQRA GAEHGPATVA IGSLIAALIF VPIGALQAGE ALWHWSVIPL GLAVAILSTA LPYSLEMIAL TRLPTRTEGT LMSMEPALAA VSGMIFLGET LTPIQLLALG AIIAASMGST LTVRKESKIK ELDIN SEQ ID NO. 63: YBJJ ORGANISM NAME: ESCHERICHIA COLI MTVNSSRNAL KRRTWALFMF FFLPGLLMAS WATRTPAIRD ILSVSIAEMG GVLFGLSIGS MSGILCSAWL VKREGTRNVI LVTMSCALIG MMILSLALWL TSPLLFAVGL GVEGASEGSA EVAINVEGAA VEREMNKTVL PMMHGFYSLG TLAGAGVGMA LTAFGVPATV HILLAALVGI APIYIAIQAI PDGTGKNAAD GTQHGEKGVP FYRDIQLLLI GVVVLAMAFA EGSANDWLPL LMVDGHGFSP TSGSLIYAGF TLGMTVGRFT GGWFIDRYSR VAVVRASALM GALGIGLIIF VDSAWVAGVS VVLWGLGASL GFPLTISAAS DTGPDAPTRV SVVATTGYLA FLVGPPLLGY LGEHYGLRSA MLVVLALVIL AAIVAKAVAK PDTKTQTAME NS SEQ ID NO. 64: YCAP ORGANISM NAME: ESCHERICHIA COLI MKAFDLHRMA FDKVPFDFLG EVALRSLYTF VLVELFLKMT GRRGVRQMSL FEVLIILTLG SAAGDVAFYD DVPMVPVLIV FITLALLYRL VMWLMAHSEK LEDLLEGKPV VIIEDGELAW SKLNNSNMTE FEFFMELRLR GVEQLGQVRL AILETNGQIS VYFFEDDKVK PGLLILPSDC TQRYKVVPES ADYACIRCSE IIHMKAGEKQ LCPRCANPEW TKASRAKRVT SEQ ID NO. 65: YDCO ORGANISM NAME: ESCHERICHIA COLI MRLFSIPPPT LLAGFLAVLI GYASSAAIIW QAAIVAGATT AQISGWMTAL GLAMGVSTLT LTLWYRVPVL TAWSTPGAAL LVTGLOGLTL NEAIGVFIVT NALIVLCGIT GLFARLMRII PHSLAAAMLA GILLRFGLQA FASLDGQFTL CGSMLLVWLA TKAVAPRYAV IAAMIIGIVI VIAQGDVVTT DVVFKPVLPT YITPDFSFAH SLSVALPLFL VTMASQNAPG IAAMKAAGYS APVSPLIVFT GLLALVFSPF GVYSVGIAAI TAAICQSPEA HPDKDQRWLA AAVAGIFYLL AGLFGSAITG MMAALPVSWI QMLAGLALLS TIGGSLYQAL HNERERDAAV VAFLVTASGL TLVGIGSAFW GLIAGGVCYV VLNLIADRNRY  SEQ ID NO. 66: YDDG ORGANISM NAME: ESCHERICHIA COLI MTRQKATLIG LIAIVLWSTM VGLIRGVSEG LGPVGGAAAI YSLSGLLLIF TVGFPRIRQI PKGYLLAGSL LFVSYEICLA LSLGYAATHH QAIEVGMVNY LWPSLTILFA ILFNGQKTNW LIVPGLLLAL VGVCWVLGGD NGLHYDEIIN NITTSPLSYF LAFIGAFIWA AYCTVTNKYA RGFNGITVFV LLTGASLWVY YFLTPQPEMI FSTPVMIKLI SAAFTLGFAY AAWNVGILHG NVTIMAVGSY FTPVLSSALA AVLLSAPLSF SFWQGALMVC GGSLLCWLAT RRG SEQ ID NO. 67: YDED (EAMA) ORGANISM NAME: ESCHERICHIA COLI MSRKDGVLAL LVVVVWGLNF VVIKVGLHNM PPLMLAGLRF MLVAFPAIFF VARPKVPLNL LLGYGLTISF AQFAFLFCAI NFGMPAGLAS LVLQAQAFFT IMLGAFTFGE RLHGKQLAGI ALAIFGVLVL IEDSLNGQHV AMLGFMLTLA AAFSWACGNI FNKKIMSHST RPAVMSLVIW SALIPIIPFF VASLILDGSA TMIHSLVTID MTTILSLMYL AFVATIVGYG IWGTLLGRYE TWRVAPLSLL VPVVGLASAA LLLDERLTGL QFLGAVLIMT GLYINVFGLR WRKAVKVGS SEQ ID NO. 68: YDGE (MDTI) ORGANISM NAME: ESCHERICHIA COLI MAQFEWVHAA WLALAIVLEI VANVFLKFSD GFRRKIFGLL SLAAVLAAFS ALSQAVKGID LSVAYALWGG FGIAATLAAG WILFGQRLNR KGWIGLVLLL AGMIMVKLA SEQ ID NO. 69: YDHC ORGANISM NAME: ESCHERICHIA COLI MQPGKRFLVW LAGLSVLGFL ATDMYLPAFA AIQADLQTPA SAVSASLSLF LAGFAAAQLL WGPLSDRYGR KPVLLIGLTI FALGSLGMLW VENAATLLVL RFVQAVGVCA AAVIWQALVT DYYPSQKVNR IFAAIMPLVG LSPALAPLLG SWLLVHFSWQ AIFATLFAIT VVLILPIFWL KPTTKARNNS QDGLIFTDLL RSKTYRGNVL IYAACSASFF AWLTGSPFIL SEMGYSPAVI GLSYVPQTIA FLIGGYGCRA ALQKWQGKQL LPWLLVLFAV SVIATWAAGF ISHVSLVEIL IPFCVMAIAN GAIYPIVVAQ ALRPFPHATG RAAALQNTLQ LGLCFLASLV VSWLISISTP LLTTTSVMLS TVVLVALGYM MQRCEEVGCQ NHGNAEVAHS ESH SEQ ID NO. 70: YDHP ORGANISM NAME: ESCHERICHIA COLI MKINYPLLAL AIGAFGIGTT EFSPMGLLPV IARGVDVSIP AAGMLISAYA VGVMVGAPLM TLLLSHRARR SALIFLMAIF TLGNVLSAIA PDYMTLMLSR ILTSLNHGAF FGLGSVVAAS VVPKHKQASA VATMFMGLTL ANIGGVPAAT WLGETIGWRM SFLATAGLGV ISMVSLFFSL PKGGAGARPE VKKELAVLMR PQVLSALLTT VLGAGAMFTL YTYISPVLQS ITHATPVFVT AMLVLIGVGF SIGNYLGGKL ADRSVNGTLK GFLLLLMVIM LAIPFLARNE FGAAISMVVW GAATFAVVPP LQMRVMRVAS EAPGLSSSVN IGAFNLGNAL GAAAGGAVIS AGLGYSFVPV MGAIVAGLAL LLVFMSARKQ PETVCVANS SEQ ID NO. 71: YDIN ORGANISM NAME: ESCHERICHIA COLI MSQNKAFSTP FILAVLCIYF SYFLHGISVI TLAQNMSSLA EKFSTDNAGI AYLISGIGLG RLISILFFGV ISDKFGRRAV ILMAVIMYLL FFFGIPACPN LTLAYGLAVC VGIANSALDT GGYPALMECF PKASGSAVIL VKAMVSFGQM FYPMLVSYML LNNIWYGYGL IIPGILFVLI TLMLLKSKFP SQLVDASVTN ELPQMNSKPL VWLEGVSSVL FGVAAFSTFY VIVVWMPKYA MAFAGMSEAE ALKTISYYSM GSLVCVFIFA ALLKKMVRPI WANVFNSALA TITAAIIYLY PSPLVCNAGA FVIGFSAAGG ILQLGVSVMS EFFPKSKAKV TSIYMMMGGL ANFVIPLITG YLSNIGLQYI IVLDFTFALL ALITAIIVFI RYYRVFIIPE NDVRFGERKF CTRLNTIKHR G SEQ ID NO. 72: YDIM ORGANISM NAME: ESCHERICHIA COLI MKNPYFPTAL GLYFNYLVHG MGVLLMSLNM ASLETLWQTN AAGVSIVISS LGIGRLSVLL FAGLLSDRFG RRPFIMLGMC CYMAFFFGIL QTNNIIIAYV FGFLAGMANS FLDAGTYPSL MEAFPRSPGT ANILIKAFVS SGQFLLPLII SLLVWAELWF GWSFMIAAGI MFINALFLYR CTFPPHPGRR LPVIKKTTSS TEHRCSIIDL ASYTLYGYIS MATFYLVSQW LAQYGQFVAG MSYTMSIKLL SIYTVGSLLC VFITAPLIRN TVRPTILLML YTFISFIALF TVCLHPTFYV VIIFAFVIGF TSAGGVVQIG LTLMAERFPY AKGKATGIYY SAGSIATFTI PLITAHLSQR SIADIMWFDT AIAAIGFLLA LFIGLRSRKK TRHHSLKENV APGG SEQ ID NO. 73: YDJE ORGANISM NAME: ESCHERICHIA COLI MEQYDQIGAR LDRLPLARFH YRIFGIISFS LLLTGFLSYS GNVVLAKLVS NGWSNNFLNA AFTSALMFGY FIGSLTGGFI GDYFGRRRAF RINLLIVGIA ATGAAFVPDM YWLIFFRFLM GTGMGALIMV GYASFTEFIP ATVRGKWSAR LSFVGNWSPM LSAAIGVVVI AFFSWRIMFL LGGIGILLAW FLSGKYFIES PRWLAGKGQI AGAECQLREV EQQIEREKSI RLPPLTSYQS NSKVKVIKGT FWLLFKGEML RRTLVAITVL IAMNISLYTI TVWIPTIFVN SGIDVDKSIL MTAVIMIGAP VGIFIAALII DHFPRRLFGS TLLIIIAVLG YIYSIQTTEW AILIYGLVMI FFLYMYVCFA SAVYIPELWP THLRLRGSGF VNAVGRIVAV FTPYGVAALL THYGSITVFM VLGVMLLLCA LVLSIFGIET RKVSLEEISE VN SEQ ID NO. 74: YDJF ORGANISM NAME: ESCHERICHIA COLI MAAKDRIQAI KQMVANDKKV TVSNLSGIFQ VTEETIRRDL EKLEDEGFLT RTYGGAVLNT AMLTENIHFY KRASSFYEEK QLIARKALPF IDNKTTMAAD SSSTVMELLK LLQDRSGLTL LTNSAEAIHV LAQSEIKVVS TGGELNKNTL SLOGRITKEI IRRYHVDIMV MSCKGLDINS GALDSNEAEA EIKKTMIRQA TEVALLVDHS KFDRKAFVQL ADFSHINYII TDKSPGAEWI AFCKDNNIQL VW SEQ ID NO. 75: YDJI ORGANISM NAME: ESCHERICHIA COLI MLADIRYWEN DATNKHYAIA HFNVWNAEML MGVIDAAEEA KSPVIISFGT GFVGNTSFED FSHMMVSMAQ KATVPVITHW DHGRSMEIIH NAWTHGMNSL MRDASAFDFE ENIRLTKEAV DFFHPLGIPV EAELGHVGNE TVYEEALAGY HYTDPDQAAE FVERTGCDSL AVAIGNQHGV YTSEPQLNFE VVKRVRDAVS VPLVLHGASG ISDADIKTAI SLGIAKINIH TELCQAAMVA VKENQDQPFL HLEREVRKAV KERALEKIKL FGSDGKAE SEQ ID NO. 76: YDJK ORGANISM NAME: ESCHERICHIA COLI MEQITKPHCG ARLDRLPDCR WHSSMFAIVA FGLLVCWSNA VGGLILAQLK ALGWTDNSTT ATFSAITTAG MFLGALVGGI IGDKTGRRNA FILYEAIHIA SMVVGAFSPN MDFLIACRFV MGVGLGALLV TLFAGFTEYM PGRNRGTWSS RVSFIGNWSY PLCSLIAMGL TPLISAEWNW RVQLLIPAIL SLIATALAWR YFPESPRWLE SRGRYQEAEK VMRSIEEGVI RQTGKPLPPV VIADDGKAPQ AVPYSALLTG VLLKRVILGS CVLIAMNVVQ YTLINWLPTI FMTQGINLKD SIVLNTMSMF GAPFGIFIAM LVMDKIPRKT MGVGLLILIA VLGYIYSLQT SMLLITLIGF FLITFVYMYV CYASAVYVPE IWPTEAKLRG SGLANAVGRI SGIAAPYAVA VLLSSYGVTG VFILLGAVSI IVAIAIATIG IETKGVSVES LSIDAVANK SEQ ID NO. 77: YEAN ORGANISM NAME: ESCHERICHIA COLI MTCSTSLSGK NRIVLIAGIL MIATTLRVTF TGAAPLLDTI RSAYSLTTAQ TGLLTTLPLL AFALISPLAA PVARRFGMER SLFAALLLIC AGIAIRSLPS PYLLFGGTAV IGGGIALGNV LLPGLIKRDF PHSVARLTGA YSLTMGAAAA LGSAMVVPLA LNGFGWQGAL LMLMCFPLLA LFLWLPQWRS QQHANLSTSR ALHTRGIWRS PLAWQVTLFL GINSLVYYVI IGWLPAILIS HGYSEAQAGS LHGLLQLATA APGLLIPLFL HHVKDQRGIA AFVALMCAVG AVGLCFMPAH AITWILLFGF GSGATMILGL TFIGLRASSA HQAAALSGMA QSVGYLLAAC GPPLMGKIHD ANGNWSVPLM GVAILSLLMA IFGLCAGRDK EIR SEQ ID NO. 78: YEAS (LEUE) ORGANISM NAME: ESCHERICHIA COLI MFAEYGVLNY WTYLVGAIFI VLVPGPNTLF VLKNSVSSGM KGGYLAACGV FIGDAVLMFL AWAGVATLIK TTPILFNIVR YLGAFYLLYL GSKILYATLK GKNSEAKSDE PQYGAIFKRA LILSLTNPKA ILFYVSFFVQ FIDVNAPHTG ISFFILAATL ELVSFCYLSF LIISGAFVTQ YIRTKKKLAK VGNSLIGLMF VGFAARLATL QS SEQ ID NO. 79: YEBS ORGANISM NAME: ESCHERICHIA COLI MALNTPQITP TKKITVRAIG EELPRGDYQR CPQCDMLFSL PEINSHQSAY CPRCQAKIRD GRDWSLTRLA AMAFTMLLLM PFAWGEPLLH IWLLGIRIDA NVMQGIWQMT KQGDAITGSM VFFCVIGAPL ILVTSIAYLW FGNRLGMNLR PVLLMLERLK EWVMLDIYLV GIGVASIKVQ DYAHIQAGVG LFSFVALVIL TTVTLSHLNV EELWERFYPQ RPATRRDEKL RVCLGCHFTG YPDQRGRCPR CHIPLRLRRR HSLQKCWAAL LASIVLLLPA NLLPISIIYL NGGRQEDTIL SGIMSLASSN IAVAGIVFIA SILVPFTKVI VMFILLLSIH FKCQQGLRTR ILLLRMVTWI GRWSMLDLFV ISLTMSLINR DQILAFTMGP AAFYFGAAVI LTILAVEWLD SRLLWDAHES GNARFDD SEQ ID NO. 80: VEDA ORGANISM NAME: ESCHERICHIA COLI MRFRQLLPLF GALFALYIIW GSTYFVIRIG VESWPPLMMA GVRFLAAGIL LLAFLLLRGH KLPPLRPLLN AALIGLLLLA VGNGMVTVAE HQNVPSGIAA VVVATVPLFT LCFSRLFGIK TRKLEWVGIA IGLAGIIMLN SGGNLSGNPW GAILILIGSI SWAFGSVYGS RITLPVGMMA GAIEMLAAGV VLMIASMIAG EKLTALPSLS GFLAVGYLAL FGSIIAINAY MYLIRNVSPA LATSYAYVNP VVAVLLGTGL GGETLSKIEW LALGVIVFAV VLVTLGKYLF PAKPVVAPVI QDASSE SEQ ID NO. 90: YEEO ORGANISM NAME: ESCHERICHIA COLI MLRHILTAKN LLSNPIFKFP NCLPFLSTVC CICRQFVGEN LCSFADSPSL FEMWEHFLQL RSALNISSAL RQVVHGTRWH AKRKSYKVLF WREITPLAVP IFMENACVLL MGVLSTFLVS WLGKDAMAGV GLADSFNMVI MAFFAAIDLG TTVVVAFSLG KRDRRRARVA TRQSLVIMIL FAVLLATLIH HFGEQIIDEV AGDATTEVKA LALTYLELTV LSYPAAAITL IGSGALRGAG NTKIPLLING SLNILNIIIS GILIYGLFSW PGLGFVGAGL GLTISRYIGA VAILWVLAIG FNPALRISLK SYFKPLNFSI IWEVMGIGIP ASVESVLFTS GRLLTQMFVA GMGTSVIAGN FIAFSIAALI NLPGSALGSA STIITGRRLG VGQIAQAEIQ LRHVFWLSTL GLTAIAWLTA PFAGVMASFY TQDPQVKHVV VILIWLNALF MPIWSASWVL PAGFKGARDA RYAMWVSMLS MWGCRVVVGY VLGIMLGWGV VGVWMGMFAD WAVRAVLFYW RMVTGRWLWK YPRPEPQKCE KKPVVSE SEQ ID NO. 91: YEGH ORGANISM NAME: ESCHERICHIA COLI MEWIADPSIW AGLITLIVIE LVLGIDNLVF IAILAEKLPP KQRDRARVTG LLLAMLMRLL LLASISWLVT LTQPLFSFRS FTFSARDLIM LEGGFELLEK ATMELNERLE GKDSNNPTQR KGAKFWGVVT QIVVLDAIFS LDSVITAVGM VDHLLVMMAA VVIAISLMLM ASKPLTQFVN SHPTIVILCL SELLMIGESL VAEGEGFVIP KGYLYAAIGF SVMIEALNQL AIENRRRELS ANQTLRQRTT EAVMRLLSGQ KEDAELDAET ASMLVDHGNQ QIFNPQERRM IERVLNLNQR TVSSIMTSRH DIEHIDLNAP EEEIRQLLER NQHTRLVVTD GDDAEDLLGV VHVIDLLQQS LRGEPLNLRV LIRQPLVFPE TLPLLPALEQ FRNARTHEAF VVDEFGSVEG IVTLSDVTET IAGNLPNEVE EIDARHDIQK NADGSWTANG HMPLEDLVQY VPLPLDEKRE YHTIAGLLME YLQRIPKPGE EVQVGDYLLK TLQVESHRVQ KVQIIPLRKD GEMEYEV SEQ ID NO. 92: YGGA (ARGO) ORGANISM NAME: ESCHERICHIA COLI MESYYFQGLA LGAAMILPLG PQNAFVMNQG IRRQYHIMIA LLCAISDLVL ICAGIFGGSA LLMQSPWLLA LVTWGGVAFL LWYGFGAFKT AMSSNIELAS AEVMKQGRWK IIATMLAVTW LNPHVYLDIT VVLGSLGGQL DVEPKRWFAL GTISASFLWF FGLALLAAWL APRLRTAKAQ RIINLVVGCV MWFIALQLAR DGIAHAQALF S SEQ ID NO. 93: YFCJ ORGANISM NAME: ESCHERICHIA COLI MTAVSQTETR SSANFSLFRI AFAVFLTYMT VGLPLPVIPL FVHHELGYGN TMVGIAVGIQ FLATVLTRGY AGRLADQYGA KRSALQGMLA CGLAGGALLL AAILPVSAPF KFALLVVGRL ILGFGESQLL TGALTWGLGI VGPKHSGKVM SWNGMAIYGA LAVGAPLGLL IHSHYGFAAL AITTMVLPVL AWACNGTVRK VPALAGERPS LWSVVGLIWK PGLGLALQGV GFAVIGTFVS LYFASKGWAM AGFTLTAFGG AFVVMRVMFG WMPDRFGGVK VAIVSLLVET VGLLLLWQAP GAWVALAGAA LTGAGCSLIF PALGVEVVKR VPSQVRGTAL GGYAAFQDIA LGVSGPLAGM LATTFGYSSV FLAGAISAVL GIIVTILSFR RG SEQ ID NO. 94: YFIK (EAMB) ORGANISM NAME: ESCHERICHIA COLI MTPTLLSAFW TYTLITAMTP GPNNILALSS ATSHGFRQST RVLAGMSLGF LIVMLLCAGI SFSLAVIDPA AVHLLSWAGA AYIVWLAWKI ATSPTKEDGL QAKPISFWAS FALQFVNVKI ILYGVTALST FVLPQTQALS WVVGVSVLLA MIGTFGNVCW ALAGHLFQRL FRQYGRQLNI VLALLLVYCA VRIFY SEQ ID NO. 95: YHJE ORGANISM NAME: ESCHERICHIA COLI MQATATTLDH EQEYTPINSR NKVLVASLIG TAIEFFDFYI YATAAVIVFP HIFFPQGDPT AATLQSLATF AIAFVARPIG SAVFGHFGDR VGRKATLVAS LLTMGISTVV IGLLPGYATI GIFAPLLLAL ARFGQGLGLG GEWGGAALLA TENAPPRKRA LYGSFPQLGA PIGFFFANGT FLLLSWLLTD EQFMSWGWRV PFIFSAVLVI IGLYVRVSLH ESPVFEKVAK AKKQVKIPLG TLLTKHVRVT VLGTFIMLAT YTLFYIMTVY SMTFSTAAAP VGLGLPRNEV LWMLMMAVIG FGVMVPVAGL LADAFGRRKS MVIITTLIIL FALFAFNPLL GSGNPILVFA FLLLGLSLMG LTFGPMGALL PELFPTEVRY TGASFSYNVA SILGASVAPY IAAWLQTNYG LGAVGLYLAA MAGLTLIALL LTHETRHQSL  SEQ ID NO. 96: YIDE ORGANISM NAME: ESCHERICHIA COLI MSDIALTVSI LALVAVVGLF IGNVKFRGIG LGIGGVLFGG IIVGHFVSQA GMTLSSDMLH VIQEFGLILF VYTIGIQVGP GFFASLRVSG LRLNLFAVLI VIIGGLVTAI LHKLFDIPLP VVLGIFSGAV TNTPALGAGQ QILRDLGTPM EMVDQMGMSY AMAYPFGICG ILFTMWMLRV IFRVNVETEA QQHESSRTNG GALIKTINIR VENPNLHDLA IKDVPILNGD KIICSRLKRE ETLKVPSPDT IIQLGDLLHL VGQPADLHNA QLVIGQEVDT SLSTKGTDLR VERVVVTNEN VLGKRIRDLH FKFRYDVVIS RLNRAGVELV ASGDISLQFG DILNLVGRPS AIDAVANVLG NAQQKLQQVQ MLPVFIGIGL GVLLGSIPVF VPGFPAALKL GLAGGPLIMA LILGRIGSIG KLYWFMPPSA NLALRELGIV LFLSVVGLKS GGDFVNTLVN GEGLSWIGYG ALITAVPLIT VGILARMLAK MNYLTMCGML AGSMTDPPAL AFANNLHPTS GAAALSYATV YPLVMFLRII TPQLLAVLFW SIG SEQ ID NO. 97: YIGK (RHTB) ORGANISM NAME: ESCHERICHIA COLI MTLEWWFAYL LTSIILSLSP GSGAINTMTT SLNHGYRGAV ASIAGLQTGL AIHIVLVGVG LGTLFSRSVI AFEVLKWAGA AYLIWLGIQQ WRAAGAIDLK SLASTQSRRH LFQRAVFVNL TNPKSIVFLA ALFPQFIMPQ QPQLMQYIVL GVTTIVVDII VMIGYATLAQ RIALWIKGPK QMKALNKIFG SLFMLVGALL ASARHA SEQ ID NO. 98 YIGJ (RHTC) ORGANISM NAME: ESCHERICHIA COLI MLMLFLTVAM VHIVALMSPG PDFFFVSQTA VSRSRKEAMM GVLGITCGVM VWAGIALLGL HLIIEKMAWL HTLIMVGGGL YLCWMGYQML RGALKKEAVS APAPQVELAK SGRSFLKGLL TNLANPKAII YFGSVFSLFV GDNVGTTARW GIFALIIVET LAWFTVVASL FALPQMRRGY QRLAKWIDGF AGALFAGFGI HLIISR SEQ ID NO. 99: YIJE ORGANISM NAME: ESCHERICHIA COLI MSAAGKSNPL AISGLVVLTL IWSYSWIFMK QVTSYIGAFD FTALRCIFGA LVLFIVLLLR GRGMRPTPFK YTLAIALLQT CGMVGLAQWA LVSGGAGKVA ILSYTMPFWV VIFAALFLGE RLRRGQYFAI LIAAFGLFLV LQPWQLDFSS MKSAMLAILS GVSWGASAIV AKRLYARHPR VDLLSLTSWQ MLYAALVMSV VALLVPQREI DWQPTVFWAL AYSAILATAL AWSLWLFVLK NLPASIASLS TLAVPVCGVL FSWWLLGENP GAVEGSGIVL IVIALALVSR KKKEAVSVKRI SEQ ID NO. 100: YJII (KPTA) ORGANISM NAME: ESCHERICHIA COLI MAKYNEKELA DTSKFLSFVL RHKPEAIGIV LDREGWADID KLILCAQKAG KRLTRALLDT VVATSDKKRF SYSSDGRCIR AVQGHSTSQV AISFAEKTPP QFLYHGTASR FLDEIKKQGL IAGERHYVHL SADEATARKV GARHGSPVIL TVKAQEMAKR GLPFWQAENG VWLTSTVAVE FLEW SEQ ID NO. 101: YJIJ ORGANISM NAME: ESCHERICHIA COLI MPSSTHPVER FSFSTALFGM LVLTLGMGLG RFLYTPMLPV MMAEGSFSFS QLSWIASGNY AGYLAGSLLF SFGAFHQPSR LRPFLLASAL ASGLLILAMA WLPPFILVLL IRVLAGVASA GMLIFGSTLI MQHTRHPFVL AALFSGVGIG IALGNEYVLA GLHFDLSSQT LWQGAGALSG MMLIALTLLM PSKKHAITPM PLAKTEQQIM SWWLLAILYG LAGFGYIIVA TYLPLMAKDA GSPLLTAHLW TLVGLSIVPG CFGWLWAAKR WGALPCLTAN LLVQAICVLL TLASDSPLLL IISSLGFGGT FMGTTSLVMT IARQLSVPGN LNLLGFVTLI YGIGQILGPA LTSMLSNGTS ALASATLCGA AALFIAALIS TVQLFKLQVV TS SEQ ID NO. 102: YJIO (MDTM) ORGANISM NAME: ESCHERICHIA COLI MPRFFTRHAA TLFFPMALIL YDFAAYLSTD LIQPGIINVV RDFNADVSLA PAAVSLYLAG GMALQWLLGP LSDRIGRRPV LITGALIFTL ACAATMFTTS MTQFLIARAI QGTSICFIAT VGYVTVQEAF GQTKGIKLMA IITSIVLIAP IIGPLSGAAL MHFMHWKVLF AIIAVMGFIS FVGLLLAMPE TVKRGAVPFS AKSVLRDFRN VFCNRLFLFG AATISLSYIP MMSWVAVSPV ILIDAGSLTT SQFAWTQVPV FGAVIVANAI VARFVKDPTE PRFIWRAVPI QLVGLSLLIV GNLLSPHVWL WSVLGTSLYA FGIGLIFPTL FRFTLFSNKL PKGTVSASLN MVILMVMSVS VEIGRWLWFN GGRLPFHLLA VVAGVIVVFT LAGLLNRVRQ HQAAELVEEQ SEQ ID NO. 103: YKGH ORGANISM NAME: ESCHERICHIA COLI MREQIKQDID LIEILFYLKK KIRVILFIMA ICMAMVLLFL YINKDNIKVI YSLKINQTTP GILVSCDSNN NFACQTTMTE DVIQRITTFF HTSPDVKNRE IRLEWSGDKR ALPTAEEEIS RVQASIIKWY ASEYHNGRQV LDEIQTPSAI NSELYTKMIY LTRNWSLYPN GDGCVTISSP EIKNKYPAAI CLALGFFLSI VISVMFCLVK KMVDEYQQNS GQ SEQ ID NO. 104: YPJD ORGANISM NAME: ESCHERICHIA COLI MQRLEQRSPD AILLLFLIAQ TVDITMPVFA LLALVAYSVS LALIVPGLLQ KNGGWRRMAI ISAVIALVCH AIALEARILP DGDSGQNLSL LNVGSLVSLM ICTVMTIVAS RNRGWLLLPI VYAFALINLA LATFMPNEYI THLEATPGML VHIGLSLFSY ATLIIAALYA LQLAWIDYQL KNKKLAFNQE MPPLMSIERK MFHITQIGVV LLTLTLCTGL FYMHNLFSME NIDKAVLSIV AWFVYIVLLW GHYHEGWRGR RVVWFNVAGA VILTLAYFGS RIVQQLIS SEQ ID NO. 105: YTFF ORGANISM NAME: ESCHERICHIA COLI MPVMISGVLY ALLAGLMWGL IFVGPLIVPE YPAMLQSMGR YLALGLIALP IAWLGRVRLR QLARRDWLTA LMLTMMGNLI YYFCLASAIQ RTGAPVSTMI IGTLPVVIPV FANLLYSQRD GKLAWGKLAP ALICIGIGLA CVNIAELNHG LPDFDWARYT SGIVLALVSV VCWAWYALRN ARWLRENPDK HPMMWATAQA LVTLPVSLIG YLVACYWLNT QTPDFSLPFG PRPLVFISLM VAIAVLCSWV GALCWNVASQ LLPTVILGPL IVFETLAGLL YTFLLRQQMP PLMTLSGIAL LVIGVVIAVR AKPEKPLTES VSES SEQ ID NO. 106: YTFL ORGANISM NAME: ESCHERICHIA COLI MLNSILV1LC LIAVSAFFSM SEISLAASRK IKLKLLADEG NINAQRVLNM QENPGMFFTV VQIGLNAVAI LGGIVGDAAF SPAFHSLFSR YMSAELSEQL SFILSFSLVT GMFILFADLT PKRIGMIAPE AVALRIINPM RECLYVCIPL VWFFNGLANI IFRIFKLPMV RKDDITSDDI YAVVEAGALA GVLRKQEHEL IENVFELESR TVPSSMTPRE NVIWFDLHED EQSLKNKVAE HPHSKFLVCN EDIDHIIGYV DSKDLLNRVL ANQSLALNSG VQIRNTLIVP DTLTLSEALE SFKTAGEDFA VIMNEYALVV GIITLNDVMT TLMGDLVGQG LEEQIVARDE NSWL1DGGTP IDDVMRVLDI DEFPQSGNYE TIGGFMMFML RKIPKRTDSV KFAGYKFEVV DIDNYRIDQL LVTRIDSKAT ALSPKLPDAK DKEESVA SEQ ID NO. 107: CHLOROFLEXUS AGGREGANS (CGMCR) <400> 785 MET SER VAL THR GLY ARG LEU ALA GLY LYS ILE ALA LEU ILE THR GLY 1       5          10         15 GLY ALA GLY ASN ILE GLY SER GLU MET THR ARG ARG PHE LEU ALA GLU       20           25        30 GLY ALA THR VAL ILE ILE SER GLY ARG ASN SER ALA LYS LEU ALA ALA     35         40           45 LEU ALA GLU ARG LEU ARG SER GLU ALA GLY VAL PRO ALA LYS ARG ILE   50         55         60 ASP LEU GLU VAL MET ASP GLY SER ASP PRO ALA ALA VAL ARG ALA GLY 65         70         75         80 VAL ALA ALA ILE ILE GLY ARG HIS GLY HIS ILE ASP ILE LEU VAL ASN         85           90         95 ASN ALA GLY SER THR GLY ALA GLN ARG ARG LEU ALA GLU ILE PRO LEU       100         105        110 ASN GLU THR ASP ARG ASP LEU ASP ASP GLU GLU ALA LEU SER THR SER     115       120          125 VAL ALA ASN LEU LEU GLY MET ALA TRP HIS LEU MET ARG ILE LEU SER   130         135        140 PRO HIS MET PRO PRO GLY SER ALA ILE ILE ASN ILE SER THR ILE PHE 145         150        155          160 SER ARG ALA GLU TYR TYR GLY ARG ILE PRO TYR VAL VAL PRO LYS ALA         165        170         175 ALA LEU ASN THR LEU THR GLN ILE ALA ALA ARG GLU LEU GLY ILE ARG       180        185         190 GLY ILE ARG VAL ASN THR ILE PHE PRO GLY PRO ILE GLU SER GLU ARG     195          200         205 ILE GLN THR VAL PHE GLN ARG MET ASP GLN LEU LYS GLY ARG PRO GLU   210         215         220 GLY ASP THR ALA SER GLN PHE LEU ALA THR MET ARG LEU TYR ARG ALA 225         230        235          240 ASN ASP GLN GLY GLN LEU GLU ARG ARG PHE PRO THR ILE CYS ASP VAL         245         250        255 ALA ASP ALA ALA VAL PHE LEU ALA SER ASP GLU ALA ALA ALA LEU THR       260         265         270 GLY GLU THR ILE GLU VAL THR HIS GLY MET GLU LEU PRO THR SER SER     275         280         285 GLU THR SER LEU LEU ALA ARG THR ASP LEU ARG THR ILE ASP ALA ASN   290        295         300 GLY ARG THR THR LEU ILE CYS ALA GLY ASP GLN ILE GLU GLU VAL MET 305        310          315         320 ALA LEU THR GLY MET LEU ARG THR CYS GLY SER GLU VAL ILE ILE GLY         325         330        335 PHE ARG SER GLU ALA ALA LEU ALA GLN PHE GLU GLN ALA ILE GLY GLU       340         345         350 SER ARG ARG LEU ALA GLY GLU SER PHE ILE PRO PRO ILE ALA LEU PRO     355         360        365 ILE ASP LEU ARG ASN PRO SER THR ILE ASP ALA LEU PHE ASP TRP ALA   370          375        380 GLY GLU ASN THR GLY GLY ILE HIS ALA ALA VAL ILE LEU PRO ALA SER 385        390         395          400 GLY ARG GLU PRO ALA THR GLN VAL ILE ASP ILE ASP ASP ALA HIS VAL         405        410        415 GLN ALA PHE LEU ASN ASP GLU ILE VAL GLY SER ILE ILE ILE ALA SER       420        425          430 ARG LEU ALA ARG TYR TRP GLN ALA GLN ARG ILE ALA PRO GLY ALA ARG     435        440         445 ALA ARG GLU PRO ARG VAL ILE PHE LEU SER ASN GLY ALA SER THR ALA   450        455        460 GLY ASN PRO TYR GLY ARG ILE GLN SER ALA ALA ILE GLU GLN LEU ILE 465        470         475          480 ARG VAL TRP ARG HIS GLU ALA ALA LEU ASP TYR GLU ARG ALA THR ALA        485          490         495 ALA GLY GLU ARG VAL LEU PRO ALA VAL TRP ALA SER GLN ILE VAL ARG      500        505          510 PHE ALA ASN ARG SER LEU GLU GLY LEU GLU PHE ALA CYS ALA TRP THR     515        520         525 ALA GLN LEU LEU HIS SER GLN ARG ARG ILE ASN GLU ILE THR LEU THR   530        535          540 ILE PRO ALA ASP ILE SER ALA THR THR GLY ALA ARG SER ALA SER VAL 545         550          555         560 GLY TRP ALA GLU SER LEU ILE GLY LEU HIS LEU GLY LYS VAL ALA LEU         565         570          575 ILE THR GLY GLY SER ALA GLY ILE GLY GLY GLN ILE GLY ARG LEU LEU       580         585          590 ALA LEU SER GLY ALA ARG VAL MET LEU ALA ALA ARG ASP PRO HIS LYS     595        600          605 LEU GLU GLN ILE GLN ALA THR ILE ARG ALA GLU LEU ALA GLU VAL GLY   610         615         620 TYR THR ASP VAL GLU GLU ARG VAL GLN ILE ALA PRO GLY CYS ASP VAL 625         630        635         640 SER SER GLU GLU GLN LEU VAL ASP LEU VAL GLU ARG THR LEU ALA ALA        645         650         655 PHE GLY THR VAL ASP TYR LEU ILE ASN ASN ALA GLY ILE ALA GLY VAL      660         665           670 GLU GLU MET VAL ILE ASP MET PRO VAL GLU GLY TRP ARG ASN THR LEU    675         680        685 TYR ALA ASN LEU ILE SER ASN TYR SER LEU MET ARG LYS LEU ALA PRO   690        695          700 LEU MET LYS LYS GLN GLY SER GLY TYR VAL LEU ASN VAL SER SER TYR 705         710         715        720 PHE GLY GLY GLU LYS ASP ALA ALA ILE PRO TYR PRO ASN ARG ALA ASP         725         730         735 TYR ALA VAL SER LYS ALA GLY GLN ARG ALA MET ALA GLU VAL PHE ALA       740         745         750 ARG PHE LEU GLY PRO GLU ILE GLN ILE ASN ALA ILE ALA PRO GLY PRO     755         760         765 VAL GLU GLY ASP ARG LEU ARG GLY THR GLY GLU ARG PRO GLY LEU PHE   770         775        780 ALA ARG ARG ALA ARG LEU ILE LEU GLU ASN LYS ARG LEU ASN GLU LEU 785         790         795        800 HIS ALA ALA LEU ILE THR ALA ALA ARG THR ASP ASN ARG PRO MET ARG         805          810        815 GLU LEU VAL GLU LEU LEU LEU PRO ASN ASP VAL ALA ALA LEU ALA GLN      820         825         830 HIS PRO ALA ALA PRO ASP VAL LEU ARG THR LEU ALA LYS ARG PHE GLN     835         840        845 SER GLU GLY ASP PRO ALA ALA SER SER SER SER PHE LEU LEU ASN ARG   850        855         860 SER ILE ALA ALA LYS LEU LEU ALA ARG LEU ILE ASN GLY GLY TYR ASP 865          870         875         880 LEU PRO ALA ASP ILE PHE ALA ASN LEU ALA VAL PRO PRO ASP PRO PHE         885         890         895 PHE THR ARG ALA GLN ILE ASP ARG GLU ALA ARG LYS VAL ARG ASP GLY       900         905         910 ILE MET GLY MET LEU TYR LEU GLN ARG MET PRO THR GLU PHE ASP VAL      915         920        925 ALA MET ALA THR VAL TYR TYR LEU ALA ASP ARG ASN VAL SER GLY GW   930        935         940 THR PHE HIS PRO SER GLY GLY LEU ARG TYR GW ARG THR PRO THR GLY 945         950         955         960 GLY GLU LEU PHE GLY LEU PRO ALA PRO GLU ARG LEU ALA GLU LEU VAL         965         970          975 GLY SER THR VAL TYR LEU ILE GLY GLU HIS LEU THR GLU HIS LEU ASN      980          985          990 LEU LEU ALA ARG ALA TYR LEU GLU ARG TYR GLY ALA ARG GLN VAL VAL     995         1000        1005 MET ILE VAL GLU THR GLU ALA GLY ALA GLU LYS MET ARG HIS LEU   1010         1015         1020 LEU HIS ASP HIS VAL GLU ALA GLY ARG LEU PRO ILE ILE VAL ALA   1025         1030          1035 GLY ASP GLN ILE GLU ALA ALA ILE ASP GLN ALA ILE ALA ASN TYR   1040        1045           1050 GLY ARG PRO GLY PRO VAL VAL CYS THR PRO PHE ARG PRO LEU PRO   1055        1060           1065 SER ALA PRO LEU VAL GLY ARG LYS ASP SER ASP TRP SER THR VAL   1070        1075           1080 LEU SER GLU ALA GLU PHE ALA GLU LEU CYS GLU HIS GLN LEU THR   1085        1090           1095 HIS HIS PHE ARG VAL ALA ARG LYS ILE ALA LEU SER ASP GLY ALA   1100        1105           1110 SER LEU ALA LEU VAL THR PRO GLU THR THR ALA THR SER SER THR   1115        1120           1125 GLU GLN PHE ALA LEU ALA ASN PHE VAL LYS THR THR LEU HIS ALA   1130        1135           1140 PHE THR ALA THR ILE GLY VAL GLU SER GLU ARG THR ALA GLN ARG   1145        1150           1155 ILE LEU ILE ASN GLN VAL ASP LEU THR ARG ARG ALA ARG ALA GLU   1160        1165           1170 GLU PRO ARG ASP PRO ARG GLU ARG GLN GLN GLU LEU GLU ARG PHE   1175        1180           1185 ILE GLU ALA VAL LEU LEU VAL THR ALA PRO LEU PRO PRO GLU ALA   1190        1195           1200 ASP THR ARG TYR ALA GLY ARG ILE HIS ARG GLY ARG ALA ILE THR VAL   1205        1210           1215 SEQ ID NO. 108: MCR OSCILLOCHLORIS TRICHOIDES (OTMCR) MFMTRLNDKIALITGGAGTIGEVITRRYLEEGATVVMAGRNRDKLDRYRERLITEFHALP ERVMVVRMDGSSNAEVRMGIAAVVAHFGRIDILVNNAGSAGARQRLPAIPLLRSELQADE TETLADSIGNLIGITWNLIRAAAPFMPAGSSVINISTIFARTDYYGRIPYVVPKAALHAL TLAAATELGERGIRVNQINPGPIDSDRIRTVFRRMDELKGVPEQSTADGFFQMMRLRRPN AEGDLVKGFPKILDVANVAVFLGSAESAALSGETLDVTHGMAVPTESRTTLTSRPGLRAV DGSGHTTLICVGDQIEEAAALTGVLRACGAEVVIGFRSRAAIARFDHLIERGRHLPSQEH VAPVLLYLNPTEPESIDQALRWMATNLDLPTSVIILPAQRQPLPPSVVRASDEEVAYFLR DELSGMIVLASRLARFWQQATLAPGNAPIQPRVLFMTNPDDGQGNLYAEILRAGVEQLCR VWRHESQLDYTRLAQMDAHPPHIRPVWANQLVRFANNEQENLEYCCAWVAKILLSERTIE ELNLYLPRQIGSTTGSRQPSFGWAENLIGLHLGKTALITGGSAGIGSQIARLLALSGARV MLCARDERKLIQMRDMIIAELTEVGYNQUESRVQICAGCDVGEEEQLEIAVQRTLDLFGH VDYLINNAGIAGAEEMVLDLPLEAWQRTLRTNLISNYSLIRKLAPQMKSRGSGYILNVSS YFGGEKYAAIPYPNRADYAVSKAGQRALGEALARLLGPEVQINAMAPGPVEGERLRGSGD RPGLFLRRGRLILENKRLNDLHATLIAAERETQVGMRDLLARLLHNDVCALIDDPAAPTH LRALAERIWEQSDPNSYARAFFMNANIATKLLARLFNADQIDAQTFHTSQPNLPPEPFFA RTQIDREARRVRDGVMSMLYLQRMPTEEDVALATVYYLNDRSVSGETFHPSGGLRHERTP TGAELYGSPAPQRLASLAGSTVYLIGESMAAHLEALARAYIERYAATRVVLICATPAGVE RFSHHLADHLASGALAILSAEEGIEAALSEALRREGPPGPVVSTPFQPLPSQPLIGRNDS DWSTVLDVAGESAMCEQQLTHHERVIRKLSLVAGVSLVLVTPETDSHSSTEQFALANFVK TTLHAFTATVGVECERTAHRILVNQVDLGRQARAEEPRSPAEQAQEMERFIDAIMLITAP IPAEEDNRYTGRIYRGRAITV SEQ ID NO. 109: CHLOROFLEXUS AURANTIACUS (CAMCR) MSGTGRLAGKIALITGGAGNIGSELTRRFLAEGATVIISGRNRAKLTALAERMQAEAGVP AKRIDLEVMDGSDPVAVRAGIEAIVARHGQIDILVNNAGSAGAQRRLAEIPLTEAELGPG AEETLHASIANLLGMGWHLMRIAAPHMPVGSAVINVSTIFSRAEYYGRIPYVTPKAALNA LSQLAARELGARGIRVNTIFPGPIESDRIRTVFQRMDQLKGRPEGDTAHHELNTMRLCRA NDQGALERREPSVGDVADAAVFLASAESAALSGETIEVTHGMELPACSETSLLARTDLRT IDASGRTTLICAGDQIEEVMALTGMLRTCGSEVIIGFRSAAALAQFEQAVNESRRLAGAD FTPPIALPLDPRDPATIDAVFDWGAGENTGGIHAAVILPATSHEPAPCVIEVDDERVLNF LADEITGTIVIASRLARYWQSQRLTPGARARGPRVIELSNGADQNGNVYGRIQSAAIGQL IRVWRHEAELDYQRASAAGDHVLPPVWANQIVRFANRSLEGLEFACAWTAQLLHSQRHIN EITLNIPANISATTGARSASVGWAESLIGLHLGKVALITGGSAGIGGQIGRLLALSGARV MLAARDRHKLEQMQAMIQSELAEVGYTDVEDRVHIAPGCDVSSEAQLADLVERTLSAFGT VDYLINNAGIAGVEEMVIDMPVEGWRHTLFANLISNYSLMRKLAPLMKKQGSGYILNVSS YEGGEKDAAIPYPNRADYAVSKAGQRAMAEVFARFLGPEIQINAIAPGPVEGDRLRGTGE RPGLFARRARLILENKRLNELHAALIAAARTDERSMHELVELLLPNDVAALEQNPAAPTA LRELARRERSEGDPAASSSSALLNRSIAAKLLARLHNGGYVLPADIFANLPNPPDPFETR AQIDREARKVRDGIMGMLYLQRMPTEEDVAMATVYYLADRNVSGETFHPSGGLRYERTPT GGELFGLPSPERLAELVGSTVYLIGEHLTEHLNLLARAYLERYGARQVVMIVETETGAET MRRLLHDHVEAGRLMTIVAGDQIEAAIDQAITRYGRPGPVVCTPFRPLPTVPLVGRKDSD WSTVLSEAEFAELCEHQLTHHFRVARKIALSDGASLALVTPETTATSTTEQFALANFIKT TLHAFTATIGVESERTAQRILINQVDLTRRARAEEPRDPHERQQELERFIEAVLLVTAPL PPEADTRYAGRIHRGRAITV 

1.-23. (canceled)
 24. A genetically modified microorganism comprising a heterologous gene encoding an acetyl-CoA carboxylase (ACCase) polypeptide fusion wherein the polypeptide fusion comprises at least two subunits of an ACCase enzyme selected from the group consisting of accA-accB, accA-accC, accA-accD, accB-accC, aca-accD, accC-accD, accA-accB-accC, accA-accB-accD, accA-accC-accD, accB-accC-accD and accA-accB-accC-accD, wherein the genetically modified microorganism further comprises a genetic modification to a nucleotide encoding a protein with at least 80% sequence identity to D- lactate dehydrogenase, pyruvate formate- lyase, phosphate acetyltransferase, pyruvate oxidase, methylglyoxal synthase, acetate kinase, phosphotransacetylase-acetate kinase, or any combination thereof.
 25. The genetically modified microorganism of claim 24, wherein the nucleotide encoding for D-lactate dehydrogenase comprises IdhA from E. coli.
 26. The genetically modified microorganism of claim 24, wherein the nucleotide encoding for pyruvate formate-lyase comprises pflB from E. coli.
 27. The genetically modified microorganism of claim 24, wherein the nucleotide encoding for phosphate acetyltransferase comprises pta from E. coli.
 28. The genetically modified microorganism of claim 24, wherein the nucleotide encoding for the pyruvate oxidase comprises poxB from E. coli.
 29. The genetically modified microorganism of claim 24, wherein the nucleotide encoding for methylglyoxal synthase comprises mgsA from E. coli.
 30. The genetically modified micororganism of claim 24, wherein the nucleotide encoding for acetate kinase comprises ackA from E. coli.
 31. The geneticAy modified microorganism of claim 24, wherein the nucleotide encodings for phosphotransacetylase-acetate kinase comprises pta-ack from E. coli.
 32. A genetically modified microorganism comprising a heterologous gene encoding an acetyl-CoA carboxylase (ACCase) polypeptide fusion wherein the polypeptide fusion comprises at least two subunits of an ACCase enzyme selected from the group consisting of accA-accB, accA-accC, accA-accD, accB-accC, accB-accD, accC-accD, accA-accB-accC, accA-accB-accD, accA-accC-accD, accB-accC-accD and accA-accB-accC-accD, wherein the genetically modified microorganism is capable of producing a C4 to C 18 fatty acid chain product.
 33. The microorganism of Claim 32, wherein the fatty acid chain product is selected from the group consisting of fatty acid ethyl esters and fatty acids. 